Transcriptional profiling of the inflamed peritoneum by Uceda Fernandez, Javier









A Thesis submitted to Cardiff University in accordance to the 





Javier Uceda Fernández BSc (Hons) 
 
March 2018
  II 
Declaration 
This work has not been submitted in substance for any other degree or award at 
this or any other university or place of learning, nor is being submitted concurrently 
in candidature for any degree or other award. 
 
Signed …………………………… (candidate)  Date ……………… 
 
STATEMENT 1 
This thesis is being submitted in partial fulfillment of the requirements for the 
degree of PhD. 
 
Signed …………………………… (candidate)  Date ……………… 
 
STATEMENT 2 
This thesis is the result of my own independent work/investigation, except where 
otherwise stated, and the thesis has not been edited by a third party beyond what is 
permitted by Cardiff University’s Policy on the Use of Third Party Editors by 
Research Degree Students. Other sources are acknowledged by explicit references.  
The views expressed are my own. 
 
Signed …………………………… (candidate)  Date ……………… 
 
STATEMENT 3 
I hereby give consent for my thesis, if accepted, to be available online in the 
University’s Open Access repository and for inter-library loan, and for the title and 
summary to be made available to outside organizations. 
 
Signed …………………………… (candidate)  Date ……………… 
 
STATEMENT 4: PREVIOUSLY APPROVED BAR ON ACCESS 
I hereby give consent for my thesis, if accepted, to be available online in the 
University’s Open Access repository and for inter-library loans after expiry of a bar 
on access previously approved by the Academic Standards & Quality Committee.  
 
Signed …………………………… (candidate)  Date ……………… 
  III 
Summary 
Interleukin (IL)-6 is a pleiotropic cytokine associated with host defence, 
resolution of inflammation and chronic disease progression. During acute bacterial 
peritonitis, mice lacking IL-6 are unable to contain infection and display increased 
bacterial dissemination. To understand how IL-6 contributes to the local 
containment of infection, studies established an RNA-sequencing and 
bioinformatics pipeline to examine the role of the stromal tissue compartment in 
anti-microbial host defence. Investigations compared the host response to infection 
during both acute resolving peritoneal inflammation and under an inflammatory 
situation where pro-fibrotic CD4 T-cells contribute to the immune response. 
Molecular pathway analysis identified roles for IL-6 acting via the Jak-STAT 
signalling pathway in iron sequestration, complement regulation, and the control 
of leukocyte adhesion and activation. For example, stromal IL-6 signalling 
orchestrated responses relevant to the priming or activation of neutrophils, and 
infiltrating peritoneal neutrophils from infected Il6-/- mice displayed impaired 
phagocytic and respiratory burst capabilities. Previously we have shown that the 
IL-6-mediated expansion of peritoneal interferon (IFN)-g-producing CD4 T-cells 
(Th1 cells) promotes peritoneal fibrosis in response to recurrent bacterial 
peritonitis. To mimic this environment, acute resolving inflammation was 
established in mice receiving ex vivo expanded Th1 cells. The presence of Th1 cells 
promoted IFN-g-mediated STAT1 signalling in the peritoneum, which altered the 
expression of genes associated with the homeostatic turnover of extracellular 
matrix. Importantly, the presence of these cells also rescued the defective anti-
microbial activities observed in the membrane of Il6-/- mice. This recovery was 
associated with a shift in the relative activation of STAT1 over that of STAT3. Taken 
together, these data provide a novel holistic view of IL-6 signalling in stromal tissue, 
and highlights the importance of STAT1 and STAT3 in shaping the course of 
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 General Introduction 
  2 
1.1.  The Immune system 
1.1.1.  The Immune system 
The immune system provides protection from infection, injury and trauma, 
and relies on cellular communication between leukocytes and cells located within 
tissues and organs. The primary role of the immune system is to recognise and 
distinguish between ‘self’ and ‘non-self, and ensure the preservation of the body. 
This includes the provision of both immediate and more sustained forms of cellular 
and host defence. During infection, the immune system is designed to prevent the 
entry of infectious agents (e.g., bacteria, fungi, viruses and parasites), attack and 
destroy invading pathogens and minimize adverse tissue damage [1]. 
1.1.2.  Mechanisms of anti-microbial host defence 
To provide effective protection against such a broad range of pathogenic and 
environmental stimuli, the immune response has evolved into a highly coordinated 
process that incorporates several lines of defence. The first line of defence relies on 
exterior anatomical barriers including the skin and epithelial surfaces lining the 
lungs, intestines and genitourinary tract; and chemical secretions lubricating these 
sites. For example, the secretion of antimicrobial peptides and enzymes in the skin, 
respiratory track, saliva, tears and breast milk constitute an additional mechanism 
of defence, and the acidic environment of the gut provides an extreme chemical 
environment for the survival of pathogens. In addition, commensal microflora 
further restrict the colonisation of more pathogenic forms of bacteria at these sites 
[1]. However, periodic pathogenic infections are not always sufficiently contained 
and out-competed at these sites, and additional processes support the control of 
infection. For example, mechanical forms of protection including coughing and 
sneezing, which help to clear pathogens from the respiratory track, and the flushing 
of lining surface with tears or urine. In the airways and gastrointestinal track, cilia 
present on the epithelia surface removes pathogens that become trapped in the 
mucosal layer through peristaltic movements. 
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Pathogens that evade these barrier defences encounter cells of the immune 
system (leukocytes). These cells, together with other soluble mediators and 
communication molecules, orchestrate a response to invading pathogens that is 
termed inflammation. The main function of the inflammatory response is to recruit 
leukocytes from the bloodstream to the tissues, and direct the local immune 
response to infection, trauma or injury through the control of innate and adaptive 
immunity (see Sections 1.1.3 & 1.1.4) [1]. This control relies on soluble mediators 
such as cytokines, complement factors, bioactive lipids and acute phase proteins. 
The importance of these factors in host immunity is perhaps best illustrated by 
protein mimicry and decoy strategies employed by some viruses to evade immune 
detection [2]. Taken together, inflammation helps to combat and contain the 
infectious episode, and ensures restoration of normal tissue homeostasis (see Section 
1.1.5).  
1.1.3.  Innate immunity 
The innate immune response is defined as a rapid, non-specific mechanism 
that represents the first line of defence against invading microbes. The innate 
immune system shows remarkable evolutionary conservation in multi-cellular 
organisms, and has coevolved with microbes to protect the host from infection [3].  
Activation of innate immunity is driven by several innate sensing 
mechanisms that recognise defined cell determinants on invading pathogens 
(termed pathogen-associated molecular patterns; PAMPs) or endogenous 
molecules produced by damaged cells (termed damage-associated molecular 
patterns; DAMPs). These sensing mechanisms include receptors for lipid 
derivatives, bacterial flagellin, viral RNA and oligodeoxynucleotide DNA, and are 
termed pattern recognition receptors (PRRs) [4]. Recognition of DAMPs and 
PAMPs by PPRs trigger cellular responses that promote antimicrobial and pro-
inflammatory activities. These mechanisms aim to clear infections and limit host 
damage. The activation of these systems also provides a bridge to regulation of 
adaptive immune responses and sustained memory immunity [1, 5].  
The cellular arm of the innate immune system is composed of specialised 
leukocytes that survey the tissue microenvironment and eliminate pathogens. 
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These include phagocytic cells (e.g., neutrophils, monocytes and macrophages, 
eosinophils, mast cells, basophils), dendritic cells (DCs), and innate lymphoid cells 
(e.g., ILCs including natural killer (NK) cells) [1]. The main function of phagocytes 
is to internalize and kill microbes. They also produce and secrete soluble mediators 
that promote the immune response. These activities include control of adaptive 
immunity and the release of resolution factors that dampen the inflammatory 
response and restore immune homeostasis. Here, resident tissue macrophages, 
dendritic cells and infiltrating monocytic cells play vital roles in the presentation of 
antigen to T-cells, and in the clearance of neutrophils from sites of inflammation 
[6] (Section 1.1.8). Similarly, mast cells, eosinophils and basophils provide host 
immunity against parasitic infections and various allergens [7]. Innate lymphoid 
cells are involved in the immune response against intracellular viruses and bacteria, 
and damaged and cancerous cells [8]. The immunological processes regulated by 
these leukocyte populations are supported by the activities of several soluble factors 
that support the detection by the immune system. These include natural antibodies 
(e.g., IgM, IgG3), components of the complement system, pentraxins, collectins 
and ficolins [1]. The binding of these soluble mediators to microbes facilitates their 
uptake by professional phagocytes and also promotes the progression of 
inflammation and the transition from innate to adaptive immunity [9].  
1.1.4.  Adaptive immunity 
Adaptive immunity provides long-term protection against pathogens and 
other antigens (derived from the term antibody generating response). The 
mechanisms that control adaptive immunity are more elaborate than those 
described for innate immunity, and are an evolutionary feature of host defence in 
vertebrates [1, 10]. In this regard, adaptive immunity delivers three fundamental 
immune functions – (1) The capacity to distinguish between self and non-self 
antigens, (2) The generation of anti-microbial host responses that are tailored to 
eliminate specific extracellular or intracellular pathogens, and (3) The generation 
of immunological memory recall. These actions are mediated by specific subsets of 
lymphocytes known as B-cells, CD4 T helper cells and CD8 cytotoxic T cells.  
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Effector responses directed by the adaptive immune system rely on 
receptors expressed on B cells (the immunoglobulin BCR; B cell receptor formed 
from either membrane-bound IgM or IgD) and T cells (TCR; T cell receptor). 
Although functionally distinct, both receptors are members of the immunoglobulin 
superfamily. These are encoded by select combinations of specific gene clusters 
termed variable, diverse and joining (V(D)J) genes. The large repertoire of BCRs 
and TCRs is acquired by V(D)J recombination during B cell and T cell 
differentiation [11]. A complex array of inherent gene editing mechanisms gives 
rise to the generation of diversity, and the affinity binding characteristics for each 
receptor is unique to each individual T-cell or B-cell clone.  
During the adaptive immune response, the interaction of antigen-presenting 
cells (e.g., B-cells, dendritic cells and other specialised monocytic populations) 
with lymphocytes promotes the development of antigen-specific responses and the 
survival and long-term maintenance of effector and memory subsets with defined 
inflammatory or regulatory characteristics [12, 13]. In this regard, immunological 
memory is a hallmark of the adaptive immunity and forms the basis of vaccination 
strategies against bacteria and viruses [14].  
1.1.5.  Inflammation 
Inflammation is not a disease, but an active consequence of a disease process. 
It is therefore designed to offer protection. However persistent, recurrent or 
uncontrolled inflammation can promote various inflammatory or autoimmune 
diseases. The fundamental features of inflammation are defined by rubor (redness), 
calor (warmth), dolor (pain) and tumor (swelling) [15]. These hallmarks of 
inflammation arise from the accumulation of immune cells, plasma proteins and 
fluids at site of infection, injury or trauma. This response is however highly 
coordinated and ensures: (1) Recruitment of effector molecules and leukocytes to 
the inflamed tissue where they fight infection or damage; (2) Prevent the 
dissemination of the invading pathogen to other tissues; (3) Ensure the resolution 
of the inflammatory process to restore normal tissue homeostasis.  
Acute inflammation refers to the initiation of a short-term response that 
develops quickly and resolves within 2-3 days. In this regard, a tight 
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communication between the local stromal compartment and the infiltrating 
effector cells during inflammation is essential to ensure the appropriate activation, 
maintenance and resolution of inflammatory cells (see Sections 1.1.6-1.1.8) 
(Figure 1.1) [9, 16, 17]. Persistent or recurrent acute inflammation leads to tissue 
damage and injury (e.g., fibrosis), and may give rise to chronic inflammatory 
disease [1]. These outcomes are regulated in a context-dependent manner, and are 
shaped by specific cytokines and soluble factors released as part of the disease 
process.  
1.1.6.  Induction and early phase of inflammation 
Recognition of invading pathogens by the PPRs expressed by host cells 
(including tissue resident macrophages, dendritic cells and stromal epithelial cells) 
leads to the production of inflammatory mediators that initiate and amplify the 
inflammatory response – bioactive lipids (e.g., prostaglandins, leukotrienes), 
chemokines (chemotactic cytokines) and cytokines [18]. These include pro-
inflammatory cytokines such as tumour necrosis factor (TNF)-a, interleukin 
(IL)-1b and IL-6, which control the expression of adhesion molecules and 
chemokines responsible for the trafficking of inflammatory cells from the blood 
into the inflamed tissue compartment [1, 16, 17] (Section 1.2.1). Here, changes in 
expression patterns of chemokines and adhesion molecules (e.g., selectins, 
integrins) ensure the timely recruitment of innate and adaptive immune cells to 
sites of inflammation. In particular, the early expression of neutrophil-activating 
chemokines by resident monocytic cells and stromal cells supports the rapid 
recruitment and activation of neutrophils to sites of bacterial infection [16]. 
Neutrophil recruitment, activation and effector activities will be extensively 
detailed in Section 1.7.  
1.1.7.  Maintenance and late phase of inflammation 
The next stage in the inflammatory process is characterised by the clearance 
of the initial neutrophil influx and their replacement by a more sustained 
population of mononuclear cells [9]. This replacement is controlled by a shift in the 
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expression of neutrophil directing molecules, including chemokines (Section 1.2.2) 
and bioactive lipids (e.g., lipoxygenase-derived lipid mediators, lipoxins) [19], to 
monocyte [20] and lymphocyte directing molecules [21]. For example, the shift 
from leukotriene (e.g., LTB4) to lipoxin production collectively inhibits neutrophil 
chemotaxis and promotes the extravasation of circulating monocytes and 
lymphocytes to the inflamed tissue [22]. This switch in leukocyte recruitment is 
supported by the selective expression of monocyte-specific cell adhesion molecules 
(CAMs) in the vascular endothelium [23, 24], and the clearance of apoptotic 
neutrophils through a mechanism known as nonphlogistic phagocytosis [25].  
Importantly, this selective recruitment allows antigen presentation by 
inflammatory macrophages to lymphocytes and the generation of long-term 
immunological memory. 
1.1.8.  Resolution of inflammation  
Finally, the inflammatory response has to cease in order to prevent tissue 
damage and injury. Resolution of inflammation relies in both cease of pro-
inflammatory signals and induction in pro-resolving signals with the aim of: (1) 
Remove the microbes, dead cells and debris; (2) Restore the vascular integrity and 
perfusion; (3) Regenerate the inflamed tissue [26]. In this regard, the engulfment 
of apoptotic neutrophils by inflammatory macrophages  induces a switch from pro- 
to anti-inflammatory macrophage phenotype that initiates their apoptosis [27] or 
egress from the inflamed local tissue to the nearest draining lymph node [28]. In 
addition, phagocytosis of apoptotic cells also induces the release of anti-
inflammatory mediators such as transforming growth factor-b1 (TGF-b1), platelet 
derived growth factor (PDGF) and vascular endothelial growth factor (VEGF), 
which stimulate the proliferation of epithelial cells to surround the injury site and 
ensures the repair of endothelial and epithelial tissues [29]. Taken all together, 
these signals promote the resolution of the inflammatory process, tissue repair and 
restores normal homeostasis [6]. 
 
 










Figure 1.1. Stages of inflammation. The inflammatory response can be 
divided in three different stages attending the leukocyte population at the site of 
infection or injury. It is characterised by an initial influx of neutrophils during the 
early stage, followed by the recruitment of a more sustained population of 
monocytes and lymphocytes at the late phase. Finally, the inflammatory response 
is resolved, inflammatory leukocyte number reduce, and the tissue returns to 
homeostasis. 
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1.1.9.  Acute resolving inflammation versus inflammation associated tissue 
damage 
Inflammation induced tissue injury is often an unavoidable consequence of 
anti-microbial immune response, and ultimately is the result of the interaction 
between the host and the invading microorganism [30]. This is probably best 
illustrated in the case of bacterial commensalism versus infection, where 
commensalism is defined as a state of host–microorganism interaction that does not 
result in host damage [30]. While tissue injury arises from bacterial, fungal or viral 
infection, overt innate or adaptive immune responses have the potential to promote 
cellular damage and an alteration in tissue architecture. For example, processes 
that control oxidative stress or fibrosis. Thus, leukocyte infiltration and clearance 
during acute inflammation must be tightly regulated to ensure both competent host 
defence and correct resolution of inflammation [9].  
Dysregulation of the inflammatory process can arise from persistent, 
recurrent or unresolved inflammation; allergy responses; autoimmune reactions 
and radiation [31]. Eventually, it leads to chronic inflammation and results in 
changes in local tissue architecture, tissue injury, cell death and the replacement of 
viable cells and parenchyma with fibrosis [30]. These events have been proposed to 
be useful in the containment of the early stages of infection [32]. For example, we 
have previously shown that recurrent episodes of resolving bacterial peritonitis lead 
to peritoneal fibrosis in a murine model of peritoneal inflammation [33]. This 
process relies on the local expansion and retention of effector CD4 T-cells in the 
peritoneal cavity. Here, fibrosis may similarly be a host response focused to limit 
bacterial dissemination. 
Importantly, peritoneal fibrosis is a major cause of treatment failure in end 
stage renal failure patients in peritoneal dialysis. Here, treatment duration but also 
the incidence of bacterial peritonitis in these patients is linked with thickening of 
the sub-mesothelial compact zone and peritoneal fibrosis [34-36]. In particular, the 
onset of fibrosis after recurrent bacterial infection is strictly IL-6 depended [33].  
While these observations present significant clinical relevance, they also illustrate 
the thin line between successful host defence and tissue damage, and will be the 
focus of the current thesis.  
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1.2.  Cytokines and chemokines 
As discussed previously in this Chapter, the inflammatory response is a 
process that must be tightly regulated. This control relies on complex signalling 
networks that include protein and lipid mediators, such as cytokines, chemokines, 
prostaglandins and leukotrienes. The following section will introduce the basic 
principles in chemokine and cytokine signalling, and will focus specially in the 
cytokine interleukin (IL)-6.  
1.2.1.  Cytokines 
Cytokines are small molecular weight proteins that control cellular 
proliferation, differentiation and survival. They are produced by both 
haematopoietic (immune) and non-haematopoietic (stromal) cells to promote 
specific gene regulation through the activation of receptors expressed by target 
cells. They can act on the same cells that produce them (autocrine signalling), on 
cells in close contact (termed contact-dependent or juxtacrine signalling), on 
adjacent cells (paracrine signalling), or via the circulation to distant cells (endocrine 
signalling) [1, 37]. In addition, while one same cytokine can elicit multiple biologic 
effects in diverse cell types (termed pleiotropism), multiple cytokines can present 
overlapping activities (termed redundancy). For example, the IL-6 cytokine family 
includes several members that, despite being encoded in separate genes, induce the 
expression of hepatic acute phase proteins in addition to other unrelated biological 
properties [38]. 
Cytokines can be classified according two functional classes. 
Haematopoietic cytokines are secreted by tissue resident macrophages and stromal 
cells and provide local environment for haematopoiesis; whereas immune 
cytokines are produced by leukocytes, lymphocytes and stromal cells, and have 
activities relevant to immune homeostasis and disease [1, 37]. Importantly, some 
cytokines like IL-6 are responsible for both of these classifications. 
In the context of immune homeostasis, cytokine signalling is essential for 
control of the inflammatory response, and they can act as pro- or anti-inflammatory 
mediators. Examples of pro-inflammatory cytokines are TNF-a or IL-1b [1], 
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which are produced at the early stages of inflammation and coordinate many aspects 
of the inflammatory response. Conversely, IL-10 or IL-27 have potent immuno-
modulatory and anti-inflammatory properties [39, 40]. Finally, other cytokines 
such as IL-6 act as pleiotropic factors, and present both pro- or anti-inflammatory 
activity depending on the context in which IL-6 deeds [41]. As the present thesis 
focus on the impact of IL-6 signalling in educating the immune response, this 
cytokine will be discussed in detail in Section 1.3. 
1.2.2.  Chemotactic cytokines – Chemokines 
Those cytokines that elicit chemotactic functions are termed chemokines. 
Chemokines are a family of structurally homologous cytokines that stimulate 
leukocyte trafficking and migration from blood to tissues in favour of their gradient 
[1]. These small proteins are divided in four subfamilies based on the number and 
location of N-terminal cysteine residues: CC family (e.g., monocyte chemotactic 
protein, MCP-1; CC-chemokine Ligand-1, CCL1), where the cysteine residues are 
adjacent; CXC (e.g., interleukin-8, IL-8; CXC-chemokine Ligand-8, CXCL8) and 
CX3C (e.g., fractalkine; CX3C-chemokine Ligand-1, CX3CL1) families, where 
the cysteine residues are separated by one or three amino acids, respectively; and 
C (e.g., lymphotactin; C-chemokine Ligand-1, CL1) family, with only one cysteine 
[1]. Systematic nomenclature designates each individual chemokine with their 
subfamily followed by a number and L or R, referring to ligand or receptor 
respectively [42]. Chemokine receptors show structural hallmarks of seven-
transmembrane G-protein coupled receptors. Binding of a given chemokine to its 
respective receptors induces changes in the target cell’s cytoskeleton and lipid 
membrane that induces movement along the chemokine gradient in a process 
known as chemotaxis [43].  
Chemokines are involved in several biological processes, including 
lymphoid tissue organization and the recruitment of leukocytes involved in innate 
and adaptive immunity. During inflammation, time-dependent regulation of 
chemokine production ultimately dictates leukocyte trafficking, clearance and 
eventual resolution the inflammatory process. Among those regulators of 
chemokine expression are PRRs as well as cytokines. In the context of bacterial 
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peritonitis, IL-6 plays a pivotal role in controlling leukocyte recruitment by 
switching the production of different chemokines [9], which will be discussed 
extensively in Section 1.3. 
 
1.3.  Interleukin-6 
The importance of IL-6 in innate immunity is perhaps best illustrated by the 
identification of a conserved IL-6-like cytokine system in Drosophila melanogaster. In 
particular, the binding of the secreted ligand unpaired-3 (IL-6-like) to the receptor 
Domeless (gp130-like) forms a signalling network that eventually promotes innate 
immunity [44-46]. Furthermore, several viruses have evolved to mimic or disrupt 
IL-6 signalling. For example, human herpesvirus 8 expresses a viral form of IL-6 
that shares ~60% amino acid similarity with its human counterpart and can block 
the recruitment of neutrophils [47]. Taken together, these observations highlight 
the fundamental role of IL-6 in innate immunity and pathogen control [41].The 
following sections will review our current understanding of IL-6 signalling and its 
implication in health and disease.  
1.3.1.  Interleukin-6 
Interleukin-6 (IL-6) is a cytokine of 26 kDa consisting of 4 long polypeptide 
a-helices (A, B, C and D) arranged in an up-up-down-down topology (Figure 
1.2A) [48]. Prior to its naming as a single cytokine, IL-6 was characterised as 
b2-interferon (IFN-b2) [49], B-cell stimulatory factor 2 (BSF-2) [50], 26 kDa 
protein [51], hybridoma/plasmacytoma growth factor (HPGF or IL-HP1), 
hepatocyte stimulatory factor (HSF) [52] and monocyte granulocyte inducer type 
2 (MGI-2). While these factors were discovered to be the same molecule in 1987 
[53], these studies illustrate the characteristic of IL-6 of being a truly pleiotropic 
cytokine that has a broad impact in both stromal and immune cells.  
Interleukin-6 is very promptly and transiently produced in response to 
infection and tissue injury. While the main cellular sources of IL-6 are monocytes 
and resident macrophages at the site of inflammation, mesenchymal cells, 
endothelial cells, fibroblasts, and many other stromal cells are also involved in the 
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production of IL-6 in response to various stimuli [54, 55]. Here, recognition of 
damage or infection by PRRs (e.g., toll-like receptors (TLRs) and retinoic acid-
inducible gene-1-like receptors) trigger the activation of a range of signalling 
pathways that enhance the transcription of the mRNA of inflammatory cytokines, 
including IL-6. For example, peritoneal infection by gram positive bacteria 
activates TLR2 and the transcription factor NF-kB by resident peritoneal 
macrophages and stromal cells, which lead to the production and release of IL-6 – 
among other cytokines – to the peritoneal cavity [9, 56].  
In the context of the immune response, IL-6 has been associated to promote 
the population expansion and activation of T-cells [57], the differentiation of B-
cells [58] and regulation of acute phase responses [59, 60]. Interleukin-6 has also 
been shown to be essential for host defence against bacteria, viruses and parasites 
[61-65]. Unpublished observations in our laboratory are in close agreement with 
these findings. In particular, we have shown that Il6-/- mice have a reduced capacity 
to successfully clear infection during Staphylococcus epidermidis induced peritonitis.  
The beneficial role of IL-6 in acute resolving infection is counteracted by its 
implication in chronic disease such as arthritis [66] and Crohn’s disease [67], and 
cancer progression [68]. A more in-depth look at the role of IL-6 during 
inflammation will be discussed in Sections 1.3.4 & 1.3.5. 
1.3.2.  IL-6 receptor signalling 
Interleukin-6 signalling relies on two receptors: the non-signalling 
a-receptor (CD126, IL-6Ra, encoded by the Il6ra gene) and the signal transducing 
b-receptor glycoprotein 130 kDa (CD130, gp130, encoded by Il6st) [48]. The 
stoichiometry of this interaction is 2:2:2 (Figure 1.2B), where each IL-6-IL-6R 
complex contacts two b-receptor subunits of gp130 [69]. This interaction allows 
the proximity of the two gp130 subunits and trigger the intracellular signalling [69], 
that will be detailed in Section 1.3.3. 
Interleukin-6 can bind to both the membrane bound or soluble IL-6R 
(sIL-6R) in the site I (Figure 1.2A & 1.3) [70]. IL-6 signalling via the membrane 
bound receptor is referred as “classical IL-6 receptor signalling” [48] (Figure 1.3). 
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The expression of the membrane bound IL-6Ra is restricted to hepatocytes, 
leukocytes, megakaryocytes and some specialised stromal cells [41]. Therefore, 
only those cells are responsive to IL-6 classical signalling. IL-6 acting via its soluble 
receptor is termed “IL-6 trans-signalling” (Figure 1.3). Soluble IL-6R can be 
produced by proteolytic cleavage of the extra cellular domain by the enzyme 
adamylsin and disintegrin-associated metalloprotease (ADAM)-17 and -10 [71], or 
by differential splicing of Il6ra gene to produce a protein without the membrane 
anchor region. Both sIL-6R isoforms are termed proteolytic cleavage (PC)-sIL-6R 
and differential splicing (DS)-sIL-6R, and share similar structure and functional 
properties. IL-6R shedding is induced by several physiological activators, including 
C-reactive protein [72], complement component 5a (C5a) [73], platelet activating 
factor (PAF) [74], chemokines, such as CXCL8 [75], and other chemoattractants 
such as N-formylmethionyl-leucyl-phenylalanine (fMLP) [76]. In this regard, IL-6 
binding to sIL-6R can initiate signal transduction in those cells not expressing IL-6R 
but expressing gp130. Another mechanism of IL-6 signalling has been recently 
proposed by Heink and colleagues, who showed that DCs using their membrane 
bound IL-6Ra trans-presented IL-6 to T cells during the process of cognate 
interaction [77]. This mechanism was termed IL-6 trans-presentation, and was 
found to be important for the generation of Th17 cells in vivo [77].  
Both classical IL-6 receptor signalling and IL-6 trans-signalling rely on the 
membrane bound gp130 to initiate signal transduction (Figure 1.3). Here, IL-6 
binds to each gp130 of the receptor complex via sites II and III respectively (Figure 
1.2A) [70]. Gp130 is ubiquitously expressed in almost every cell type except red 
blood cells. A soluble form is gp130 (sgp130) is also generated by alternative 
splicing of the Il6st gene, and to a lesser extent by proteolytic cleavage [78, 79]. 
This sgp130 is an antagonist of IL-6 trans-signalling (Figure1.3) [78, 80], and an 
Fc-dimerized version of sgp130 (sgp130-Fc; olamkicept) has shown therapeutic 
efficacy in models of inflammatory disease and cancer [81-83]. The mechanisms of 









1.3.3.  IL-6 intracellular signalling – paradigm of Jak/STAT signalling pathway  
Cytokine engagement of the IL-6 receptor complex promotes signalling via 
the Janus-activated kinase/signal transducers and activators of transcription 
(Jak/STAT) pathway. This pathway represents a landmark in cell biology and 
provides a direct mechanism to translate an extracellular signal (mediated by 
hormones, interferons, colony-stimulating factors, and interleukins) into a 
transcriptional response [84, 85]. The signalling mechanism is relatively simple and 
relies on very few principal components. Intracellular activation occurs when 
ligands bind to their respective receptors and induce their multimerization. This 
allows proximity of the intracellular domains of the receptors and the association 
of the Jak tyrosine kinases (Jak1, Jak2, Jak3 and Tyk2), which results in their intra- 
or intermolecular phosphorylation [85]. Tyrosine phosphorylation induces the 
activation of the Jaks catalytic domain, which now can phosphorylate several 
tyrosine residues in the carboxy-terminus of the cytoplasmic tail of the receptors. 
Here, tyrosine phosphorylation promotes the recruitment of STAT factors to the 












Figure 1.2. Interleukin-6 and its receptor complex form a trimeric 
dimer. A. The structure of IL-6 comprises 4 long alpha helices that are arranged 
in an up-up-down-down topology (Figure obtained from ref 48). B. The binding 
of IL-6 to IL-6R promotes the contact to the b-receptor subunits gp130 and the 
formation of a trimeric homodimer that allows the proximity of the two gp130 
subunits (Figure adapted from ref 69).   
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proteins. Activated STATs can now form homo- (e.g., STAT1-STAT1 dimers) and 
to a lesser extent hetero-dimers (e.g., STAT1-STAT3 heterodimers), which 
promotes translocation to the nucleus, DNA binding to defined DNA consensus 
binding motifs (e.g., GAS motifs) and the initiation of gene transcription [85]. 
In particular, IL-6 activates Jak1, Jak2 and Tyk2, and the latent transcription 
factors STAT1, STAT3 and to a lesser extent STAT5 [70] (Figure 1.3). In addition 
to STAT activation, IL-6 signalling also regulates activation of the mitogen activated 
protein kinase (MAPK) cascade [48]. This signalling pathway is initiated with the 
recruitment of the SH2 domain containing protein tyrosine phosphatase (SHP-2) 
to the tyrosine-759 (in humans; tyrosine-757 in mice) residue of gp130 [86]. SHP-2 
is phosphorylated by Jak1 to initiate links with the Grb-SOS complex and the 
downstream activation of Ras, Raf and components of the MAPK cascade. 
Furthermore, phosphorylated SHP-2 can form a complex with Gab and PI3K that 
leads to the activation of the Akt pathway [48, 87]. Finally, IL-6 can activate the 
tyrosine kinases Src and Yes, which leads to the activation of the YAP-Notch 
pathway and promotes epithelial regeneration [88].  
Interleukin-6 signalling is strictly regulated. One regulatory mechanism 
involves the hydrolysis of the phosphorylated tyrosine residues in Jaks, STATs and 
upstream receptors by a broad number of phosphatases, including SHP-2 and other 
protein tyrosine phosphatases (PTPs) [89]. Another mechanism involves proteins 
of the PIAS (protein inhibitor of activated STATs) family, which suppress STAT 
activities by allosteric interactions in the nucleus [90]. They also promote STATs 
sumoylation in a manner that resembles the action of RING-type ubiquitin E3 
ligases [91]. Finally, activation of STAT1/3 respectively induces the transcription 
of suppressors of cytokine signalling (SOCS) 1 and 3, which act as negative 
feedback regulators for STAT signalling. For example, SOCS3 binds to the SH2 
domain and inhibits the activation of SHP-2 and STAT pathways [92]. SOCS3 also 
limits the activation of STAT1 by IL-6 by ensuring that STAT3 has priority in 
binding to activated gp130 [93].  
  





Figure 1.3. IL-6 signal transduction. The binding of two complex of IL-6-
IL-6R to two molecules of gp130 allows the proximity of the cytoplasmic tails of 
gp130. This proximity leads to the activation of Jaks, which can now phosphorylate 
several tyrosine residues in the c terminus of the cytoplasmic tail of gp130. This 
phosphorylated Tyr acts as docking sites for the recruitment of several proteins 
including STAT1, STAT3 and SHP-2, where they become phosphorylated by the 
Jaks. Phosphorylation of STATs facilitates the formation of STAT dimers, which 
translocate to the nucleus to regulate gene expression. Alternatively, the activation 
of SHP-2 by phosphorylation leads to the activation of the MAPKs pathway or the 
Akt pathway. Finally, the activation of the kinases Src and Yes leads to the activation 
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1.3.4.  IL-6 in acute inflammation 
The pleotropic properties of IL-6 are best illustrated by its key role in both 
the resolution of inflammation and chronic disease progression [41]. The following 
sections will discuss the contribution of IL-6 in directing competent host defence 
versus inflammation induced tissue damage in the context of peritoneal 
inflammation.  
Interleukin-6 is rapidly induced during peritonitis in response to innate toll-
like receptor signalling [9, 56]. The molecular and cellular events that characterise 
this model are depicted in Figure 1.4. Here, gram-positive bacterial (e.g., 
S. epidermidis) activation of TLR2 leads to the expression of the pro-inflammatory 
cytokines TNF-a, IL-1b and IL-6, and neutrophil-activating chemokines such as 
CXCL1 and CXCL8. Stimulation of human peritoneal mesothelial cells (HPMCs) 
with TNF-a and IL-1b also induces the production of IL-6 [94]. CXCL1 and 
CXCL8 mediate the recruitment of neutrophils to the peritoneal cavity, where they 
are activated to shed IL-6R [20].  
While peritoneal mesothelial cells do not express IL-6R, the availability of 
sIL-6R promotes IL-6 trans-signalling in the mesothelium and the activation of 
STAT3 [21]. In this regard, IL-6 trans-signalling promotes the transition from the 
early influx of neutrophils to the more sustained mononuclear cell infiltrate. This 
transition is controlled through the induction of monocytic chemoattractants such 
as CCL2, and the inhibition of CXCL1 and CXCL8 [20]. This differential 
chemokine modulation was found to be STAT3 and not STAT1 dependent [95]. 
These responses are supplemented by the role of IL-6 in promoting angiogenesis 
and the differential expression of several adhesion molecules [76, 96, 97]. In 
addition, IL-6 suppresses the expression of pro-inflammatory cytokines and 
induces the release of the soluble p55 TNF-a receptor and the IL-1R antagonist 
[98, 99]. Finally, IL-6 also mediates neutrophil apoptosis [25], which facilitates 
neutrophil clearance by the infiltrating monocytes. Taken all together, these events 
illustrate the role of IL-6 in ensuring the correct progression of the inflammatory 
response (Section 1.1.7). 







































Figure 1.4. IL-6 governs leukocyte recruitment and clearance during acute peritonitis. A. TLR activation leads to the 
expression and release of several chemokines (CXCL1) and cytokines (TNF-a, IL6) to the peritoneal cavity. B. CXCL1 promotes the 
recruitment of inflammatory neutrophils, that rapidly shed their IL-6R upon transmigration. C. The complex IL-6-sIL-6R binds to gp130 
in the peritoneal lining to induce the expression of several genes, including MCP-1, which promotes the recruitment of mononuclear cells 
and the eventual resolution of inflammation (D). IL-6 is also essential for the correct clearance of the pathogen through mechanisms not 
yet determined.  
D 
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The ability of IL-6 to dictate transition from innate to acquired immunity is 
represented by the ability of IL-6 to induce T-cell chemokines CXCL10, CCL4, 
CCL5, CCL11 and CCL17 in the peritoneal membrane [25]. This is accompanied by 
the IL-6-signalling mediated expression of CCR3, CCR4, CCR5, and CXCR3 on the 
CD3+ infiltrate during the late stages of inflammation [21]. IL-6 trans-signalling also 
promotes the generation and maintenance of Th17 cells in the peritoneal cavity 
[100], which play an important role in the defence against bacterial infection [101].  
In this regard, recent studies from our laboratory have shown that IL-6 is 
essential in the control of infection during acute bacterial peritonitis. Here, Il6-/- 
mice showed reduced bacterial clearance at the peritoneal cavity and increased 
dissemination to the blood stream. These results are accompanied by an impaired 
systemic acute phase response characterised by a reduction in the levels of serum 
amyloid a protein (SAA1) in the blood. These findings are in close agreement with 
other studies in the literature that highlight the importance of IL-6 in host defence 
against different pathogens [61-65]. For example, during gram positive bacterial 
infection, IL-6 promotes the expression of haptoglobin, serum amyloid A and other 
acute phase proteins in the liver [61]. In addition, IL-6 enhances antibody responses 
that provide long-term protection against influenza virus [64]. Importantly, 
reconstitution of IL-6 trans-signalling in the peritoneal cavity correlated with 
improved bacterial clearance and reduced dissemination in a dose dependent 
manner. In line with these studies, Onogawa and co-workers have demonstrated that 
local delivery of sIL-6R improved bacterial clearance during S. aureus induced 
peritoneal infection in mice [102]. Taken together, this data stresses the pivotal role 
of IL-6 in directing a successful host defence during acute inflammation.  
1.3.5.  IL-6 in chronic inflammation 
The beneficial role of IL-6 during acute inflammation is darkened by its 
involvement in the onset of chronic inflammation. For example, early studies have 
shown that IL-6 is present in the synovial fluids of patients with rheumatoid arthritis 
[103] and the psoriatic plaques of patients with psoriasis [104].  In addition, elevated 
IL-6 levels have been found in the serum of patients with various forms of chronic 
diseases including colitis and systemic juvenile idiopathic arthritis [105, 106]. These 
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findings are supported by other studies that demonstrated that Il6-/- mice are resistant 
to the development of experimental models of chronic disease such as arthritis [107, 
108] and autoimmune encephalomyelitis [109]. Interestingly, the pro-inflammatory 
properties of IL-6 seem to be mediated by IL-6 trans-signalling in many of these 
conditions [110]. Here, blockade of IL-6 trans-signalling using sgp130-Fc has been 
beneficial in several models of chronic inflammatory bowel disease [111]. In 
rheumatoid arthritis, reconstitution of IL-6 trans-signalling (but not classical IL-6 
receptor signalling) promotes disease progression. Here, changes in leukocyte 
recruitment, synovial hyperplasia and joint erosion are inhibited by action of sgp130 
[107]. These findings have led to the clinical development of a specific IL-6 trans-
signalling inhibitor under the drug name olamkicept [112]. 
In the context of end stage renal failure patients in peritoneal dialysis, 
repetitive episodes of bacterial infection and treatment duration lead to peritoneal 
fibrosis, which a major cause for treatment failure [34, 113]. Using a murine model 
of peritoneal inflammation, we have demonstrated that this process is strictly IL-6 
dependent [33]. After four episodes of acute resolving peritonitis, IL-6 mediates the 
expansion of IFN-g producing Th1 cells at the site of infection. IFN-g signalling in 
the peritoneal membrane via STAT1 promotes fibrosis, which was not observed in 
mice deficient in IL-6, IFN-g or STAT1 [33] (Figure 1.5). In this model, a relative 
increase in stromal STAT1 activity led to fibrosis through an alteration in the 
physiological turnover of extracellular matrix (ECM) by proteases [33]. The 
mechanisms of fibrosis will be further discussed in Section 1.5. Overall, this setting 
illustrates the importance of IL-6 in determining transition from competent host 
defence to inflammation induced tissue damage. 
 

















Figure 1.5. IL-6 as a key cytokine in determining the transition from 
competent host defence to inflammation induced tissue damage. 
While acute resolving peritonitis relies in IL-6 for the successful resolution of the 
infection, repetitive episodes of bacterial peritonitis leads to the IL-6 mediated 
expansion of Th1 cells and the production of IFN-g in the peritoneal cavity. IFN-g 
signalling via STAT1 in the peritoneal lining leads to peritoneal fibrosis, which is 
a major cause of peritoneal dialysis failure as replacement treatment for end-stage 
renal failure patients. nTcell, naïve T cell; S. epi, Staphylococcus epidermidis. 
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1.4.  Interferon-g 
Interferon (IFN)-g is a dimerized soluble cytokine that is the only member of 
the type II IFN. Each monomer consists of a core of six alpha helix and an unfolded 
sequence in the C-terminal region [114]. IFN-g is produced by many cell types, 
including NK cells, B cells, professional antigen-presenting cells (APCs; e.g., 
macrophages and dendritic cells), CD4+ Th1 cells and CD8+ cytotoxic T 
lymphocytes [115]. Such broad expression illustrates the importance of this cytokine 
in both innate and adaptive immunity. For example, secretion of specific cytokines 
such as IL-12 by APCs mediates naïve CD4+ T-cell differentiation to Th1 [116]. In 
return, Th1-derived IFN-g promotes the activation of APCs to enhance Th1 
differentiation. What is more, IFN-g inhibits IL-4 secretion and Th2 polarization 
[117]. Thus, both IL-12 and IFN-g coordinate the link between pattern recognition 
by innate immune cells and the induction of specific adaptive immunity by mediating 
a positive feedback loop to amplify the Th1 responses [118].  
As well as IL-6, IFN-g elicits a broad variety of biological functions, including 
antiviral, immunoregulatory and anti-tumour activities [117]. For example, IFN-g 
derived antiviral mechanisms rely on the induction of key antiviral enzymes such as 
protein kinase R (PKR), which also presents anti-proliferative activity and suppress 
tumour progression [119]. In the context of peritoneal inflammation, we have 
previously shown that IFN-g controls the initial recruitment of neutrophils to the 
peritoneal cavity [120]. Together with IL-6 acting via its soluble receptor, IFN-g also 
regulates neutrophil clearance [25]. Finally, IFN-g activation of STAT1 signalling in 
the peritoneal membrane disrupts the correct turnover of ECM by matrix 
metalloproteinases (MMPs), which eventually leads to peritoneal fibrosis (Section 
1.3.5) [33]. Taken all together, these studies emphasise the importance of the 
interplay between IL-6 and IFN-g in controlling every stage of the inflammatory 
response. 
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1.4.1.  IFN-g signalling 
IFN-g signalling relies on two receptors: a ligand-binding subunit, termed 
IFNGR1, and a signal transducing subunit, termed IFNGR2. Both subunits belong to 
the class II cytokine receptor family [117]. The stoichiometry of this interaction is 
2:2:2, where each IFN-g dimer binds to two subunits of IFNGR1, that then associate 
to two subunits of IFNGR2 [121] (Figure 1.6).  
Downstream receptor signalling can be divided into canonical and non-
canonical signalling pathways. Canonical signalling refers to IFN-g acting via the 
Jak/STAT pathway (Section 1.3.3) [122]. In particular, IFN-g binding to the 
constitutively assembled IFNGR1-IFNGR2 leads to recruitment and activation of 
Jak1 and Jak2, and the latent transcription factor STAT1. Recruited STAT1 
undergoes tyrosine phosphorylation, dimerization and nuclear translocation in 
response to Jak activation [122]. Alternatively, recruitment of adaptor proteins 
associated to IFNGR2 such as MAL [123] and Fyn [124] results in non-canonical 
signalling that activates alternative pathways including PI3K pathway and others 
[125].  
Negative regulation of IFN-g signalling occurs at every level of the signalling 
cascade. Following signal transduction, the ligand-receptor complex internalizes and 
dissociates [126]. Also, STAT1 induces the transcription of SOCS1, which acts as a 
specific feedback inhibitor of STAT1 signalling [127]. Finally, IFN-g signalling is 
controlled by the action of several phosphatases at every level of the pathway. For 
example, SHP-2 can dephosphorylate both Jaks and IFNGR1 [128], or STAT1 can 
be dephosphorylated in the nucleus by nuclear tyrosine phosphatases [129].  























Figure 1.6. Interferon-g signalling pathways. IFN-g is a dimer that binds to 
two subunits of IFNGR1 and two subunits of IFNGR2. This leads to the 
recruitment and activation of Jaks, which become active and phosphorylate specific 
tyrosine residues in the cytoplasmic tail of each IFNGR1. This leads to the 
recruitment of STAT1 and their phosphorylation by the Jaks. Phosphorylated 
STAT1 dimerize and enter the nucleus, where they control the expression of 
several genes. Receptor dimerization can also lead to the recruitment of other 
adaptor proteins such as MAL of Fyn, the eventually results in the activation of the 
Akt pathway, among others.   
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1.5.  Fibrosis 
Fibrosis is a pathological hallmark of many chronic degenerative diseases and 
is characterised by the deposition of extracellular matrix following tissue damage or 
persistent inflammation [130]. While the inflammatory processes responsible for the 
onset of tissue fibrosis are context dependent, the clinical features are often similar. 
Most fibrotic disorders are caused by persistent irritants that sustain the production 
of growth factors, pro-inflammatory cytokines and angiogenic factors that promote 
the accumulation of connective tissue components (e.g., hyaluronic acid, 
fibronectin, and interstitial collagens), and eventually alter the normal tissue 
architecture [31].  
The molecular mechanisms that drive fibrosis are intrinsically linked with 
those that promote wound healing. In the late phase and resolution of inflammation, 
inflammatory macrophages secrete different growth factors such as TGF-b1 and 
PDGF so as to regenerate the tissue and return to homeostasis (Sections 1.1.7 & 
1.1.8). These factors stimulate the proliferation of epithelial cells to surround the 
injury site and the formation of new blood vessels [31]. For example, TGF-b1 acting 
via the transcription factors Smad promotes the differentiation of fibroblasts and 
resident epithelial cells into collagen-producing myofibroblasts [131, 132]. In 
addition, the IL-6 family cytokine oncostatin-M (OSM) has also been shown to 
promote myofibroblast differentiation via Jak/STAT pathway activation. [133]. 
Activated myofibroblasts stimulate wound contraction and sustain the migration of 
endothelial and epithelial cells to regenerate the damaged tissue and complete the 
wound healing process [31].  
However, during persistent or unresolved inflammation this repair process 
becomes dysregulated and contributes to scarring. Several cell types can be 
responsible of the onset of fibrosis. In particular, myofibroblasts are one of the main 
stromal cells implicated in the production of pathological ECM proteins, including 
collagen type I [130, 134]. They also modulate the ECM properties by expressing 
cross-linking enzymes such as lysyl oxidases [135] and transglutaminases [136], which 
are responsible for collagen and elastin cross-linking and support their stability 
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against metalloproteases [135]. For example, OSM-mediated myofibroblast 
differentiation promotes idiopathic pulmonary [137] and kidney fibrosis [133]. 
In addition to myofibroblasts, macrophages also contribute to the onset and 
regulation of fibrosis [138]. However, their precise role in the pathology is 
controversial. Here, some studies have shown macrophages to promote the 
differentiation and activation of myofibroblasts, and changes in the relative 
expression of MMPs and tissue inhibitors of metalloproteinases (TIMPs) in 
macrophages at the site of injury ultimately dictates the outcome of fibrosis [138]. 
Other studies have linked macrophage activity with the resolution of fibrosis in a 
mechanism involving arginase-1 and the inhibition of myofibroblast survival [139]. 
Therefore, it is likely that specific subpopulations of macrophages dictate pro- or 
anti-fibrotic outcomes. Ultimately, these involvements are likely to be context 
dependent, and specific to tissue microenvironment. 
Effector cytokine production by CD4 T-cells plays an integral role in the 
development of fibrosis. For example, the Th2-derived cytokines IL-4 and IL-13 
promote myofibroblast differentiation and activation [140], and stimulate the 
expression and function of several pro-fibrotic genes including collagen [141], 
arginase [142] and several MMPs and TIMPs [143, 144]. While these pro-fibrotic 
Th2 type responses often support signalling through TGF-b/Smad3 pathway, these 
activities may also arise in the absence of TGF-b [145].  
While Th2 activities have historically been regarded as pro-fibrotic, Th1 
responses are frequently considered protective or anti-fibrotic [31, 146]. Indeed, 
Th1 and Th2 effector cytokine responses often oppose each other [146]. In this 
regard, several studies have shown that the Th1 cytokines IFN-g and IL-12 decrease 
collagen deposition in models of schistosomiasis [147], pulmonary [148, 149], liver 
[150] and kidney fibrosis [151]. However, these activities are typically context 
dependent, and several recent investigations challenge this Th1/Th2 paradigm. For 
example, in our model of recurrent peritoneal inflammation, fibrosis is Th1-
dependent [33]. In this model, IFN-g-mediated STAT1 signalling in the peritoneal 
membrane alters the correct turnover of the ECM and leads to fibrosis [33] (Section 
1.3.5). Importantly, in this context fibrosis onset does not rely on the traditional 
pro-fibrotic cytokines OSM, IL-4, IL-13 or TGF-b1 [33, 152]. The involvement of 
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IFN-g in tissue remodelling has further been supported by observation in double 
Tcra-/-Socs1-/- mice, where the development of colitis is promoted by excessive 
IFN-g-mediated STAT1 signalling [153]. In addition, recent studies have shown that 
Th1 cells locate in close proximity to activated hepatic stellate cells and areas of 
fibrosis in patients with biliary atresia [154]. Here, IFN-g secretion by Th1 cells 
promotes a STAT1-mediated proliferation and secretion of pro-fibrogenic markers 
by hepatic stellate cells [154]. Collectively, these studies suggest that the 
involvement of Th1 cells in fibrosis is specific to the local tissue microenvironment, 
and dependent on the inflammatory context. 
 
1.6.  The peritoneal membrane 
The peritoneal membrane is a heterogeneous, serous membrane that overlies 
the surface of all intra-abdominal organs, the diaphragm, and the parietal peritoneal 
wall. It is formed from a superficial mesothelial layer attached to a basement 
membrane. Underneath the basal membrane is a submesothelial compact zone 
consisting of connective tissue, fibroblast, peritoneal resident macrophages and 
blood vessels, and the underlying abdominal wall muscle (Figure 1.7) [155].  
The peritoneal membrane has long been used as a dialysis membrane for renal 
replacement therapy in end-stage renal failure patients [156]. Under optimal 
conditions, the peritoneum acts as semi-permeable membrane that allows the 
efficient removal of metabolites, uremic toxins, salt and water from the patient. In 
this regard, peritoneal dialysis (PD) presents several advantages when compared to 
haemodialysis, including protection of residual renal functions [157]. However, it 
also presents major obstacles to sustain a long-term treatment. Here, repetitive 
infections and deleterious functional alterations in the peritoneal membrane after 
exposure to dialysis solutions are linked with thickening of the sub-mesothelial 
compact zone and peritoneal fibrosis [34-36, 158]. The ultimate consequence of 
these alterations are loss of ultrafiltration and treatment failure, which is responsible 
of increased mortality and morbidity in patients with end-stage renal failure [158]. 
During the past few decades, several animal models have been developed to 
understand the aetiology, mechanisms and stages involved in the exacerbation of 
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peritoneal tissue injury [159, 160]. These include both acute and chronic animal 
models [161-163]. Acute models describe experiments of short duration that study 
the impact of a single dwell in the peritoneal membrane (Sections 2.3.2 & 2.3.3). 
Chronic models such as the catheter implantation and peritoneal dialysis exposure 
model evaluate the impact of peritoneal dialysis fluids used in human therapy. These 
models are designed to replicate the events associated with prolonged exposure to a 
dialysis regime [163]. Such models provide opportunities to test the impact of 




1.7.  Neutrophils 
Neutrophils are polymorphonuclear leukocytes with a nucleus segmented in 
three to five connected lobules that constitute the most abundant population of 
circulating blood cells in humans. Their cytoplasm is characterized by the presence 
of “specific” granules filled with enzymes such as lysozyme, collagenase and elastase; 
and “azuphilic” granules, which are lysosomes containing enzymes and diverse 
microbicidal substances, including defensins and cathelicidins [1]. 
Neutrophils are produced in the bone marrow from a common lineage with 












Figure 1.7. Peritoneal membrane structure. The peritoneum is a serous 
membrane formed by a superficial mesothelial layer followed by a submesothelial 
compact zone (SMC) consisting of connective tissue, fibroblast, peritoneal resident 
macrophages and blood vessels. Underneath the SMC zone lies the abdominal wall 
muscle.  
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granulocyte colony-stimulating factor (G-CSF) [1], and they are released to the 
circulation where they last for around 3-5 days [165]. Upon pathogen invasion, 
neutrophils are quickly recruited to the site of the infection and they constitute the 
main effector cells during the early stages of inflammation (Section 1.1.6).  
Historically, neutrophils have been regarded as a homogeneous cell 
population with specific functions. However, investigations by Tsuda and co-
workers have shown that different neutrophil subsets present distinct effector 
characteristics as defined by specific cytokine production, an ability to control 
macrophage activation, and the expression of TLRs and other surface antigens [166]. 
The effector characteristics of this cells, as well as the mechanisms involved in their 
activation will be discusses in the following sections. 
1.7.1.  Neutrophil recruitment 
Neutrophil recruitment to the inflammation site is a multistep process that 
requires their tethering and rolling along the endothelial surface followed by an arrest 
and transmigration into the inflamed tissue. Collectively, these processes are known 
as the leukocyte adhesion cascade, and have been extensively reviewed by Ley and 
colleagues [167]. Briefly, inflammatory activation leads to the expression of P- and 
E-selectins on the surface of activated endothelial cells [168]. Shear-stress mediated 
interactions between selectins and their ligands on the surface of circulating 
neutrophils allow them to adhere to the endothelium and roll [169]. Selectin 
engagement to their ligands as well as chemokine signalling induce integrin activation 
in the rolling neutrophil [170]. Here, interaction of the activated b2 integrin in the 
neutrophils with intercellular adhesion molecule (ICAM)-1 in the endothelium 
promotes neutrophil arrest [171] and subsequent crawl inside the high endothelial 
venules (HEV), seeking optimal sites for transmigration towards the chemoattractant 
gradient [172, 173]. Once at the site of inflammation, neutrophils become fully 
activated – or primed – to elicit their effector functions in order to eliminate the 
invading pathogens. 
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1.7.2.  Neutrophil priming 
Neutrophils in circulation are quiescent so as to minimize the release of 
reactive oxygen species (ROS) and proteolytic granules that otherwise would induce 
tissue damage [174]. Neutrophil activation is therefore required so that these cells 
are fully effective at the site of infection or injury. Neutrophil priming is usually a 
two-step process that is initiated during their extravasation from the blood to the 
inflamed tissue. This is subsequently followed by a full neutrophil activation by pro-
inflammatory stimuli local to the site of disease [174]. These priming factors can be 
divided into early-phase cytokines (e.g., TNF-a and IL-1b) and PAMPs (e.g., 
endotoxin); or late-phase chemoattractants and growth factors, including CXCL1, 
CXCL8 and LTB4 [175, 176]. Priming can also occur by interaction between the 
neutrophils and endothelial surfaces during extravasation [177], and is essential to 
ensure the optimal production of reactive oxygen species, bioactive lipid mediators 
[177] and degranulation [175, 178].  
1.7.3.  Neutrophil effector functions 
Neutrophils deliver a microbicidal response through several mechanisms. The 
following section will discuss the capacities of neutrophils to undergo phagocytosis, 
respiratory burst, degranulation and NETosis – the formation of extracellular DNA 
traps (NETs) (Figure 1.8).   
Phagocytosis 
Phagocytosis is a form of endocytosis performed by specialised cells in which 
solid particles including microorganisms, dead or dying cells and cell debris are 
engulfed from the extracellular space. To do so, neutrophils express a broad range 
of receptors capable of recognizing these solid particles. For example, Fc-receptors, 
complement receptors, scavenger receptors, integrins, lectin and TLRs [179]. Some 
receptors such as TLRs directly recognise conserved PAMPs expressed in the surface 
of invading pathogens and mediate phagocytosis. Other receptors, such as Fc-
receptors and complement receptors, rely on the recognition of pathogens by 
different host molecules to undergo phagocytosis (Figure 1.9). For example, binding 
of FcgR1 to the conserved Fc regions of IgG [180], and binding of complement 







Figure 1.8. Neutrophils elicit their antimicrobial activities by different 
mechanism. Neutrophil effector functions against pathogens include their ingest 
by phagocytosis and their degradation through the generation of free radicals 
(respiratory burst), which oxidize a broad range of organic molecules. 
Degranulation releases contents of the secretory granules, including antimicrobial 
peptides, iron binding proteins and enzymes. Neutrophils can also produce and 
release cytokines that further amplify the inflammatory cascade; and they can 
undergo NETosis, where the release of decondensed chromatin together with 
antimicrobial peptides trap the pathogens and promote their degradation.    
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Figure 1.9. Neutrophil can recognize and engulf invading pathogens 
using several phagocytic receptors. Some of these receptors (e.g., Fc 
receptors) rely on the previous opsonisation of the pathogen by different host 
molecules, such antibodies and the complement protein iC3b. Other receptors 
(e.g., TLRs) directly recognize conserved determinants in the surface of the 
microbes, resulting in the engulfment of the pathogen. Adapted from ref 179.  
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receptor CR3 to iC3b [181] mediates the phagocytosis of the respective IgG- and 
iC3b-opsonized particles.  
After internalization, microbes are contained within a phagosome, which then 
fuses with lysosome granules to form a phagolysosome. The release of the digestive 
and antibacterial compounds into the phagolysosome permits the degradation of the 
engulfed pathogens [182]. In addition, the assembling of the NADPH oxidase 
complex at the phagosome membrane allows the production of superoxide and other 
ROS within the vesicle and the killing of microbes [183]. Therefore, phagocytosis 
and the production of ROS are two processes strongly related. For a more detailed 
review of phagocytosis, referrer to [179]. 
Respiratory burst 
Phagocytosis by neutrophils is accompanied by an increase in oxygen 
consumption termed respiratory burst, which is caused by the assembly and 
activation of the NADPH oxidase complex in the membrane of the phagosomes 
[184]. There are seven members of the NADPH oxidase family (also termed NOX), 
which are implicated in different events including host defence, cellular signalling 
and the regulation of gene expression. Their structure and functions have been 
extensively reviewed before [185]. The NAPDH oxidase present in phagocytes is the 
complex NOX2, which comprises six different subunits: the catalytic subunit 
gp91phox (a flavocytochrome) and the regulatory subunits p22phox, p40phox, p47phox, 
p67phox, and RAC2. Altogether, the complex mediates the transference of an electron 
from the reduction of the substrate NADPH across the phagosome membrane to 
molecular oxygen inside the phagosome to generate superoxide (O2-) ion (Figure 
1.10) [185]. Eventually, this O2- can also be converted into other ROS either 
spontaneously or by the action of several enzymes (Figure 1.11).  
Collectively, ROS can oxidase non-specifically a broad range of organic 
molecules, damaging DNA, carbohydrates, lipid cell membranes and proteins, and 
they constitute an essential mechanism for killing microbes. The importance of the 
respiratory burst as a major antimicrobial mechanism is perhaps best illustrated in 
inherited deficiencies of the enzyme NOX2, such as chronic granulomatous disease. 
Here, genetic mutations that affect any of the 4 genes encoding protein  
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Figure 1.11. NAPDH oxidase complex initiates the production of 
superoxide. Upon neutrophil activation, the cytosolic subunit p47phox 
becomes phosphorylated and translocates to the membrane of the phagosome, 
where it interacts with the integral membrane proteins gp91phox and p22phox 
(cytochrome b558). This leads to the binding of the subunits p40phox, 
p67phox and RAC-GTP, which form the active NAPDH oxidase complex. The 
active complex transfers an electron from NAPDH across the phagosome 
membrane to molecular oxygen inside the phagosome to generate superoxide 
(O2-). 
Figure 1.10. Summary of the generation of free radicals by 
neutrophils. Superoxide produced by the NADPH oxidase complex can be 
further catalysed to hydrogen peroxidase by the enzyme superoxide dismutase. 
Hydrogen peroxide can be converted to hypochlorite by myeloperoxidase, or 
together with superoxide and transition metal ions can be spontaneously 
converted into hydroxyl radical. Nitric oxide synthase catalyses the formation 
of nitric oxide from L-arginine. Together with superoxide, nitric oxide can for 
peroxynitrite anion. 
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components of NOX2 are associated to the inability of patients to deal with 
pathogens, resulting in chronic and often fatal infections [186]. In particular, the X-
linked form of chronic granulomatosis disease arise from mutations of the catalytic 
subunit gp91phox [187], while the autosomal recessive forms are associated to 
mutations of the genes for p22phox, p47phox, or p67phox [188, 189]. 
Degranulation 
Degranulation is another neutrophil antimicrobial mechanism consisting in 
the release of cytoplasmic granules into the extracellular space or the phagosome 
[190]. Neutrophils contain four different types of granules: (1) primary granules 
(azuphilic granules), that contain toxic mediators such as elastase, cathepsins and 
defensins; (2) secondary granules (specific granules), and (3) tertiary granules, that 
contain lactoferrin and MMP9, respectively, together with other molecules; and (4) 
secretory vesicles [190].  
Upon receptor stimulation by a secretagogue, cytoplasmic granules are 
released following a four-step mechanism  [191]: (1) the granule is recruited from 
the cytoplasm to the plasma or phagosome membrane in a process that relies on the 
actin cytoskeleton remodelling; (2) the secretory vesicle outer lipid bilayer contacts 
the inner surface of the target membrane by tethering and docking; (3) a fusion pore 
is formed between both membranes, which finally (4) expands and completes the 
fusion of the granule to the target membrane and the release of the granular content 
[192]. 
Degranulation must be a tightly regulated process in order to prevent tissue 
damage, as neutrophils granules are highly enriched in tissue-degrading proteases. 
Thus, the release of granules depends on non-redundant receptor-mediated 
activation of intracellular pathways, including b-arrestins, the Rho guanosine 
triphosphatase Rac2, and others. In addition, initiation of NADPH oxidase activity 
coincides to degranulation, and occurs after the fusion between the cytoplasmic 
granules into the phagosome [193, 194]. Here, NADPH oxidase activity may control 
the pH within the granule to support optimal proteolytic activity. For a more in 
depth review on degranulation, see [190]. 
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NETosis 
NETosis is a form of cell death characterised by the release of decondensed 
chromatin and other granules to the extracellular space following nuclear and granule 
membrane disintegration [174]. It is a relative slow antimicrobial process whose 
mechanism of activation depends on a broad variety of stimuli, including cytokines 
such as TNF-a and IL-8, or PAMPs from different pathogens. For example, NETosis 
stimulated with microbial products requires NADPH oxidase activity to function 
[195], whereas the induction of NETosis by soluble immune complexes can be also 
achieved in the absence of ROS [196]. 
Extracellular traps provide antimicrobial activities by several mechanisms. 
First, the stickiness of the decondensed chromatin acts as a net that traps pathogens, 
which are then exposed to the different antimicrobial peptides linked within the 
chromatin, including myeloid peroxidase, neutrophil elastase, S100 calcium-binding 
protein A1 (S100A), and lactoferrin-chelating proteins [174]. In addition, histones 
themselves present significant antimicrobial activity [197]. Conversely, the 
abundance of pro-inflammatory mediators within the NETs have some detrimental 
effects, and excessive NET formation has been associated with several pathologies 
such as sepsis [198] and systemic lupus erythematosus nephritis [199].  
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1.8.  Aims and hypothesis 
Previous studies in the Jones laboratory have demonstrated that IL-6 acting 
via its soluble receptor is essential for competent host defence in a model of acute 
resolving peritonitis. This effective antimicrobial response is associated with STAT3 
activation in the peritoneal lining. Conversely, repetitive episodes of bacterial 
infection lead to peritoneal fibrosis, which is a major cause of treatment failure in 
end-stage renal failure patients in peritoneal dialysis. Here, fibrosis is driven by the 
IL-6-dependent proliferative expansion of Th1 cells and the activation of IFN-g-
mediated STAT1 signalling in the membrane (Figure 1.5).  
We hypothesise that changes in the relative activities of STAT1 and STAT3 in 
the peritoneum will alter the outcome of inflammation to dictate transition from 
successful resolution to deleterious tissue damage. The aim of this thesis is to provide 
a holistic interpretation of the genes regulated within the peritoneal membrane 
following inflammatory activation. Specifically, this thesis aims to: 
1.8.1.  Optimise an RNA-sequencing pipeline and library preparation from 
tissue 
Experiments will optimise RNA extraction from peritoneal tissue and cDNA 
library preparation for subsequent high-throughput RNA-sequencing. Studies aim to 
establish a comprehensive pipeline for downstream RNA-seq analysis and 
interpretation.  
1.8.2.  Identify gene targets that influence the course of inflammation during a 
“resolving” and a “pro-fibrotic” environment 
Adopting a holistic approach, experiments will explore changes in gene 
expression during acute resolving inflammation and during a pro-fibrotic setting in 
WT and Il6-/- mice. Molecular pathways analysis will be used to identify potential 
mechanisms by which the stromal compartment shapes the outcome of immune 
response against infection.  
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1.8.3.  Understand the mechanisms by which IL-6 activates the local stromal 
compartment to direct a successful host defence 
Studies will assess the impact of IL-6 trans-signalling within the stromal 
microenvironment to direct neutrophil effector function at the early stages of 
infection. Experiments will focus on how stromal derived signals indirectly 
contribute to neutrophil phagocytosis and respiratory burst.  
1.8.4.  Identify a potential novel form of murine soluble gp130 
RNA-sequencing will be used to identify a potential new form of murine 
soluble gp130 arising from alternative splicing of the Il6st gene. Experiments will 
aim to purify and characterize this novel form of this protein.  
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 Materials and Methods 
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2.1.  Reagents 
All the reagents used in this thesis were purchased from Sigma unless 
otherwise specified.  
 
2.2.  Bacterial cultures  
2.2.1.  Bacterial strains   
Staphylococcus epidermidis (strain ATTC 12228) was used to induce bacterial 
peritonitis in vivo (Section 2.3.3), and to perform in vitro phagocytosis assays (Section 
2.4.3). A clinical isolate of S. epidermidis, termed SH, was used to produce 
S. epidermidis cell free supernatant (SES) (see Section 2.3.2). Both bacterial stocks 
were stored in glycerol at -80ºC. 
2.2.2.  Growth of bacterial cultures 
Using a sterile inoculating loop, a sample of dormant S. epidermidis stock was 
streaked onto an LB agar plate (OXOID). Bacterial growth was promoted by 
incubation at 37ºC for 48 h. Single colonies were captured and used to inoculate 
125 ml flasks containing 10 ml of nutrient broth nº2 (OXOID). The culture was 
incubated for 6 h at 37ºC with gentle agitation (180 rpm) unless otherwise 
specified. To standardize the growth phase of the bacterial cultures, 60 µL of 
culture were transferred to 250 ml flasks containing 60 ml of fresh nutrient broth 
nº2, before incubation for 18 h at 37ºC with gentle agitation. 
2.2.3.  Fluorescent labelling of bacteria 
The optimal inoculum of bacteria for in vivo and in vitro experiments has 
been empirically determined by previous studies in the Jones laboratory [200]. For 
in vitro assays, cultures were diluted to an OD of 0.5 at 650 nm (corresponding to 
5.0x108 cfu/ml). For in vivo experiments, cultures were diluted to an absorbance 
of 1.10-1.15 at 650 nm (1x109 cfu/ml). The suspension was then centrifuged 
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(2000xg, 5 min) and the pellet resuspended to the same inoculum volume 
containing Cell Trace Far Red (CT-FR) (Life Technologies) (1 µM or 8 µM for in 
vitro and in vivo, respectively) in pre-warmed phosphate buffered saline (PBS; 
pH7.4) for 20 min at 37ºC. The reaction was stopped by diluting the suspension in 
5 volumes of RPMI 1640 (Gibco) containing 1% (w:v) of bovine serum albumen 
(BSA), before incubation at 37ºC for 5 min. Cultures were opsonized (Section 2.2.4, 
for ex vivo experiments) or centrifuged and washed 3 times in PBS, before re-
suspending to the initial inoculum volume in sterile PBS (for in vivo experiments). 
2.2.4.  Bacterial opsonisation  
Cell Trace Far Red stained bacteria were opsonized with serum 
corresponding to the neutrophil genotype from which they were isolated (e.g., 
neutrophils from Wild Type (WT) mice were incubated with serum obtained from 
these mice). Briefly, fluorescently labelled bacteria (Section 2.2.3) were 
resuspended in PBS containing 10% (v:v) serum and incubated for 15 min at 37ºC. 
Bacteria were pelleted by centrifugation (2000xg, 5 min) and washed 3 times in 
PBS before re-suspending in serum-free RPMI 1640. 
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2.3.  In vivo experiments 
2.3.1.  Mouse strains 
8-12 weeks old WT C57Bl/6 mice were purchased from Charles River. In-
house C57Bl/6 interleukin-6 (Il6-/-) and interleukin-6 receptor knock out (Il6ra-/-) 
mice were bred in accordance with UK Home Office regulations and procedures 
(PPL 30/2938 and PPL P05D6A456). Il6-/- and Il6ra-/- mice were generated as 
previously described [61, 100].   
2.3.2.  Preparation of Staphylococcus epidermidis cell-free supernatant (SES) 
and induction of sterile inflammation 
SES was prepared from a clinical isolate of S. epidermidis as described 
previously [20, 25]. S. epidermidis (SH strain) cultures were grown as described in 
Section 2.2.2. Bacterial growth was monitored until the culture medium went 
turbid. Bacteria were pelleted by centrifugation (2000xg for 20 min) and re-
suspended in Tyrode’s salt solution to an OD of 0.5 at 560 nm (corresponding to 
5x108 cfu/ml). The culture supernatant was collected 18-24 h later and filtered 
using a 0.22 µm Stericup filter bottle (Millipore). The bacterial extract was dialysed 
against deionized H2O at 4ºC for 8-12 h, with four changes of H2O in total. The 
dialysate was divided into 10 ml aliquots in universal tubes (gbo) and frozen 
at -20ºC overnight. Finally, aliquots were lyophilized in a freeze-drier (Edwards) 
and stored at -80ºC for up to one year.  
The bioactivity of SES was assessed in vitro. Briefly, resident peritoneal 
mononuclear cells were recovered by peritoneal lavage in complete RPMI 1640 
(RPMI 1640 supplemented with 10% (v/v) heat-inactivated foetal calf serum 
(FCS), 2mM L-glutamine, 1mM sodium pyruvate, 100U/ml penicillin, 100µg/ml 
streptomycin, and 55µM 2-mercaptoethanol; all from Life Technologies), and 
cultured as detailed in Section 2.4.1. Each vial of lyophilised SES was reconstituted 
in 1 ml of complete RPMI 1640. Cells were stimulated in a final volume of 1 ml 
containing serial dilutions of the prepared SES (1/1, 1/2, 1/4, 1/8, 1/16, 1/32). 
Control cells received complete RPMI 1640 alone. SES-conditioned media (SES-
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CM) was rendered cell free by centrifugation (500xg, 5 min), and the production 
of IL-6 and p40IL-12 measured by ELISA (Section 2.5.9) (Figure 2.1).  
Acute peritoneal inflammation was induced in WT and Il6-/- mice through 
the intraperitoneal (i.p.) administration of SES. Lyophilised SES was reconstituted 
in 0.75 ml of sterile PBS/vial (Gibco) and filtered using a 0.22 µm syringe filter 
unit (Millipore). Mice were treated with a 0.5 ml dose of the re-suspended SES 
[20, 25]. At defined time points, peritoneal lining tissue and lavage fluids were 





Figure 2.1. Validation of SES bioactivity in peritoneal monocytic cells.  
Peritoneal monocytic cells (1x106 cells/well; Section 2.4.1) were stimulated 
overnight in serial dilutions of SES (highest concentration, 1 part reconstituted SES 
to 1 part of 1 x 106 cells in complete RPMI 1640). IL-6 and p40-IL-12 production 
was quantified using ELISA in cell-free culture supernatants. Representative data 
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2.3.3.  Live model of S. epidermidis-induced peritonitis 
Live bacteria peritonitis was induced using a commercial strain of 
S. epidermidis (ATTC 12228 strain; Section 2.2.1). A single colony of S. epidermidis 
was isolated from a streaked agar plate and cultured as described in Section 2.2.2. 
The growth rate was periodically assessed by monitoring OD at 600 nm – OD of 
1.10-1.15 corresponding to 1x109 cfu/ml. Bacterial cultures (1x109 cfu/ml) were 
then centrifuged and resuspended in sterile PBS. 
Bacterial infection was induced in WT and Il6-/- mice through 
intraperitoneal injection of a non-lethal dose of 5x108 cfu/mice of S. epidermidis 
delivered in a volume of 0.5 ml of sterile PBS (Figure 2.2B).  
2.3.4.  Adoptive transfer of interferon-secreting CD4 T-helper cells   
CD4+ T-helper 1 cells were polarized and expanded according to Section 
2.4.2. For in vivo adoptive transfer, 0.5-1.0x106 Th1 cells were administered to 
WT, Il6-/- and Il6ra-/- mice (i.p.) in combination with 0.5 ml of SES (Section 2.3.2). 
Control mice received the same amount of sorted naïve CD4+ (Th0) T cells. At 3 
and 6 h after injection, peritoneal lining tissue and lavage samples were collected 
for subsequent analysis (Section 2.5) (Figure 2.2C).  
2.3.5.  In vivo neutrophil effector function assay 
To assess the activation and effector characteristics of infiltrating neutrophils 
in response to bacterial infection, mice were treated with CT-FR fluorescently 
labelled S. epidermidis (Section 2.2.3). WT and Il6-/- mice were administered (i.p.) 
with 5x108 cfu/mice of labelled S. epidermidis in 0.5 ml of sterile PBS.  
At desired time points, the peritoneal cavity was lavaged with 2 ml of RPMI 
1640 containing 5 µM of aminophenyl flueresceine (APF, from Life Technologies), 
a reactive oxygen species indicator that is sensitive for hydroxyl radical, 
hypochlorite or peroxynitrite anion (Figure 2.3). The lavage was incubated at 37ºC 
for 15 min and placed in an iced water bath. Cells were then collected by 
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centrifugation (500xg, 5 min), and stained for flow cytometry analysis using 








0 3 6 hrs.
SES +Th1C
WT Il6-/-
0 3 6 hrs.
S. epidermidis1xSESB
Figure 2.2. Murine models of peritoneal inflammation. A. Each vial of 
SES was reconstituted in 0.75 ml of sterile PBS, and wild type (WT) or IL-6 
deficient (Il6-/-) mice were intraperitoneally (i.p.) injected with 0.5 ml of 
resuspended SES. B. A defined dose of S. epidermidis (5x108 cfu/mice) was 
injected (i.p.) into WT and Il6-/- mice. C. Naïve CD4+ T cells were polarised into 
Th1 cells using anti-CD3, anti-CD28 and SES-CM, as specified in Section 2.4.2. 
Th1 cells were adoptively transfer (i.p) into WT, Il6-/-  and Il6ra-/- mice together 
with a single dose of SES. Control mice received an equivalent amount of sorted 
naïve CD4+ (Th0) T cells. At 3 and 6 h, peritoneal lavage and peritoneal tissue 
were collected for analysis. 
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2.4.  In vitro experiments 
2.4.1.  Generation of monocytic cell-derived SES-induced conditioned 
medium (SES-CM)  
Resident peritoneal mononuclear cells were recovered by peritoneal lavage 
(Section 2.5.3) from WT mice and cultured in completed RPMI 1640. Cells were 
seeded in a 24-well plate at a concentration of 1x106 cells/well and allowed to 
adhere. Non-adherent mononuclear cells were removed, and cells were stimulated 
overnight with SES at 37ºC, 5% CO2. Each vial of lyophilised SES was reconstituted 
in 1 ml of complete RPMI 1640. Cells were stimulated in a final volume of 1 ml 
containing 50% (v:v) reconstituted SES. SES-CM was rendered cell free by 
centrifugation (500xg, 5 min). 
2.4.2.  SES-CM differentiation of CD4+ T cells 
FACS-sorted WT naïve CD4+CD25-CD44loCD62Lhi cells (Table 2.2) were 
cultured in 96-well plates at a concentration of 1x105 cells/well in completed 
RPMI 1640 and activated with anti-CD3 (plate-bound, 1 µg/ml, 45-2C11) and 
anti-CD28 (soluble, 5 µg/ml, 37.51) co-stimulation in the presence of SES-CM 
(1:1) for 4 days at 37ºC and 5% CO2 [33]. After 4 days, T cells were re-stimulated 
with 50 ng/ml PMA and 500 ng/ml ionomycin in the presence of 3 µM of 
monensin for 3 h and stained with fluorescently-labelled antibodies for CD4 and 
IFN-g (Table 2.2). The proportion of IFN-g+ Th1 cells was assessed by flow 
cytometry (Section 2.5.8).  
2.4.3.  In vitro neutrophil effector function assay 
Neutrophils derived from the circulation of WT and Il6-/- mice were used 
to assess the anti-bacterial properties of these cells from the blood. Whole blood 
was collected by cardiac puncture (Section 2.5.1), diluted 1:10 and washed 3 times 
in ice cold PBS. Cells were resuspended in serum-free RPMI 1640 containing 5 µM 
of APF and incubated for 30 min at 37ºC.  
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APF-loaded cells were then split into 100 µl aliquots and cultured with the 
same volume of pre-warmed, opsonized CT-FR-stained S. epidermidis at 37ºC 
(Sections 2.2.3 & 2.2.4). Cells were incubated for pre-determined intervals 
(0-30 min) before transfer to an iced water bath. Treated cells were maintained on 
ice for the subsequent steps.  
Neutrophils were labelled with a fluorochrome-conjugated anti-Ly6G 
antibody (Section 2.5.8). After staining, cells were washed 3 times in Red Blood 
Cell lysis (Life Technologies), and resuspended in 200 µl of Flow buffer (PBS 
supplemented with 0.5% (w:v) BSA, 5mM EDTA and 7.5 mM sodium azide) for 
flow cytometry analysis (Section 2.5.8). 
 
   
Fe3+



















Figure 2.3. Aminophenyl flueresceine (APF) was used to monitor respiratory 
burst in neutrophils. This fluorescent probe can detect peroxynitrite anions, 
hydroxyl radical and hypochlorite (outlined in green).  
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2.5.  Sample collection and processing 
2.5.1.  Collection of whole blood 
Total blood from WT and Il6-/- was collected by cardiac puncture (1 ml 
syringe, 25G needle; both from BD) as to minimise platelet activation. Blood was 
immediately transferred to a BD™ Vacutainer™ Plastic K2EDTA tube (BD) 
containing EDTA as anticoagulant. Tubes were gently inverted 180º and back 8 to 
10 times to ensure mixing with the wall-coated EDTA and placed on ice until use.  
2.5.2.  Collection of blood serum  
Total blood was collected (Section 2.5.1) and transferred to a sterile tube 
before incubation for 30 min at room temperature to allow blood coagulation. 
Samples were rendered cell free by centrifugation at 2000xg for 10 min and the 
serum carefully transferred to a new tube.   
2.5.3.  Peritoneal lavage 
To harvest resident peritoneal mononuclear cells, the peritoneal cavity was 
lavage with 5 ml of complete RPMI 1640 (21G needle, BD) (see Section 2.3.2 & 
Section 2.4.2). For the immunodetection of inflammatory mediators, the peritoneal 
cavity was lavaged with 2 ml of sterile PBS (21G needle). Lavaged samples were 
rendered cell-free (2000xg, 5 min, 4ºC) and stored at -80ºC. For in vivo neutrophil 
phagocytosis assays, the cavity was lavaged with 2 ml of RPMI 1640 (21G needle) 
containing 5 µM of APF as described in Section 2.3.5.  
2.5.4.  Peritoneal membrane collection 
Parietal peritoneal membrane was collected using standard aseptic 
techniques. Two sections of the peritoneal lining were harvested (Figure 2.4) and 
immediately snap frozen in liquid nitrogen. Tissues sections were stored at -80ºC 
for RNA extraction (Section 2.5.5) and additional validation purposes.  




2.5.5.  Total RNA extraction from peritoneal membrane 
Total RNA was extracted using the RNeasy Mini Kit (QIAGEN). Here, the 
manufacturer’s protocol for total RNA extraction was adapted for fibrous tissue. 
All steps were performed in a laminar flow hood. Peritoneal membranes (Section 
2.5.4) were weighed and homogenised in 1 ml of RLT Buffer supplemented with 
b-Mercaptoethanol (1:100 v:v) per 80 mg of tissue using a D1000 Handheld 
Homogenizer (Benchmark Scientific). The suspension (600 µl) was diluted with 2 
volumes of RNase-free water and treated with proteinase K (Invitrogen, 
0.2 mg/ml final concentration) for 10 min at 55ºC. Samples were centrifuged at 
10,000xg for 5 min to remove debris, and the supernatant transferred to a new 
tube containing an equal volume of 70% (v:v) ethanol. Total RNA was extracted 
using a 15 min in-column DNase digestion protocol as outlined in the 
manufacturer’s instructions (QIAGEN). RNA was eluted in 50 µl of RNase-free 
water, and its quantity, purity and integrity assessed using a NanoDrop 2000 
Spectrophotometer (Thermo Scientific) and RNA Nano chip analysis on the Agilent 
2100 Bioanalyser (Agilent).  
2.5.6.  Complimentary (c)DNA synthesis 
Total RNA was reverse transcribed into c DNA using a random 
oligonucleotide primer method (Precision nanoScript 2 Reverse Transcription kit; 
Primer design). For all samples, cDNA was generated from 1 µg of total RNA 
(Section 2.5.5) as described in the manufacturers’ instructions. Resulting cDNA was 
diluted 1:2 to obtain a final concentration of 25 ng/µl and stored at -20oC for up 
to 6 months. 
Figure 2.4. Representation of the mouse 
abdomen. The parietal peritoneal membrane 
was sampled in two halves. Half 1 was used to 
extract RNA. Half 2 was stored for further 
validation. 
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2.5.7.  Quantitative Polymerase Chain Reaction (qPCR)  
Gene expression was quantified by qPCR using TaqMan Gene Expression 
Assay (Applied Biosystems) chemistry, and following manufacturers’ instructions. 
The reaction was performed in a MicroAmp Optical 384-well Reaction Plate with 
Barcode (Applied Biosystems), using 5 µl of TaqMan Fast Advanced Master Mix, 
0.5 µl of TaqMan Gene Expression Assay (consisting in the primers and probes; 
Table 2.1), 3.5 µl of nuclease-free water and 1 µl of cDNA (generated as outlined 
in Section 2.5.6), and using the Fast protocol in the QuantStudio 12K Flex Real-
Time PCR system (Applied Biosystems). 
Data was analysed using a comparative threshold cycle (Ct) method [201, 
202]. This method equates the expression of the gene of interest as relative to an 
internal housekeeping control gene. Here, Ct values are defined as the PCR cycle 
number in which the signal of the reporter crosses an arbitrary placed threshold 
within the exponential phase of amplification. Ct is inversely related to the amount 
of amplicon or target gene present in the sample. Thus, a more abundant amplicon 
reaches the exponential phase of amplification sooner, resulting in a lower Ct value.  
Ct values for each gene of interest are then standardised against a comparative 
analysis of control housekeeping genes. In the present thesis, the gene Tbp was used 
as internal housekeeping control.  
 
 
Table 2.1. List of primers used in this thesis 
 
Gene Specie Assay ID Dye Amplicon Length 
Tbp Mouse Mm00446971_m1 FAM-MGB 93 
Socs3 Mouse Mm00545913_s1 FAM-MGB 76 
Irf1 Mouse Mm01288580_m1 FAM-MGB 66 
Isg15 Mouse Mm01705338_s1 FAM-MGB 107 
Il1b Mouse Mm00434228_m1 FAM-MGB 90 
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2.5.8.  Flow cytometry  
For antibody staining of cell surface markers, cells (2x105 cells) were 
resuspend in 50 µl of Blocking Buffer (Flow buffer containing 0.008% (v:v) Fc-
Block; anti-CD16/CD32), and incubated for 10 min at 4ºC. After blocking, 50 µl 
of fluorochrome-conjugated antibodies specific for cell surface proteins were added 
and incubated for 30 min at 4ºC. See Table 2.2 for specific information on 
antibodies used in flow cytometry. Cells were washed twice in Flow buffer, 
resuspended in 200 µl Flow buffer and immediately acquired using a Beckman 
Coulter Cyan-ADP flow cytometer. For imaging flow cytometry, cells were 




Table 2.2. List of antibodies used in this thesis 
 
Antibody Specie Conjugated Clone Company 
CD62L anti-mouse FITC MEL-14 eBioscience 
CD25 anti-mouse PE PL61.5 eBioscience 
CD44 anti-human/mouse APC IM7 eBioscience 
CD4 anti-mouse PerCP-Cyanine5.5 RM4-5 eBioscience 
IFN-g anti-mouse FITC XMG1.2 eBioscience 
Ly6G rat anti-mouse v450 1A8 BD Bioscience 
CD16/ 
CD32 rat anti-mouse - 2.4G2 BD Bioscience 
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2.5.9.  Enzyme-linked immunosorbent Assay (ELISA) 
Inflammatory cytokines were quantified in peritoneal lavage, cell cultures 
supernatant and serum samples using commercially available ELISA. All ELISA 
protocols were based on the manufacturer’s instructions. Table 2.3 summarizes the 
assays used and provides information relevant to the capture and detection 
antibodies, as well as the sensitivity range of the assay. 
 
 
Table 2.3. List of ELISA kits used in this thesis 
 
  









R&D Systems DY406 2.0 µg/ml 1000-15.6 pg/ml 150 ng/ml 
IL-6R R&D Systems DY1830 3.0 µg/ml 3000-46.9 pg/ml 400 ng/ml 
gp130 R&D Systems DY468 2.0 µg/ml 8000-125 pg/mL 100 ng/ml 
IFN-g R&D Systems DY485 4 µg/ml 
2000-31.3 
pg/ml 400 ng/ml 
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2.6.  Statistical analysis 
The resource equation was used to determine the most appropriate 
statistical group size for in vivo experiments where no previous data was available 
for power analysis. 
Resource equation:  E=N-T-B 
Where; E =10-20, N=total number of animals, T=Number of treatments and 
B=Block degrees of freedom in the Analysis of variants (ANOVA). 
When preliminary data was available, power calculation (0.95 power) was 
performed using G power software. While individual experiments were conducted 
with small group numbers, comparisons between independent experiments and 
historical data showed a high degree of consistency. In addition, experimental 
mouse numbers were often restricted by the availability of mice, and where 
possible the study design was adapted to accommodate the principles of the 3Rs in 
animal research [203]. 
Statistical analysis was performed using Graph Pad Prism version 6. One-
way analysis of variance (ANOVA) with Bonferroni correction was used to 
determine significant difference between the means of three or more independent 
groups. Time course experiments consisted of two variables (time and treatment) 
and therefore were analysed by two-way ANOVA, with Bonferroni post-tests to 
compare treatments between individual time points and conditions. Correlation 
between two variables was assessed by linear regression.  p <0.05 were considered 
significant, and all data points plotted as mean ± SEM as outlined in the individual 
figure legends. 
Specific mathematical modelling and statistical analysis for clustering is 
detailed in Chapter 3 and 4 (Sections 3.2.11 & 4.2.2). 
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 RNA-sequencing of the inflamed 
peritoneal membrane 
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3.1.  Introduction 
DNA sequencing methods have revolutionised the way in which we study 
genomic and epigenetic information. Sequencing reactions were traditionally built 
around the ‘first generation’ automated Sanger method. Sanger sequencing 
dominated the industry for many years and contributed to the first annotated 
sequence of the human genome [204]. Recent advances have led to the 
development of next-generation sequencing (NGS) platforms that are cheaper, 
faster and more accurate [204]. The introduction of these methods enabled the 
study of genetics, gene regulation, epigenetics and large-scale population-based 
investigations. 
Advances in the next generation sequencing of RNA (termed RNA-
sequencing or RNA-seq) has displaced hybridization-based approaches (i.e. 
microarrays) for transcriptome analysis. These methods offer several advantages. 
Unlike microarrays, RNA-seq is not limited to detecting transcripts that 
correspond to already known genome sequences [205, 206]. In addition, RNA-seq 
now allows studies of coding and non-coding RNAs, and investigations of 
differential mRNA splicing and small RNA variants [205, 206]. Thus, RNA-seq 
provides a holistic and unbiased interpretation of gene regulation. 
In this Chapter, experiments describe the development of an RNA-seq 
platform and downstream bioinformatics pipeline for the study of inflammation-
induced gene changes in the peritoneal membrane of SES challenged mice.  
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3.2.  Materials and Methods 
3.2.1.  In vivo models of inflammation and samples  
RNA-seq was established to profile the transcriptome of the peritoneal 
membrane during acute resolving inflammation. This approach allowed a 
computational analysis of STAT1 and STAT3 gene signatures in response to IL-6, 
and settings where IFN-g secreting Th1 cells contribute to the local inflammation 
[33]. Acute inflammation was induced in WT and Il6-/- mice by the (i.p.) 
administration of a single dose of SES (Section 2.3.2). Parietal peritoneal tissue was 
extracted at 3 and 6 h post SES administration (Section 2.5.4). These coincide with 
the optimal timing of STAT1 and STAT3 activation in the peritoneal membrane of 
SES challenged mice [33]. Unchallenged WT and Il6-/- mice were used as controls. 
Recurrent peritoneal inflammation promotes peritoneal fibrosis through the 
expansion of IFN-g secreting CD4+ Th1 cells [33]. To replicate this pro-fibrotic 
state, ex vivo expanded Th1 cells were adoptively transferred into mice together 
with SES (Section 2.3.3). In this regard, the adoptive transfer of ex vivo SES-polarised 
Th1 cells restores peritoneal fibrosis in Il6-/- mice that are normally protected from 
this form of pathology [33]. Peritoneal tissue was harvested at 3 and 6 h post 
treatment and compared to mice adoptively transferred with an equivalent number 
of naïve CD4+ T cells (Th0).  
3.2.2.  RNA sequencing 
 High-throughput RNA sequencing was performed using the Ion Proton™ 
Next-Generation Sequencing System (Life Technologies) that uses an ion 
semiconductor sequencing technology based on the detection of hydrogen ions 
released during DNA polymerization [207, 208]. In this technology, cDNA 
libraries are loaded into Ion SpheresTM Particles (ISP), which encapsulate the 
automated amplification of the DNA template. DNA is then sequenced using an ion 
semiconductor technology (Figure 3.1) [207, 208].  
The pipeline for RNA sequencing is outlined in Figure 3.2. To minimize 
batch effects and avoid technical bias, samples were randomized within each 
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experiment (i.e. samples derived from SES alone treatment groups and those 
including Th1 cells) prior to library preparation.  
3.2.3.  Input RNA and integrity assessment 
Total RNA extracted from the peritoneal membrane of WT and Il6-/- mice 
(Section 2.5.5) was used as input. Samples displaying an RNA Integrity Number 
(RIN) of >8 were selected for the construct of libraries for sequencing (Figure 
3.2B). While high integrity and purity is critical for the success of RNA-based 
approaches (i.e. transcriptome analysis), samples with a similar RIN value ensure a 
consistent and comparable output for subsequent differential gene expression 
analysis [209]. RIN was calculated using the RNA Integrity Number Algorithm with 
the Agilent 2100 Bioanalyser system software (Agilent) [210]. This approach takes 
into account characteristics of different regions of the electropherogram (a 
visualised trace of the electrophoresis) recorded by the Agilent 2100 Bioanalyser to 
get a robust and reliable prediction of the RNA integrity.  
For library preparation, 2-4 µg of total RNA was used as an input. This 
concentration of RNA was optimised to reduce the number of duplicate reads 
derived from the final library preparation (Sections 3.2.9 & 3.3.4). 
  






Figure 3.1. Overview of the Ion Proton System for NGS. A. Templates are 
attached to the Ion Spheres Particles (ISP), where they are amplified by PCR. B. 
ISPs are then loaded in the microchip’s wells. The wells are loaded sequentially 
with dATP, dCTP, dGTP and dTTP. Upon inserted of one of these nucleotides 






Figure 3.2. RNA sequencing workflow. A. Schematic overview of the RNA-
seq pipeline. B. Total RNA was extracted from WT and Il6-/- mice. Only samples 
with RIN of >8 were used. C. Ribosomal RNA (rRNA) was depleted from 4 µg of 
total RNA input. D. rRNA-depleted total RNA was then fragmented. E. The 
fragmented, rRNA depleted RNA was converted into cDNA and amplified (using 
10 cycles of PCR). Final libraries were diluted to a final concentration of 35 pM 
and barcoded for sequencing. F. Reads were mapped to the Mus musculus reference 
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3.2.4.  Ribosomal RNA depletion  
The RiboMinusTM Eukaryote System v2 (ambion) was used to remove 
cytoplasmic (5S, 5.8S, 18S and 28S) and mitochondrial (12S and 16S) ribosomal 
(r)RNA from the extracted RNA sample. This system utilises oligonucleotide 
process designed against highly conserved regions of eukaryotic rRNA. Probes are 
bound to magnetic beads, and rRNA removed by negative selection using magnetic 
separation. 
Residual rRNA contamination was assessed on an Agilent 2100 Bioanalyser. 
All samples showed <1% rRNA contamination following treatment (Figure 3.2C). 
To test the efficiency of the RNA-seq pipeline, an internal standard was added to 
the reaction mix using recommendations from the External RNA Controls 
Consortium (ERCC) – termed the ERCC RNA Spike-In Control Mixes (ambion) 
[211].  
3.2.5.  Fragmentation of rRNA-depleted RNA and library preparation 
Libraries were constructed using the Ion Total RNA-Seq Kit v2 (Life 
Technologies). The kit provides reagents to fragment, purify and concentrate the 
rRNA-depleted RNA, and is able to reverse transcribe the RNA into cDNA. 
Reagents are also provided to amplify, purify and quantify the cDNA sample before 
sequencing. Each step of the library preparation is detailed below: 
Fragmentation of the rRNA-depleted RNA – 10 µl of the rRNA-depleted 
RNA were used in this step. Samples were incubated at 37ºC with RNase-III as 
outlined in the manufacturer’s instructions. Samples containing <100 ng of RNA 
were incubated for 3 min, while samples of >100 ng of RNA were incubated for 
10 min. To stop the reaction, 20 µl of ice-cold nuclease-free water was added and 
the tubes placed on ice. The fragmented RNA was purified using the Magnetic Bead 
Purification Module (Life Technologies). To assess the yield and size distribution 
of the fragmented RNA, a 1 µl aliquot was loaded onto an RNA Pico Kit chip 
(Agilent) and run on the Agilent 2100 Bioanalyser. This protocol generates a 
fragmentation profile with an average size of 100-200 nucleotides (Figure 3.2.D). 
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Reverse Transcription – Samples of total fragmented RNA (11 µl) were 
concentrated using the Centrivap Concentrator (Labconco) to a final volume of 
3 µl. Complimentary RNA oligonucleotide adapters were hybridized (65ºC for 
10 min, 5 min at 30ºC) and ligated (1 h at 30ºC) to each sample (see manufacturer’s 
instructions). Ligated samples were reverse transcribed into cDNA (70ºC for 
10 min, followed by 30 min at 42ºC) and purified using the Magnetic Bead 
Purification Module. Purified cDNA was amplified as detailed in Table 3.1. To 
increase the quality of the cDNA libraries and reduce the introduction of duplicated 
sequences (Sections 3.2.9 & 3.3.4), the number of PCR amplification cycles was 
reduced from 16 to 10 using a total RNA input quantity of 4 µg. During 
amplification, all libraries were barcoded using the Ion Xpress RNA-seq Barcode 
01-16 kit (Life Technologies) to multiplex the NGS reads within a single reaction. 
Samples were purified using the Magnetic Bead Purification Module. The quality 
and integrity of the DNA libraries was assessed on the Agilent 2100 Bioanalyser 
using the Agilent High Sensitivity DNA Kit (Agilent). Library preparations were 
evaluated for the percentage of DNA fragments that were <160 bp in size. 
Analysed showed that <20% of DNA fragments resided within this threshold 
(Figure 3.2E). 
Library quantification and pooling – Generated libraries were quantified by 
PCR (qPCR) using the Ion TaqMan quantitation assay (Life Technologies). This is 
a direct quantification test that uses an Escherichia coli DH control library as a 
standard. Quantification was performed as per manufacturer’s instruction using a 
standard curve ranging from 0.05-34.0 pM DNA. To obtain an accurate 
quantification, samples were assessed at three different dilutions. These were 
derived from the results obtained from the Bioanalyser (generally 1:1000, 
1:10000, 1:20000). All Libraries were adjusted to an optimal concentration of 35-
50 pM for downstream sequencing. To ensure an accurate dilution before 
sequencing, samples were again quantified by qPCR, and dilutions adjusted where 
necessary.  
Libraries were loaded onto the Ion Proton™ Chip at a ratio of 2:1 using the 
Ion Chef™ Instrument as outlined in the manufacturer’s instructions (Life 
Technologies). Final libraries concentrations were optimised to minimise aberrant 
IPS polyclonality and to maximise the chip load for sequencing (Section 3.3.2). 
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Table 3.1. Library amplification  
 
Stage Temperature Time 
Hold 94ºC 2 min 
Cycle (x2) 
94ºC 30 sec 
50ºC 30 sec 
68ºC 30 sec 
Cycle 
(x10-16) 
94ºC 30 sec 
62ºC 30 sec 
68ºC 30 sec 
Hold 68ºC 5 min 
 
3.2.6.  RNA sequencing analysis run 
The Ion Proton™ System for Next-Generation Sequencing uses the Torrent 
SuiteTM Software to monitor each sequencing reaction. For example, it provides an 
RNA-seq plugin to analyse the cDNA reads resulting from the sequencing reaction. 
With this tool, reads are aligned to the reference genomes hg19 and mm10 using 
STAR [212] and Bowtie2 [213]. Although these applications can be used to provide 
a complete analysis (e.g., differential gene expression analysis, isoform 
expression), these platforms were only used to align the genes to the reference 
genome (Figure 3.3).  
3.2.7.  Sequencing quality control (QC) 
Two quality control (QC) measures were included in each sequencing 
reaction. The Ion Proton™ System provided a documentation of ISP density (i.e. 
number of ISP loaded with cDNA template), percentage of usable reads (here, 
polyclonal ISPs are discarded), and the mean length of each read. Analysis using the 
fastQC software (Braham Institute) [214] provided an independent QC assessment 
and also identified any issues related to the quality of the starting library (e.g., 
percentage of GC content). 
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3.2.8.  Reads mapping strategy and quality control of mapping 
RNA-seq raw reads were mapped using the STAR and Bowtie2 aligners 
within the Torrent SuiteTM Software RNA-seq plugin (Figure 3.3). Here, the STAR 
algorithm ensures the accurate mapping of reads spanning between two exons 
[212], while the Bowtie2 algorithm reports the fraction of total reads represented 
by rRNA [213]. The samtools statistical package ‘stats’ (http://www.htslib.org) 
in the GitHub platform was used to assess the quality of the mapped data (e.g., the 
number of mapped reads, number of duplicates, percentage of forward and reverse 
strands). 
3.2.9.  Assessment of duplicated reads  
One of the issues associated with the analysis of RNA-sequencing data 
relates to whether the computational removal of duplicated sequencing reads (e.g., 
introduced through potential PCR bias) improves the accuracy of the downstream 
analysis [215-219]. Although the general consensus is to retain the duplicated reads 
for analysis, some key considerations must be taken into account [215]. For 
example, it is important to determine whether the number of duplicate reads 
assigned to a given gene biased the overall expression level for that gene within the 
dataset. To address this issue, all datasets were applied to the Bioconductor package 
dupRadar [219]. 
3.2.10.  Differential gene expression analysis  
The DESeq2 package from Bioconductor was used to identify significantly 
regulated genes based on changes in fold expression and associated statistical 
evaluation [220]. DESeq2 compares the differences in mapped reads for a given 
gene using shrinkage estimation for dispersion and fold change within each 
condition to improve stability and interpretability of the estimates [220].   
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3.2.11.  Statistical analysis of changes in gene expression over time  
All differentially regulated genes were grouped in clusters according to their 
level of expression over the 3-6 h time course. This analysis was performed in 
collaboration with Dr Barbara Szomolay (Systems Immunity University Research 
Institute, School of Medicine, Cardiff University), and provided an opportunity to 
study genes with similar patterns of expression in each experimental condition. 
Several methods were applied to determine the optimal number of clusters: 
silhouette [221], the visual ‘elbow method’ [222], and gap statistics [223]. Genes 
were then assigned to each defined cluster by K-means clustering [224]. This 
method partitions the data into a previously defined number of clusters in which 





Figure 3.3. Schematic overview of the RNA-seq data analysis strategy. 
A. Raw reads were QC using the Ion Proton System Torrent Suite and FastQC. B. 
Reads were mapped using the STAR and Bowtie2 aligners. C. Differential gene 
expression together with statistical data analysis and differential exon usage analysis 
was performed on the merged files. Differential exon usage analysis will be detailed 
in Chapter 7. 
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3.3.  Results 
3.3.1.  Defined Ion Chip loading ensures higher amount of usable reads 
Next generation sequencing was performed using the Ion Proton System. 
Initial optimisation experiments assessed how the library input concentration 
influenced both the polyclonality and sequencing quality (Figure 3.4). This was 
evident at both a low (35 pM) and high (50 pM) library concentration. Diluting the 
samples to 40 and 35 pM reduced polyclonality whilst ensuring sufficient library 
template for sequencing. Thus, 35 pM of template were found to be the optimal 
library concentration for ISP loading (Figure 3.4).  
3.3.2.  Higher total RNA input and lower amplification cycles reduce sequence 
duplications 
Inadvertent PCR amplification contributes substantially to sequencing biases 
associated with library generation and downstream RNA-seq analysis.  Although 
difficult to control, several measurements were undertaken to minimise the 
introduction of bias. The Ion Total RNA-Seq Kit v2 recommends 1-5 µg of RNA 
as input and 16 cycles of PCR for library amplification in its protocol. Our first 
libraries were therefore generated using 2 µg of total RNA and 16 cycles of 
amplification (Figure 3.5A & B). However, the mapping statistics showed a 
substantial amount of duplication. While duplicated reads may not necessarily be 
indicative for PCR bias (as stated earlier), the amount of RNA starting material was 
increased and the amplification cycles reduced to determine whether the number 
of duplicates could be reduced. Thus, subsequent experiments used 4 µg of input 
RNA and 10 cycles of PCR amplification. This strategy slightly reduced the 
percentage of duplicated reads (Figure 3.5A & B).  
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Figure 3.4. Optimisation of the RNA-sequencing loading run. SES 
experiment was used to optimise the sequencing run. Correlation between the 
amount of input cDNA loaded for sequencing (Library concentration), the chip 
loading, the ISP polyclonality and the amount of low quality reads. Each dot 
















































Figure 3.5. Mapping statistics. A. Number of duplicated reads per input within 
the SES experiment. B. Number of duplicates per total PCR cycles for each input 
in the SES experiment. C. Number of mapped reads per sample for both SES and 
Th1 experiments. For A and C, data is represented as box plots with extending 
bars to the lowest and highest values 
r2 = 0.7955 
p < 0.001 
r2 = 0.5859 
p < 0.001 
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3.3.3.  Ion torrent provides sufficient depth of coverage and optimal mapping 
The mapping of the raw NGS reads was performed using STAR and Bowtie2 
aligners from the RNA-seq plugin within the Torrent SuiteTM software (Section 
3.2.8). As this mapping strategy is optimised for the Ion ProtonTM Technology, it 
provided the highest percentage of mapped genes to the reference genome. The 
samtools statistical package ‘stats’ (Section 3.2.8) was used to assess the quality of 
the mapping. Following this strategy, more than 95% mapping was achieved in 
both experiments (Table 3.2). The distribution between forward and reverse 
strand was ~50% (Table 3.2). Only samples with more than 2.0x107 mapped reads 

















SES 95.86 ± 0.31 55.02 ± 0.90 44.98 ± 0.90 
Th1 96.92 ± 0.19 54.83 ± 0.51 45.17 ± 0.51 
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3.3.4.  Duplication does not affect the differential gene expression analysis 
The Bioconductor package dupRadar was used to determine whether 
duplicated reads had an impact on the subsequent differential gene expression 
analysis. For a given sample, the number of duplicated reads within each gene was 
plotted against its fold change when compared its control (Figure 3.6).  
High duplication did not correlate with an increased fold change (Figure 
3.6). Thus, based on the data from Figure 3.5 and Figure 3.6, there was no 
evidence for the introduction of a PCR-derived bias within the datasets. Duplicated 



















Figure 3.6. Duplicated reads do not bias differential gene 
expression. The number of duplicates for a given gene was compared to 
the relative fold change against untreated controls. Representative dot plot 
was generated by the package dupRadar.  
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3.3.5.  Differential gene expression 
Mapped reads were tested for differential gene expression using the DESeq2 
package [220]. To establish the cut-off that will be used throughout the analysis, 
differences between mice receiving naïve CD4+ T-cells (Th0) and SES or SES alone 
were compared at 3 h. The introduction of Th0 cells had minimal impact on gene 
expression and was used as a baseline threshold for the identification of genes 
selectively induced by inflammation. Using this approach, analysis considered all 
genes with a statistical variation of p<0.01, and an absolute fold change of >1.75. 
All pseudogenes or genes with a transcript support level of 5 (TSL5) were excluded 
from the analysis [225]. TSL is a method to assess whether a given transcript is 
supported by primary data (mRNA and Expressed Sequence Tag) from the Ensembl 
and UCSC projects [225]. Transcripts annotated with a TSL5 mean that no single 
mRNA transcript has been found to support the model structure, and therefore 
their annotation should be considered speculative [225]. 
For the SES experiment, baseline control data for each genotype were 
compared to gene changes seen at 3 and 6 h post SES treatment. In this regard, 
analysis of datasets from non-challenged WT and Il6-/- mice identified 64 
differentially regulated genes. These differences included immune-related genes, 
such as Ccl6, Ccl9, Il31ra, Nos3 or Ly6D. Subsequent analysis therefore took into 
account the basal expression of these genes when comparing across genotypes.  
Evaluation of gene regulation across the time course of SES activation 
identified 377 (at 3 h) and 185 (at 6 h) differentially regulated genes in SES 
stimulated WT mice (Table 3.3). A comparable analysis of SES treated Il6-/- mice 
identified 267 and 213 genes at 3 and 6 h. The addition of Th1 cells dramatically 
enhanced the number of regulated genes under SES activation (Table 3.3). These 
equated to 782 and 1280 genes in WT mice at 3 and 6 h, and 1262 and 1195 at 3 
and 6 h in Il6-/- mice.  
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3.3.6.  There are three distinct patterns of genes expression over time in both 
conditions 
Computational analysis of the RNA-seq data was used to cluster genes 
displaying similar temporal patterns of regulation (Section 3.2.11) [226]. Analysis 
was conducted in the genes significantly regulated in at least one of the 
experimental conditions when compared to respective controls. This equated to 
677 genes for the SES experiment and 2307 genes for the Th1 experiment. For the 
SES experiment, the silhouette, gap statistics and elbow methods all suggested 3 as 
the optimal number of clusters for both WT and Il6-/- (Figure 3.7A). Analysis was 
also performed for the Th1 adoptive transfer experiment. Here, the three methods 
also identified 3 distinct patterns of gene regulation in SES stimulated WT and Il6-/- 
mice receiving Th1 cells (Figure 3.7B).  
Once the optimal number of clusters was identified, significantly regulated 
genes were assigned to each cluster according their temporal pattern of expression 
over the 6 h time course by K-means clustering [224] (Figure 3.8). This clustering 
strategy will be used in subsequent sections of this thesis to explore functional 
associations within each pattern of temporal gene expression (see Chapters 4 & 5). 
 
Table 3.3. Differentially expressed genes 
  Time (h) p<0.05 p<0.01 p<0.01, FC>1.75 
SES 
WT 3 706 452 377 
6 396 219 185 
Il6-/- 3 573 335 267 
6 657 290 213 
Th1 
WT 3 1937 1296 782 
6 3169 2108 1280 
Il6-/- 3 3595 2289 1262 
6 3612 2181 1195 
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Figure 3.7. Identification of the optimal number of cluster for the RNA-
seq datasets for WT and Il6-/-. The silhouette, gap statistics and elbow methods 
were used to determine the optimal number of clusters to organise differentially 
regulated genes from SES treated (A) and SES together with Th1 adoptive transfer 
treated mice (B).  
Silhouette method
A SES
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Figure 3.8. Cluster analysis. Genes were clustered according to their changes 
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3.4.  Discussion 
Studies outlined herein established RNA-seq methodologies and an analysis 
pipeline for evaluation of peritoneal lining tissue using the Ion Proton™ Next-
Generation Sequencing System. The Ion Proton technology has the capacity to 
sequence fragments of a higher length than other platforms, and provides sufficient 
sequence coverage to map reads for transcript discovery [227]. During the first part 
of this Chapter, experiments evaluated the optimal input library concentration to 
minimise ISP polyclonality and maximise sequencing quality. This ensured a 
consistent and sufficient amount of useable sequencing reads throughout the 
experiments.  
One important aspect of the sequencing QC determined whether it was 
appropriate to remove computationally duplicated sequencing reads. These can 
arise both from natural duplicates or PCR-duplicates – i.e. reads that originate 
from the same RNA molecule as a result of aberrant PCR amplification [215]. In 
line with previous studies in the literature [215-219], gene expression analysis 
showed that duplicates did not affect the overall gene expression fold change. Thus, 
replicates were not removed from the analysis.  
Statistical data analysis was used to evaluate changes in gene expression over 
time. This analysis enabled the clustering of the differentially regulated genes 
according their pattern of expression over the course of inflammation. The 
importance of such approach resides in his potential to obtain an integrated 
understanding of the biological processes occurring in the peritoneal membrane 
during acute and chronic inflammation. In this regard, Eisen and co-workers have 
previously shown that genes that share a similar pattern of expression also share 
common roles in cellular processes [226]. Thus, the use of this analysis to organise 
our data provided holistic information of the dynamical changes in the 
transcriptome of the peritoneum during the inflammatory course.
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 Transcriptomic analysis of the 
peritoneal membrane during acute resolving 
inflammation 
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4.1.  Introduction 
Inflammation in response to bacterial infection promotes anti-microbial 
immunity. Here, acute resolving inflammation ensures competent host defence and 
the restoration of tissue homeostasis [15]. However, a persistent or recurrent 
activation of inflammation can cause chronic inflammation and deleterious tissue 
damage. Therefore, the inflammatory response must be appropriately regulated [9, 
15].  
Cellular communication between leukocytes and local resident tissue cells 
controls the initiation, maintenance and resolution of the inflammatory episode [9]. 
This interaction promotes the transition from innate to adaptive immunity, and 
ensures the successful resolution of inflammation [228]. Several mediators 
including chemokines, cytokines, and bioactive lipids are involved in this crosstalk 
[26, 41, 229]. The inflammatory cytokine IL-6 is integral to this process and directs 
the transition from innate to adaptive immunity [9], and is essential for anti-
microbial defence against viruses, bacteria and parasites [61-65]. In the context of 
peritonitis, studies in our laboratory have shown that Il6-/- mice are less able to 
contain bacterial infection, and display a heightened dissemination of infection into 
the bloodstream and wider tissues. Experiments described in this Chapter will 
identify the IL-6 regulated gene changes in the peritoneum that are associated with 
this outcome during acute resolving inflammation. 
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4.2.  Materials and Methods 
4.2.1.  Data visualization  
Heatmaps – The software GENE-E [230] or the online tool Morpheus [231] were 
used to identify differences in gene regulation. Heat map visualisations were 
presented as either the normalised read counts (FPKMs; Fragments Per Kilobase of 
exon per Million fragments mapped per sample) of those genes differentially expressed 
in at least one of the experimental conditions; or as the log2 transformation of the 
fold change (log2FC) when compared to respective controls. All datasets were 
hierarchically clustered using Spearman’s rank correlation coefficient. Spearman’s 
rank correlation is a non-parametric measure of correlation between the rank of 
two variables (in the present study, gene expression and condition), which does 
not assume linear association between those variables.  
Venn diagrams – Venn diagrams were used to visualise the gene overlap between 
different conditions with the web tool Venn [232]. 
Volcano plots – To illustrate the distribution of genes either induced or 
suppressed, datasets were visualised by volcano plots. Data was expressed as a 
log2FC against the log10 adjusted p value using the R package ggplot2 [233]. 
4.2.2.  Statistical data analysis 
The identified clusters reported in Chapter 3 were tested to establish 
potential relationships between the inflammatory response observed in WT and 
Il6-/- mice. In collaboration with Dr. Barbara Szomolay, analysis considered the 
non-overlapping genes between groups to study the differences between the 
clusters in WT and Il6-/- mice using the two-sample two-dimensional Kolmogorov-
Smirnov (Two-sample 2D K-S) test [234] and the multivariate Kruskal-Wallis 
(MVK) test [235]. Analysis assessed changes in gene expression at each time point 
and from across the entire time course (0-6 h) to establish statistical evaluation 
between WT and Il6-/- mice. In this regard, the MVK test is a non-parametric test 
that determines whether the medians of two groups are different. The non-
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parametric two-sample 2D K-S test compares the distance between the empirical 
distribution functions of two conditions.  
4.2.3.  Data interpretation: Ingenuity pathway analysis 
Molecular pathway analysis was conducted using Ingenuity Pathway 
Analysis (IPA; version 2.1) [236], which employs both bespoke in-house developed 
algorithms and manually curated databases (Ingenuity Knowledge Base) to identify 
associations with pathways, networks and genes of interest. “Comparison Analysis” 
identified gene changes based on the classification of ‘Canonical Pathways’, ‘Upstream 
Regulators’ and ‘Downstream Effects’.  
Canonical Pathways identifies the most significantly regulated pathways 
affected by the genes of interest. It also predicts whether these pathways are 
activated or suppressed based on changes in the expression of genes. 
The Upstream Regulator Analysis feature predicts the identity of upstream 
molecules, including receptors and transcription factors responsible for directing 
gene expression within the dataset.  
Downstream Effects Analysis anticipates increases or decreases in downstream 
biological activities based on the direction of change of the genes in the dataset.  
For IPA analysis, all 677 differentially expressed genes as identified in 
Chapter 3 (Section 3.3.5 & 3.3.6) were used. Genes from each cluster were 
uploaded separately using the statistical cut offs applied in Chapter 3 (p< 0.01; fold 
change>1.75). This allowed a comparison of those genes significantly altered 
between conditions.    
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4.3.  Results 
4.3.1.  Experimental validation of acute resolving peritonitis 
Acute resolving inflammation was induced following peritoneal stimulation 
with SES (Section 2.3.2). Changes in inflammation were quantified using ELISA and 
qPCR (Figure 4.1). Two aspects of IL-6 activity were evaluated – (1) components 
of the IL-6 receptor cassette, and (2) some IL-6 regulated STAT1 or STAT3 target 
genes. Interleukin-6 was only detected in the peritoneal lavage of WT mice at 3 h 
post SES administration. The levels of sIL-6R peaked at 3 h in both WT and Il6-/- 
mice, while sgp130 levels were reduced in Il6-/- mice at 6 h (Figure 4.1A). 
Quantitative PCR analysis of mRNA derived from the inflamed peritoneal lining 
evaluated several STAT1 and STAT3 target genes (Figure 4.1B). Socs3 was strongly 
upregulated in WT mice 3 h after SES injection, while Irf1 showed a slight increase 
in both genotypes. Il1b expression was used as control and was enhanced at 3 h in 
both genotypes as a result of the acute TLR activation (Figure 4.1B). 
4.3.2.  Transcriptomic analysis of SES activated peritoneal tissue 
Spearman’s rank correlation was used to establish similarities in the 
transcriptome profile of WT and Il6-/- mice after SES stimulation. This approach 
grouped the experimental samples away from the non-treated controls. Within the 
SES treatment samples, the Il6-/- SES 6 h dataset grouped furthest away from the 
others, suggesting that IL-6 plays an important role in regulating the transcriptional 
response following SES challenge at this latter time point (Figure 4.2). SES 
triggered changes in 377 and 185 genes in WT mice at 3 h and 6 h, respectively. In 
Il6-/- mice, 267 genes at 3 h and 213 genes at 6 h were altered (Figure 4.3). Most 
of these genes were unique to an individual condition or time point (Figure 4.3B). 
Most of the genes controlled by SES in WT mice were substantially induced. 
(Figure 4.3A). This was particularly evident at 3 h post SES challenge. Conversely, 
Il6-/- mice show a distinctive number of genes strongly down-regulated (Figure 
4.3A). 
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Figure 4.1. Experimental validation. Peritonitis was induced as detailed in 
Section 2.3.2 A. The levels of IL-6, sIL-6R and sgp130 were evaluated by ELISA. 
B. The expression of STAT1 and STAT3 target genes Socs3 and Irf1 was evaluated 
by qPCR. Il1b expression was measured as a positive control for TLR-
inflammasome activation. n= 4 mice per group. Statistical analysis was performed 






Figure 4.2. Impact of IL-6 in the transcriptome. Hierarchical cluster analysis 
(by Spearman’s rank correlation) of WT and Il6-/- mice at 0 h (untreated), 3 h (SES 
3 h) and 6 h (SES 6 h) based on the expression level of the 677 genes being 
differentially regulated in at least one of the experimental conditions. The 
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Figure 4.3. Volcano plot analysis of differentially expressed genes in 
WT and Il6-/- mice after SES stimulation. A. Data shows the differential 
expression of genes in WT and Il6-/- mice at 3 and 6 h after SES stimulation 
compared to corresponding untreated controls. B. Venn diagram demonstrates the 
number of genes that are commonly or uniquely expressed in each condition. 
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4.3.3.  Both WT and Il6-/- mice show 3 distinct patterns of gene expression 
over time 
Cluster analysis previously identified three distinct patterns of differential 
gene expression within our RNA-seq datasets from both WT and Il6-/-mice 
following SES stimulation (Figure 3.8). To test whether these patterns of 
expression were statistically related, data from WT and Il6-/-mice were compared 
using different statistical test (Section 4.2.2) (Table 4.1 and 4.2). Statistical analysis 
was performed over the 0-6 h time period using the Two-sample 2D K-S test and 
MVK test on the following data: (1) log2FC gene expression at 3 h and 6 h, and (2) 
rate of change of log2FC gene expression at 3 h and 6 h (termed “slope”). These 
methods identified close similarities between the patterns identified in WT and 
Il6-/- mice (Figure 4.4). For example, Cluster-1 from WT mice is closely related 
to Cluster-3 from Il6-/- mice (Tables 4.1 & 4.2). These groups therefore share 
similar patterns of gene expression or gene “Behaviours” – termed “Behaviour 1” 
(B1), “Behaviour 2” (B2) and “Behaviour 3” (B3) (Figure 4.4). 
Studies evaluated the identity of the genes assigned to each behaviour. Even 
though both WT and Il6-/- mice share three distinct patterns of gene expression, 
24% of the genes do not overlap between genotypes (Figure 4.4B). Individually, 
the Jaccard index [237] between pairwise Behaviours is < 0.63 (Figure 4.4C). The 
Jaccard index is a statistic used to compare the similarity between two sample sets. 
When both sets are identical, the Jaccard index equals one 1. In our datasets, a 
Jaccard index of 1 would indicate that, for example, Cluster-3 from WT mice 
comprises the same genes that Cluster-1 from Il6-/- mice. However, this is not the 
case, suggesting that IL-6 has an important impact in the control of peritoneal 
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Cluster 1 Cluster 2 Cluster 3  
Il6-/- 
Cluster 1 
2.39E-41 1.38E-42 0.0018 slope 
1.16E-40 8.62E-49 0.0005 log2FC at 3 and 6 h 
Cluster 2 
1.25E-49 0.0001 1.18E-61 slope 
5.23E-46 0.0002 1.09E-62 log2FC at 3 and 6 h 
Cluster 3 
0.0194 1.12E-52 1.44E-15 slope 
0.0253 1.33E-50 3.46E-21 log2FC at 3 and 6 h 
 
Clusters from WT and Il6-/- regulated genes were tested for similarly using the two-
sample two-dimensional Kolmogorov-Smirnov. The p value associated to each 
comparison is shown (significance level of 0.1%). Data outlined in blue highlight 
clusters with the closest similarities. Slope = rate of change of log2FC gene 
expression at 3 and 6 h. 
 
 




Cluster 1 Cluster 2 Cluster 3  
Il6-/- 
Cluster 1 222.87 318.17 24.37 log2FC at 3 and 6 h 
Cluster 2 230.66 20.74 317.73 log2FC at 3 and 6 h 
Cluster 3 12.91 265.33 158.68 log2FC at 3 and 6 h 
 
Clusters from WT and Il6-/- regulated genes were tested for similarly using the 
Multivariate Kruskal-Wallis. The variance associated to each comparison is shown. 
The critical value of chi2 statistics is 13.8155 at significance level of 0.1%. Data 
outlined in blue highlight clusters with the closest similarities. 
  




Figure 4.4. Cluster analysis and overlap between the differentially 
expressed genes in WT and Il6-/- mice after SES stimulation. A. Genes 
were plotted according to their expression over time (0-3-6 h). Red lines represent 
the mean expression within each group (centroid). Cluster analysis shows three 
patterns of expression (termed “Behaviours”) similar in WT and Il6-/- mice. The 
Venn diagrams show the gene overlap in terms of absolute number between 
common Behaviours. B & C. Representation of the percentage of overlap between 
each Behaviour over the total 677 differentially expressed genes (B), and the 
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4.3.4.  Control of STAT1 and STAT3 over the transcriptome 
The importance of STAT1 and STAT3 activity in the control of gene 
expression after SES challenge was evaluated using “Upstream Regulator Analysis” 
in IPA (Figure 4.5). Only genes within B1 and B3 predicted a significant activation 
of STAT1 and STAT3 as upstream regulators in IPA (z-score>2). Here, STAT3 is 
a strong gene regulator in WT in both B1 and B3, while STAT1 is predicted to be 
active mainly in B1 of Il6-/- mice (Figure 4.5A & 4.5C). Studies next focused on the 
genes associated to both transcription factors in WT and Il6-/- mice. The total 
number of genes regulated by STAT1 and STAT3 (as predicted by IPA) is presented 
for both B1 and B3 (Figure 4.5B & 4.5D). In B1, a vast proportion of genes were 
commonly regulated by STAT1 or STAT3 in both WT and Il6-/- mice (Figure 
4.5B). On the other hand, most of the genes controlled by STAT1 or STAT3 in B3 
were unique to WT mice (Figure 4.5D). SES is an activator of TLR2 [56, 238], and 
its predicted activation in IPA was used as control. Here, TLR2 is predicted to be 
active at the early stages of inflammation in WT and Il6-/- mice in B1.  
Using the same criteria, analysis next considered the top canonical pathways 
activated in the membrane as a result of SES challenge. Again, only B1 and B3 
predicted canonical pathways with a z-score > 2 (Figure 4.5E). Here, pathways 
including acute phase response signalling, TREM1 signalling and iNOS signalling 
were selectively enriched in datasets from WT mice as compared to Il6-/- mice.  
4.3.5.  Impact of acute inflammation in the biological functions within the 
stromal compartment   
To gain further insight into the biological functions associated with each 
gene Behaviour, IPA was used to perform “Downstream Effects Analysis” (Figure 
4.6). This provided insight into the downstream biological activities associated with 
the identified genes of interest. 
The top functional categories defined for B1 and B3 are shown in Figure 
4.6A & 4.6C. The functions associated with B1 corresponded to those related to 
immune cell trafficking and movement, haematological processes, cell-to-cell 
signalling and the regulation of inflammation. These include genes induced at 3 or   
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Figure 4.5. Upstream regulator and canonical pathway analysis by IPA. 
A & C. STAT1, STAT3 and TLR2 activation was predicted in IPA for Behaviour 1 
(A) and 3 (C), and their relative z-score plotted in a heat map. B & D. Common 
and unique genes to WT and Il6-/- datasets that are predicted to be under STAT1 
and STAT3 control in B1 (B) and B3 (D). E. Top 5 canonical pathways 
(z-score > 2) in B1 and B3. 
  85 
6 h as a consequence of peritoneal SES challenge. For example, genes linked with 
B1 contributed to changes in phagocyte migration and chemotaxis. In WT mice, 
these included definitions relevant to the activation of phagocytes and leukocytes, 
cellular adhesion and angiogenesis (Figure 4.6B).  
On the other hand, genes in B3 accounted for more homeostatic functions 
– cell development and survival, tissue morphology and haematological system 
development and function (Figure 4.6C & 4.6D). Interestingly, some function 
related to cell movement are upregulated in WT mice when compared to IL-6 
deficient counterparts. This may account for those genes involved in trafficking that 
are dependent on IL-6.  
4.3.6.  Genes associated to competent host defence  
Unpublished observations in our laboratory suggest that mice lacking Il6 are 
unable to successfully control infections. Bioinformatics analysis of the described 
RNA-seq data is in close agreement with these findings.  
Under B1, Il6-/- mice showed impaired immune signatures relevant to the 
activation of leukocytes, degranulation of cells and the production of reactive 
oxygen species when compared to WT (Figure 4.6). An exhaustive transcriptome 
analysis was therefore performed using these genes. Among the 56 genes involved 
in the activation of leukocytes, 9 of them were predicted to be under STAT3 
regulation in WT mice (Cx3cl1, Cdkn1a, Il4r, Ccl12, Lbp, Ccr5, C5ar1, Saa1 and 
Fcgr1a) (Figure 4.7A). The expression of these genes was significantly suppressed 
in Il6-/- mice (Figure 4.7B). This difference in expression between WT and Il6-/- 
mice was especially notable for Il4ra, Lbp and Saa1.  
Cellular adhesion plays a vital role in leukocyte recruitment and priming 
[175, 239]. Twenty genes involved in phagocyte adhesion were shown to be 
differentially expressed between WT and Il6-/- mice as a result of SES stimulation 
(Figure 4.8A). These included the adhesion molecules E-selectin, P-selectin, 
Intercellular Adhesion Molecule-1 (ICAM-1), and Vascular Cell Adhesion 
Molecule-1 (VCAM1) (Sele, Selp, Icam1 and Vcam1, respectively). For example, 
Selp shows a very transient and strong increase in WT mice at 3 h (Figure 4.8B), 
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Figure 4.6. Biological function analysis. A & C. Top functional categories 
enriched in B1 (A) and B3 (C). B & D. The most significant functions (z-score > 
3.5) associated to the genes in B1 (B) and B3 (D). 
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and it was identified as one of the most prominently regulated genes in WT mice 
at 3 h (Figure 4.2). Conversely, Vcam1 is strongly upregulated at 3 h, especially in 
Il6-/- mice. 
Functions related to chemotaxis and cell migration were also observed in 
B3 (Figure 4.8C). Here, leukocyte and phagocyte migration functions were 
substantially enhanced in WT mice. They included genes involved in cellular 
adhesion (Cd44, Vcan), ECM remodelling (Ddr2, Mmp9, Col4a1) and cytoskeletal 
rearrangement (Vav1, S1pr1, Pdpn) (Figure 4.8D). Interestingly, the gene encoding 
for the Atypical Chemokine Receptor 1 (Ackr1, also known as Duffy Antigen 
Receptor for Chemokines, DARC) was also upregulated in WT mice (Figure 
4.8D). IPA predicted that ten of these genes were controlled by STAT3 (Myd88, 
Serpine1, Vcan, Cd40, S1pr1, Hif1a, Mmp9, Fas, Plaur and Tnf).  
Taken together, these findings support the idea that stromal signals 
modulate a successful host response and that this response is defective in the Il6-/- 
mice. 
  












































































































































































































Figure 4.7. STAT3 control over host defence.  A. Genes extracted from 
activation of leukocytes that are under the control of STAT3 in WT mice. Genes 
are plotted using the log2 fold change transformation. B. These genes show a 
behaviour that changes from B1 in WT to B3 in Il6-/- mice. C. Normalised read 
counts of the selected genes. 




Figure 4.8. Impact of phagocyte migration and adhesion in the immune 
response against infection. A & C. Heat map showing the expression (log2FC) 
of genes in B1 involved in the function adhesion of phagocytes (A) and in B3 
involved in migration of phagocytes (C). B & D. Normalised counts from RNA-
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4.3.7.  Impact of SES in tissue damage and homeostasis 
Genes under B3 were involved in tissue morphology and cellular 
homeostasis (Figure 4.6C and D). Previous studies in our laboratory demonstrated 
that the onset of fibrosis was due to an altered turnover of the ECM by proteases 
[33]. Therefore, the influence of these proteases during acute inflammation was 
investigated. Several matrix metalloproteinases (MMPs) and their inhibitors 
(TIPMs) were differentially expressed in response to SES. These included Mmp3, 
Mmp8, Mmp9, Mmp13 and Timp1 (Figure 4.9A). Importantly, Timp1 expression was 
rapidly induced in WT at 3 h post SES challenge and maintained through the 6 h 
time point (Figure 4.9D).  
Collagens play an important role in the homeostasis of the ECM and are key 
components of the peritoneal membrane. Five collagen genes were differentially 
expressed in our dataset (Col27a1, Col3a1, Col4a1, Col5a2 and Col4a2) (Figure 
4.9B). Col3a1 and Col5a2, which correspond to fibrillary collagens [240], were 
specifically upregulated in WT mice over the time course (Figure 4.9D).  
Among the genes most highly upregulated in our dataset are those encoding 
for solute carriers (SLCs). These proteins are essential for the transport of sugars, 
amino acids, nucleotides, inorganic ions and drugs across biological membranes 
[241]. Given the use of the peritoneal membrane as a semipermeable barrier for 
the exchange of fluids in peritoneal dialysis, the expression of solute carriers in our 
dataset was investigated (Figure 4.9.C). Here, 16 genes encoding for the SLCs 
were differentially regulated in at least one of the conditions, and included Slc10a6, 
Slc12a2, Slc25a34, Slc26a10, Slc26a3, Slc38a2 and Slc39a14. 
Finally, the regulation of ion transport (e.g., iron, zinc) by the host is an 
important anti-microbial activity [242]. Several molecules implicated in iron 
sequestration and metabolism were differentially regulated in WT and Il6-/- mice 
after SES administration (Hp, Lcn2, Hif1a and Txnip) (Figure 4.10). 
 






Figure 4.9. Tissue remodelling and morphology markers. A, B & C. Heat 
map showing the MMPs and TIMPs (A), collagens (B) and solute carrier (C) genes 
differentially express under SES stimulation in WT and Il6-/- mice. Genes are 
plotted using the log2 fold change transformation. D. Normalised counts from 













































































































































































































































































Figure 4.10. Importance of iron sequestration and redox status to host 
defence. Normalised counts for several genes involved in iron transport (Hp) and 
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4.4.  Discussion 
There is extensive literature relating to the role of IL-6 in host defence 
against infections [61-64]. As a truly pleiotropic cytokine, IL-6 regulates multiple 
aspects relevant to the control of tissue homeostasis, the immune response to 
infection, and the appropriate regulation of inflammation [9, 41]. Previous studies 
in our laboratory have emphasized the anti-microbial properties of this cytokine in 
controlling bacterial peritonitis. Specifically, Il6-/- mice are unable to successfully 
clear the infection, and show increased bacterial dissemination as compared to WT 
controls.  
This Chapter provides a holistic overview of the changes occurring in the 
peritoneal membrane after an episode of acute resolving inflammation. First, a 
detailed transcriptome analysis of the peritoneum over a 6 h time course is 
presented for both SES challenged WT and Il6-/- mice. RNA-seq identified three 
distinct patterns of gene expression that are shared by both genotypes. However, 
approximately a quarter of the differentially expressed genes do not share common 
overlaps between WT and Il6-/- mice, which emphasises the major role of IL-6 in 
controlling the stromal inflammatory responses to SES. 
Studies focussed on the impact of STAT1 and STAT3 in regulating gene 
expression within the peritoneal membrane. While IL-6 activation of STAT3 
contributes to host defence during acute inflammation [21, 95, 243], STAT1 
activity after recurrent episodes of peritonitis is linked to fibrosis [33]. The results 
outlined in this Chapter are in line with these observations. Here, IPA analysis 
predicted a strong activation of STAT3 in WT mice after acute resolving SES-
induced peritonitis.  
Computational analysis showed that STAT3 activation was associated to the 
upregulation of immune-related canonical pathways and downstream biological 
effects. For example, TREM1 signalling is proposed to be an important pathway 
involved in the protective immunity against bacterial infection, and relationships 
between IL-6, TLRs and TREM1 have been previously suggested [244-246]. In 
addition, several key genes were identified to be differentially regulated as a result 
of IL-6 signalling. These included some soluble antimicrobial peptides such as Lbp; 
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molecules implicated in complement activation (C5ar1), leukocyte migration 
(Ackr1) and adhesion (Selp, Icam1); and EMC remodelling (Timp1, Col3a1 and 
Col5a1). Interestingly, the increase in collagen production may be important to 
prevent bacterial dissemination during the early stages of the infection [32].  
The peritoneum is a serous, semi-permeable membrane that forms the 
lining of the abdominal cavity. It is used as a dialysis membrane for the removal of 
metabolites, uremic toxins, salts and water from end-stage renal failure patients 
[155]. In this regard, SLCs may be important in peritoneal dialysis as they facilitate 
the transport of sugars, amino acids, nucleotides, inorganic ions and drugs through 
biological membranes [241]. Our datasets show that the expression of specific SLCs 
is enhanced during inflammation. For example, the family 39 (Slc39) transporter 
which are responsible for iron transport [241]. In this regard, iron is often used as 
an essential cofactor in the generation of anti-microbial immunity [242, 247], and 
the control of iron availability by the host also constitutes an important mechanism 
of anti-microbial defence. For example, neutrophil lipocalin (Lcn2) interferes with 
iron acquisition by binding to bacterial ferric siderophores [248], and mice deficient 
in Lcn2 display impaired bacterial clearance during lung infection [249]. Similarly, 
haptoglobin (Hp) can bind haemoglobin released from damaged erythrocytes, and 
thereby limits the bioavailability of free iron for uptake by microbes [247]. Finally, 
the inflammatory expression of hypoxia-inducible factor-1a (Hif1a) in the tissue 
microenvironment has been shown to improve the bactericidal capacities of 
neutrophils [250]. Thus, the upregulation of genes that regulate iron availability 
(e.g., Lcn2, Hif1a and Hp) in WT but not Il6-/- mice emphasise the importance of 
this metal in host defence and may account for additional support in the overall 
anti-microbial response.  
Taken together, the data suggest that the stromal compartment modulates 
the innate immune response in a coordinate way: not only ensures the correct 
infiltration and activation of innate cells, but also potentially provides and 
antimicrobial environment and structural support to prevent bacterial growth and 
dissemination from the site of infection. 
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 Adaptation of the transcriptional 
profile of the peritoneal membrane by Th1 cells 
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5.1.  Introduction 
IL-6 controls both innate and adaptive immune responses essential for 
competent anti-microbial host defence [9, 228]. For example, IL-6 regulates CD4+ 
T cell proliferation, differentiation and survival [9, 251], and is implicated in the 
development of CD4+ T cell memory recall [252, 253]. 
Our laboratory has previously described the IL-6-mediated expansion of 
CD4+ effector T-cells in response to recurrent episodes of peritoneal inflammation 
[33]. Repeated inflammation led to the generation and maintenance of peritoneal 
IFN-g-secreting Th1 cells. These Th1 cells were identified as pro-fibrotic. In this 
regard, IFN-g induced STAT1 signalling in the peritoneal membrane was shown to 
distort the physiological turnover of extracellular matrix to drive peritoneal fibrosis 
[33]. This process is completely IL-6 dependent. It is however unclear what impact 
the presence of pro-fibrotic CD4+ T-cells may have on the host defence against 
bacteria.  
To address this question, ex vivo expanded Th1 cells were adoptively 
transferred to mice receiving SES challenge. Experiments considered the following:  
a. The impact of pro-fibrotic Th1 cells on the transcriptomic profile of the 
peritoneal membrane during inflammation. 
b. How an alteration in the balance between STAT1 and STAT3 signalling may 
influence the control of anti-microbial host defence versus inflammation 
induced tissue damage.  
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5.2.  Material and Methods 
5.2.1.  Adoptive transfer of ex vivo SES-CM polarised Th1 cells  
Th1 cells were generated from naïve CD4+ T-cells by anti-CD3 and anti-
CD28 co-stimulation in the presence of conditioned media from SES treated 
peritoneal resident cells (see Section 2.4.2). SES-polarised Th1 cells were adoptively 
transfer into WT and Il6-/- mice together with SES as described in Sections 2.3.4. 
Mice receiving a comparable amount of sorted naïve CD4+ T-cells (Th0) were used 
as controls.  
5.2.2.  Data visualization and interpretation 
The reader is referred to methods outlined in Chapter 4 (Section 4.2).   
 
  
  97 
5.3.  Results 
5.3.1.  Impact of naïve CD4+ T-cell transfer on the transcriptomic profile of the 
inflamed peritoneum 
To mimic the pro-fibrotic environment conducive to the development of 
peritoneal fibrosis, WT and Il6-/- mice were adoptively transfer with ex vivo 
expanded Th1 cells co-administered with SES. Control mice received an equivalent 
number of sorted naïve CD4 T-cells (Th0) together with SES (Section 2.2.4). At 3 
and 6 h time points, peritoneal lavage and peritoneal stromal tissue were harvested 
for cytokine quantification and transcriptomic analysis, respectively.  
Transfer of Th1 cells promoted an increase in peritoneal IFN-g and the 
activation of STAT1 within the peritoneal stromal tissue obtained from SES treated 
WT, Il6-/- and Il6ra-/- mice [33] (Figure 5.1). No change in IFN-g activity was 
observed following the transfer of control Th0 cells. The presence of IFN-g in the 
peritoneal cavity boosted the expression of IL-6 in WT mice after SES challenge 
(Figure 5.1C). STAT1 and STAT3 activity within the peritoneal membrane was 
confirmed using qPCR analysis for target genes controlled by these transcription 
factors (Figure 5.1D). 
Studies next tested the impact of Th0 cells on the transcriptome of WT and 
Il6-/- mice receiving SES (Figure 5.1E). Here, responses in mice receiving Th0 cells 
and SES were directly compared to mice receiving SES alone (Chapter 3). All 
differentially regulated genes were subjected to a hierarchical clustering using 
Spearman’s rank correlation, and presented as a heat map (Figure 5.1E). These data 
revealed that the presence of Th0 cells had a minimal impact on the transcriptional 
output seen during SES-induced inflammation. To allow us to identify gene changes 
attributed to the action of adoptively transferred Th1 cells, all datasets derived from 
these mice were corrected to mice receiving control Th0 cells. 




Figure 5.1. Analysis of Th1 and Th0 signalling in the peritoneum. A. The 
levels of IFN-g in the lavage of Il6ra-/- mice 3 h after the transfer of sorted naïve 
(Th0) or SES-polarised Th1 cells together with SES were assessed by ELISA. B. 
Western blot of pY-STAT1 in the peritoneal membrane of Il6ra-/- mice 3 h after 
the transfer of Th0 or Th1 cells together with SES (A and B have been obtained 
from ref 33). C. The levels of IFN-g and IL-6 were measured in WT and Il6-/- mice 
after the transfer of Th0 or Th1 cells together with SES by ELISA. D. qPCR of 
target genes for STAT1 (Irf1, Isg15) and STAT3 (Socs3). E. The genes differentially 
expressed between WT and Il6-/- mice receiving either a single dose of SES or SES 
together with Th0 cells were plotted as a heat map. The expression level is 
represented as normalised read counts per gene (FPKM). Samples were 
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5.3.2.  Transcriptomic analysis of the peritoneal membrane following Th1 
adoptive transfer 
Transcriptomic analysis of the peritoneal membrane after adoptive Th1 cell 
transfer identified 2307 genes as differentially expressed in at least one of the 
experimental conditions when compared to Th0 controls. Hierarchical cluster 
analysis grouped all experimental (Th1) samples together, and these were distinct 
from the controls (Th0) (Figure 5.2).  
Among the 2307 genes identified, 782 were differentially expressed at 3 h 
in WT mice, and 1262 in Il6-/- mice following transfer of Th1 cells. At 6 h, 1280 
and 1195 genes were changed in WT and Il6-/- mice, respectively (Figure 5.3). A 
total of 407 genes were commonly regulated in all conditions (Figure 5.3B). The 
adoptive transfer of Th1 cells strongly induced a large number of genes in both 
genotypes (with an absolute fold change > 4) (Figure 5.3A). 
5.3.3.  Th1 cells control 3 distinct patterns of gene regulation 
Using the statistical approaches outlined in Section 3.2.11, three distinct 
patterns of Th1-mediated gene expression were identified within the peritoneal 
stromal tissue from SES stimulated WT and Il6-/- mice (Figure 3.8). These patterns 
were comparable in both genotypes. Two-sample 2D K-S test and the MVK test 
(described in Chapter 4; Section 4.2.2 & 4.3.3) identified similarities between gene 
clusters (Table 5.1 & 5.2; Figure 5.4). Clusters 1, 2, & 3 from WT mice 
corresponding with Clusters 2, 3 & 1 from Il6-/- mice, respectively. Consistent with 
the nomenclature outlined in Chapter 4, these gene “Behaviours” were termed – 
“Behaviour 4” (B4), “Behaviour 5” (B5) and “Behaviour 6” (B6) (Figure 5.4). 
To investigate the degree of overlap between these Behaviours, the 
percentage of commonly regulated genes over the total 2307 genes was calculated 
(Figure 5.4B & 5.4C). Overall, 89% of all the differentially expressed genes shared 
a common Behaviour between WT and Il6-/- mice (Figure 5.4B). Here, the Jaccard 
index calculated an individual overlap of 0.63 for B4; 0.88 for B5; and 0.8 for B6 
(Figure 5.4C). 
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Figure 5.2. Hierarchical cluster analysis of WT and Il6-/- mice at 3 and 
6 h after receiving SES together with T-cell adoptive transfer. WT and 
Il6-/- mice were administered (i.p.) with a dose of SES together with either sorted 
naïve T-cells (Th0) or ex vivo polarised Th1 cells. The heat map represents the 
expression level of the 2307 genes being differentially regulated in at least one of 
the experimental conditions (Th1) when compared to their correspondent control 
(Th0). The expression level is represented as normalised counts per gene (FPKM). 
Samples were hierarchically clustered using Spearman’s rank correlation.  
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Figure 5.3. Volcano plot analysis of differentially expressed genes in 
WT and Il6-/- mice after the transfer of Th1 cells together with SES. A. 
Data shows the differential expression of genes in WT and Il6-/- mice at 3 and 6 h 
after Th1 adoptive transfer with SES when compared to corresponding Th0 
controls. B. Venn diagram demonstrates the number of genes that are commonly 
or uniquely regulated in each condition.  
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Table 5.1. Two-sample two-dimensional Kolmogorov-Smirnov test 
 
 WT  
Cluster 1 Cluster 2 Cluster 3  
Il6-/- 
Cluster 1 
1.81E-97 1.38E-130 1.36E-03 slopes 
1.07E-107 2.44E-131 1.53E-03 log2FC at 3 and 6 h 
Cluster 2 
2.09E-05 1.84E-257 5.75E-74 slopes 
2.80E-05 1.20E-272 7.68E-105 log2FC at 3 and 6 h 
Cluster 3 
1.12E-244 5.28E-05 1.56E-150 slopes 
6.80E-255 1.22E-04 2.05E-149 log2FC at 3 and 6 h 
 
Clusters from WT and Il6-/- regulated genes were tested for similarly using the two-
sample two-dimensional Kolmogorov-Smirnov. The p value associated to each 
comparison is shown (significance level of 0.1%). Data outlined in blue highlight 
clusters with the closest similarities. Slope = rate of change of log2FC gene 
expression at 3 and 6 h 
 
Table 5.2. Multivariate Kruskal-Wallis test 
 
 WT  
Cluster 1 Cluster 2 Cluster 3  
Il6-/- 
Cluster 1 678.47 740.72 7.38 log2FC at 3 and 6 h 
Cluster 2 28.28 1575.02 674.67 log2FC at 3 and 6 h 
Cluster 3 1529.88 19.39 910.01 log2FC at 3 and 6 h 
 
Clusters from WT and Il6-/- regulated genes were tested for similarly using the 
Multivariate Kruskal-Wallis. The variance associated to each comparison is shown. 
The critical value of chi2 statistics is 13.8155 at significance level of 0.1%. Data 
outlined in blue highlight clusters with the closest similarities. 
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Figure 5.4. Cluster analysis and overlap between the differentially 
expressed genes in WT and Il6-/- mice after Th1 adoptive transfer. A. 
Genes were plotted according to their expression over time (0-3-6 h). Red lines 
represent the mean expression within each group (centroid). Cluster analysis 
showed three patterns of expression (termed “Behaviours”) common in WT and 
Il6-/- deficient mice. The Venn diagrams show the gene overlap in terms of absolute 
number between common Behaviours. B & C. Representation of the percentage 
of overlap between each Behaviour over the total 2307 differentially expressed 
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5.3.4.  Control of STAT1 and STAT3 in the stromal responses to Th1 adoptive 
transfer 
The transfer of Th1 cells promotes an alteration in the relative activation of 
STAT1 and STAT3 within the peritoneal membrane of SES challenged mice. To 
consider the impact of these changes, “Upstream Regulators Analysis” was 
performed in IPA (Figure 5.5). Only B4 and B6 were predicted to have an 
activation of STAT1 and STAT3 above 2 (z-score > 2) (Figure 5.5A & C). Here, 
STAT3 was regulated in WT mice under B4, and in Il6-/- under B6. On the other 
hand, STAT1 activity was enhanced in Il6-/- mice in B4 and in both genotypes under 
B6. This was specific to the 6 h time point.  
Next, studies evaluated the genes predicted as linked to STAT1 and STAT3 
activity in both B4 and B6 (Figure 5.5B & D). Here, most of the genes associated 
with STAT1 and STAT3 were common to both WT and Il6-/- mice. While this was 
particularly evident in B4, genes common to both genotypes were also abundant in 
B6. Top “Canonical Pathway Analysis” of the genes within B4 and B6 showed that 
Th1 adoptive transfer enhanced pathways linked with interferon signalling (Figure 
5.5E). These were observed in both genotypes. 
5.3.5.  Th1 control of the biological functions 
IPA explored the downstream biological functions associated with the genes 
assigned to each pattern of gene regulation. The top functional categories defined 
for B4, B5 and B6 are shown in Figure 5.6. Computational analysis included 
signatures associated to cellular movement and immune cell trafficking, tissue 
morphology, cellular function and inflammatory response. Interestingly, these 
functions were enriched in a similar fashion for both WT and Il6-/- animals. These 
findings demonstrate that the effect of Th1 cell transfer on to the transcriptomic 
profile of the peritoneum is independent of IL-6. 
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Figure 5.5. Pathway analysis. A & C. STAT1, STAT3 and TLR2 activation was 
predicted in IPA for B4 (A) and B6 (C), and their relative z-score plotted in a heat 
map. B & D. Common and unique genes to WT and Il6-/- datasets that are 
predicted to be under STAT1 and STAT3 control in B4 (B) and B6 (D). E. Top 5 
canonical pathways (z-score > 2) in B4 and B6. 
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Figure 5.6. Top functional categories in each Behaviour. Genes within 
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5.3.6.  Host defence-associated functions impaired in Il6-/- are rescued by Th1 
adoptive transfer 
As outlined in Section 4.3.5, biological functions associated with host defence 
were found to be impaired in Il6-/- mice receiving SES alone (Chapter 4). In 
contrast, IPA analysis predicted that the inflammatory response to SES was 
comparable between WT and Il6-/- mice after Th1 transfer (Figure 5.6).  
Subsequent analysis therefore explored the impact of Th1 cells on the 
control of host defence in the peritoneal cavity (Figure 5.7). “Comparison Analysis” 
of the biological functions regulated during single SES stimulation or SES 
stimulation together with Th1 adoptive transfer was performed using IPA (Figure 
5.7A). Functions impaired in Il6-/- mice during acute inflammation were restored 
following Th1 cell transfer, including signatures relevant to activation and immune 
response of leukocytes and phagocytes. This was especially evident at the 6 h time 
point (Figure 5.7A). Interestingly, 136 genes out of the 343 that were uniquely 
regulated in WT mice after SES stimulation were significantly regulated after the 
addition of Th1 cells in both genotypes. What is more, several of these 
corresponded to genes associated in Chapter 4 with host defence, including Lcn2, 
Saa1, Ccr5, Selp, Hp and Vcan, among others.  
“Comparison Analysis” between both experiments was also used to 
determine the contribution of STAT1 and STAT3 in the transcriptome profile of 
the inflamed peritoneum for both WT and Il6-/- mice. Bioinformatic analysis 
focused on the genes that were differentially regulated across all conditions. The 
relative and absolute activation of STAT1 and STAT3, as predicted by IPA 
“Upstream Regulators Analysis”, is presented in Figures 5.7C & D. STAT3 was 
uniquely activated in WT mice after single SES challenge. In the presence of Th1 
cells, STAT1 signalling events were markedly increased and appeared to dampen 
the involvement from STAT3. This increase in STAT1 was observed in both WT 
and Il6-/- mice. This computational approach likely reflects the enhanced stromal 
tissue response to IFN-g signalling seen in mice receiving CD4 Th1 cells. Here, the 
impact of Th1 cells on STAT3 is interesting (Figure 5.7C). These data may reflect 
a statistical over representation of STAT1 signatures and pathways within the 
datasets, but may also support a negative regulation of STAT3 activity by STAT1. 







Figure 5.7. Biological functions associated to host defence. All 
differentially expressed genes in WT and Il6-/- mice during either acute SES-driven 
inflammation or inflammation induced with SES together with Th1 transfer were 
uploaded to IPA, and tested for “Comparison Analysis”. A. Selected biological 
functions under the category Immune Response are presented in a heat map 
showing relative z-score. B. Overlap between the genes uniquely regulated in WT 
mice during SES and genes controlled by Th1 and SES in WT and Il6-/- mice. C & 
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5.3.7.  Impact of STAT1 signalling in tissue remodelling and damage 
Our previous work has shown that enhanced peritoneal STAT1 signalling 
disrupts the homeostatic turnover of extracellular matrix by tissue proteases [33]. 
While this outcome is observed as a result of recurrent episodes of acute resolving 
peritonitis, studies now investigated whether the single adoptive transfer of Th1 
cells is also associated to pro-fibrotic marks in the inflamed peritoneum. RNAseq 
datasets were therefore interrogated to explore changes in the expression of matrix 
proteases and their inhibitors (Figure 5.8). Here, the inflammatory regulation of 6 
ADAMTS (A Disintegrin And Metalloproteinase with Thrombospondin motifs), 4 
ADAMs (A Disintegrin And Metalloproteinase), 7 MMPs and 2 TIMPs was altered 
in response to Th1 cell transfer. A further 10 collagen-encoding genes were also 
differentially regulated by the introduction of Th1 cells (Figure 5.9). Surprisingly, 
all of these genes except one (Col6a5) were differentially downregulated as a result 
of IFN-g signalling in the peritoneal membrane. Collagen fibrils are crosslinked by 
enzymes lysyl oxidases (LOX) to ensure a stable ECM [254-256]. Three lysyl 
oxidases were also differentially regulated in this dataset (Figure 5.9). Interestingly, 
Loxl4 expression was inhibited in Il6-/- mice after SES challenge; and rescued as a 
result of Th1 transfer. Finally, hyaluronic acid (HA) is another large component of 
the ECM [240, 257]. HA is synthetized in the plasma membrane by the enzymes 
Hyaluronic Acid Synthases (HAS) [258], and simultaneously secreted to the 
extracellular space [259]. Has1 and Has2 were differentially regulated within the 
datasets derived from WT and Il6-/- mice (Figure 5.9). Collectively, these data 
suggest that Th1-mediated cell signalling in the peritoneal membrane distorts the 


































































Figure 5.8. Genes related to ECM remodelling. Heat map showing the MMPs 
and TIMPs, ADAMs and ADAMTs genes differentially express under Th1 transfer 
in WT and Il6-/- mice. Genes are plotted using the log2 fold change transformation. 
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Figure 5.9. Genes related to ECM composition and structure. A. Heat 
map showing the differential expression in terms of log2 fold change in the SES and 
Th1 transfer experiment. B. Normalised read counts of selected genes. For Th1 
experiment, the normalised counts under Th1 condition were compared 
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5.4.  Discussion 
Studies in the Jones laboratory have linked the recruitment and local 
expansion of Th1 cells to the development of peritoneal fibrosis as consequence of 
recurrent inflammatory activation. Here, fibrosis is strictly IL-6 dependent [33]. 
At the same time, mice lacking IL-6 also show a defective immune response against 
infection. However, the impact of Th1 cells on the local anti-microbial response is 
unknown. This chapter aimed to understand the holistic changes occurring in the 
peritoneal membrane following Th1 cell expansion and recruitment. 
The ability of IL-6 to signal via STAT3 and to a lesser extend via STAT1 is 
well documented [48]. IL-6 activation of STAT3 contributes to host defence during 
acute inflammation by various mechanisms [21, 95, 243]. IFN-g signals via STAT1 
[117], and the importance of IFN-g-secreting Th1 cells in antimicrobial immunity 
has been broadly recognised [260-262]. Both cytokines have been shown to 
collectively influence neutrophil recruitment and apoptosis during acute 
inflammation [25]. Our findings are in close agreement with these studies, and the 
presence of IFN-g significantly enhanced the peritoneal levels of IL-6. 
A major finding in this Chapter was the evidence that the adoptive transfer 
of Th1 cells into Il6-/- mice restored the regulation of genes important for 
competent anti-microbial defence. Specifically, genes associated with neutrophil 
activation and iron sequestration that were defective in Il6-/- mice challenged with 
SES that did not receive Th1 cells. Importantly, this restoration was linked with a 
switch from a predominant STAT3 to a STAT1 signature in the peritoneal 
membrane. While these findings were derived from a computational analysis of the 
datasets, further studies are required to illustrate the functional significance of this 
potential signalling interplay. These findings also emphasise the congruence 
between IFN-g and IL-6 acting via its soluble receptor in orchestrating innate 
immune responses [25, 263, 264]. Such interactions may also influence 
mechanisms essential for the homeostatic regulation of the extracellular matrix 
[257]. Here, Th1 cells affected changes in the expression of tissue proteases and 
their inhibitors, structural proteins and enzymes required for maintaining the 
integrity of the peritoneal lining [135, 257, 265, 266]. Such processes are relevant 
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to the development of tissue fibrosis. For example, Has2 expression in humans is 
regulated by pro-inflammatory cytokines such as TNF-a, IFN-g and IL-1b [267].  
This enzyme catalyses the production of hyaluronic acid (HA), which contributes 
to angiogenesis [268] and immune regulation [269].  
During acute resolving peritonitis, IL-6 signalling differentially regulated 
the expression of several collagen genes. The presence of Th1 cells significantly 
reduced the expression of these genes. However, Th1 cells dramatically altered the 
expression of collagen type VI (Col6a5) in both WT and Il6-/- mice. Interestingly, 
collagen type VI is increased during fibrogenesis in adipose tissue and liver [270-
273], and its degradation by MMPs is considered an early indicator of liver fibrosis 
[272, 273]. In this regard, the alpha 2 chain of type VI collagen sequestrates pro-
MMPs and inhibits their conversion to the active form [274], stressing the 
importance of this gene in ECM remodelling.  
While these changes in gene expression following adoptive Th1 cell transfer 
suggest an altered control of ECM turnover, it is still unclear whether a single 
challenge of SES together with Th1 cells is sufficient to drive fibrosis. In this 
particular model, the recruitment of Th1 cells only occurs after the four challenges 
with SES [33]. Future studies will investigate whether Th1/IFN-g-driven STAT1 
activation in the membrane is sufficient to trigger peritoneal fibrosis, or whether 
recurrent episodes of inflammation are a prerequisite to prime the stroma for the 
onset of fibrosis. 
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 Tracking neutrophil effector 
functions in inflammation 
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6.1.  Introduction  
Interleukin-6 is essential for host defence against different pathogens [61-
65]. Unpublished data for our laboratory (provided by Coles, Colmont, 
Hammond, Topley & Jones) demonstrate that Il6-/- mice have a reduced capacity 
to resolve peritoneal S. epidermidis infection. This was illustrated by a reduction in 
bacterial clearance from the site of infection and an increased dissemination to the 
bloodstream (Figure 6.1). 
 
 
Figure 6.1. Il6-/- mice display reduced bacterial clearance and increased 
bacterial dissemination compared to WT mice. Peritonitis was induced in 
WT and Il6-/- by a single i.p injection of fluorescently labelled Staphylococcus 
epidermidis (5 x 108 CFU; Section 2.3.3). The peritoneal cavity was lavaged with 2ml 
PBS and blood extracted by cardiac puncture at defined time points. Bacterial count 
was quantified by serial agar viable plate analysis of samples following leukocyte 
pellet lysis. Value represent mean ± SEM n=6. Statistical analysis performed by t-
test, * p<0.05. 
 
Neutrophils are the first inflammatory cells to arrive at sites of bacterial 
infection. Although IL-6 does not affect the rate of neutrophil infiltration, IL-6 
signalling influences the chemokine-directed trafficking [9, 20, 275] and apoptotic 
clearance of these cells [25, 275]. For example, studies in Il6-/- mice show that the 
profile of neutrophil recruitment is both heightened and more sustained in response 
to bacterial agonists (e.g., LPS, SES) [74, 276]. Moreover, neutrophils are 
important regulators of IL-6 bioactivity, and rapidly shed the IL-6R in response to 
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process is critical to both the termination of neutrophil influx and the containment 
of bacterial infection. In this regard, reconstitution of IL-6 trans-signalling in Il6-/- 
mice improves bacterial clearance [102]. The mechanisms underpinning this 
response are currently unknown. Importantly, IL-6 does not appear to directly 
activate neutrophil responses [200, 278, 279]. Given that transcriptomic analysis 
of the peritoneal membrane following SES challenge identified alterations in anti-
microbial activities as a consequence of IL-6 deficiency, and that IL-6 trans-
signalling suppresses the expression of neutrophil-activating chemokines (e.g., 
CXCL1, CXCL8) by stromal tissue, it was hypothesised that IL-6 trans-signalling 
may also control the expression of factors that influence neutrophil effector 
functions.    
Studies outlined in this Chapter will examine how IL-6 signalling influences 
the effector characteristics of the infiltrating neutrophils during acute bacterial 
infection.  
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6.2.  Materials and Methods 
6.2.1.  In vivo neutrophil effector function assay 
To assess the activation and effector characteristics of infiltrating 
neutrophils, WT and Il6-/- mice were administered (i.p.) with Cell Trace Far Red 
(CT-FR; 8 µM) labelled S. epidermidis (5x108 cfu/mice in 0.5 ml of sterile PBS) (see 
Section 2.2.3 & Section 2.3.3). At designated time points, the peritoneal cavity was 
lavaged with 2 ml of RPMI 1640 containing 5 µM of aminophenyl fluorescein (APF; 
see Section 2.3.5). Neutrophil phagocytosis and respiratory burst activity were 
examined by flow cytometry and imaging flow cytometry (Section 2.5.8). 
6.2.2.  Ex vivo neutrophil effector function assay 
Whole blood was collected by cardiac puncture (Section 2.5.1). Samples 
were diluted 1:10 and washed 3 times in ice cold PBS. Cells were resuspended in 
serum-free RPMI 1640 containing 5 µM of APF and incubated for 30 min at 37ºC. 
APF-loaded cells were split into 100 µl aliquots and cultured at 37ºC with an equal 
volume of pre-warmed, opsonized CT-FR-labelled S. epidermidis (Section 2.2.3 & 
Section 2.2.4). Cells were incubated for a set of pre-determined time (0-30 min) 
before transfer to an iced water bath. Treated cells were maintained on ice for all 
subsequent steps prior to analysis by means of flow cytometry (Section 2.5.8). 
6.2.3.  Imaging flow cytometry analysis of neutrophil effector function 
Neutrophils were treated as specified in Sections 6.2.1 & 6.2.2. After surface 
marker staining for Ly6G (Table 2.2), cells were resuspended in 100 µl of sterile 
PBS, and events (>8000 events per sample) were acquired at a low imaging rate 
and 60X amplification using the Amnis ImageStream®X Mark II Imaging Flow 
Cytometer (Amnis). The imaging rate is the number of cells acquired per second. 
Image amplification of 60X and a low rate of imaging ensured a high resolution and 
sensitivity during cell acquisition. 
  118 
Acquired events were gated according to Area and Aspect Ratio Intensity in 
Channel 1 to discriminate single cells using the ImageStream software IDEAS 
(Amnis). Single cells were then plotted against Gradient RMS (Root Mean Square 
of the rate of change of the image intensity profile – defines events on focus) in 
Channel 1 to select cells inside the plane of focus. Neutrophils were gated according 
to Ly6G staining, visualised in Channel 7. Here, Channel 7 was chosen to minimise 
emission spectra overlap with APF (Channel 2) and CT-FR-labelled S. epidermidis 
(Channel 11).  
Phagocytic activity was expressed as a Phagocytic Index, which reflects the 
number of bacteria ingested per a Ly6G+ neutrophil during the incubation period. 
To evaluate the phagocytic index of neutrophils undergoing phagocytosis, the 
Application “Spot Counting” in IDEAS was used. Spots were counted in Channel 
11 based on the distribution of CT-FR bacterial staining. The efficiency of 
phagocytic uptake was quantified by examining cells displaying either a low (1-2 
counts) or high number (3 counts or more) of ingested bacteria. 
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6.3.  Results 
6.3.1.  Neutrophil gating 
Flow cytometry or imaging flow cytometry were used to monitor the 
activity of both circulating and infiltrating neutrophils (Figure 6.1). Neutrophils 
were identified by conventional flow cytometry according to Ly6G antibody 
staining and Side Scatter (SSC) analysis following by doublet discrimination by 
Forward Scatter (FSC) Linear and Forward Scatter Area analysis. Debris was 
discriminated using SSC Area and FSC Area (Figure 6.2A). Neutrophils accounted 
for ~14% of the total circulating leukocytes, while neutrophils recruited to the 
peritoneal cavity reflected ~50% of the inflammatory infiltrate at 3 h post bacterial 
infection. An equivalent neutrophil gating strategy is shown using imaging flow 
cytometry (Figure 6.2B).   
6.3.2.  Optimisation of neutrophil effector function 
The application of fluorescently labelled bacteria in combination with the 
peroxidase substrate APF provides an opportunity to simultaneously evaluate the 
phagocytic uptake of bacteria and respiratory burst activity in neutrophils.  
To identify the optimal labelling protocol for tracking S. epidermidis in our 
in vivo and ex vivo model systems, bacteria were incubated with varying 
concentrations of CT-FR (see Section 2.2.3). For ex vivo studies, 1 µM provided the 
best dye concentration to distinguish CT-FR positive and negative populations 
(Figure 6.3A). This concentration was however raised to 8 µM for all in vivo studies 
(Figure 6.3B). 
Studies next determined the optimal concentration of APF for detection of 
reactive oxygen species (e.g., OH-, NO3- and ClO-) by activated neutrophils. Based 
on the manufacturer’s instructions (APF, Life Technologies) 5 µM of APF was 
deemed sufficient for both the ex vivo and in vivo experimental systems (Figure 6.3 
C & D, respectively). Importantly, 8 µM CT-FR and 5 µM APF could be used in 
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combination to simultaneously track both neutrophil phagocytosis and respiratory 




Figure 6.2. Gating strategy for neutrophil identification using flow 
cytometry (A) and ImageStream (B). A. Whole blood or peritoneal 
infiltrating leukocytes were collected by cardiac puncture or peritoneal lavage, and 
the neutrophil population assessed by flow cytometry using SSC, FSC and Ly6G 
membrane expression (A) or imaging flow cytometry using Area, Aspect Ratio 
Intensity and Gradient RMS in Channel 1 and fluorescence intensity in Channel 7 
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Figure 6.3. Optimisation of S. epidermidis Cell Trace Far Red Staining 
and APF load. A & C. Whole blood was collected by cardiac puncture and 
incubated with increased dye concentrations of CT-FR labelled S. epidermidis (A) 
or 5 µM of APF (C) for 30 min at 37ºC prior to flow cytometry. B, D & E. 
Peritoneal inflammation was established with 0.5 ml of S. epidermidis labelled with 
increasing concentrations of CT-FR dye (B) and infiltrating neutrophils collected 
by peritoneal lavage with 2 ml of RPMI 1640 containing 5 µM of APF before 
analysis by flow cytometry analysis (B & D) or ImageStream (E). 
 
 
Figure 6.4. Ex vivo neutrophil effector function. Whole blood circulating 
neutrophils from WT and Il6-/- mice were incubated with 5 µM of APF (30 min, 
37ºC) prior to stimulation with opsonized, fluorescently-labelled S. epidermidis over 
a 30 min time course at 37ºC. Flow cytometry allowed detection of neutrophils 
undergoing phagocytosis and respiratory burst. Graphs represent mean ± SEM of 
n = 2 mice per group. 
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6.3.3.  Circulating neutrophils display a similar effector function in WT and 
Il6-/- mice 
Using the parameters defined in Section 6.3.2, studies compared the effector 
characteristics of circulating neutrophils from WT and Il6-/- mice (Figure 6.4). 
Consistent with previous studies from the Jones laboratory [200], circulating 
neutrophils from WT and Il6-/- mice elicited comparable responses when evaluating 
phagocytosis and respiratory burst. 
6.3.4.  Infiltrating neutrophils elicit distinct effector function 
Studies next compared the effector characteristics of infiltrating neutrophils 
from WT and Il6-/- mice during acute bacterial peritonitis. Mice were challenged 
(i.p) with fluorescent-labelled S. epidermidis (5x108 cfu/mice; see Section 2.3.3). An 
independent group of Il6-/- mice received a dose of S. epidermidis together with the 
IL-6-sIL-6R chimeric fusion protein HDS (50 ng/ml). Six hours after bacterial 
challenge, mice were sacrificed and the peritoneal cavity lavaged with 2 ml of RPMI 
1640 containing 5 µM of APF. Phagocytosis and respiratory burst activity was 
monitored as described before (Figure 6.5). Infiltrating neutrophils from Il6-/- mice 
showed a defective neutrophil effector response when compared to WT control 
mice (Figure 6.5A). This defect was partially rescued through reconstitution of IL-6 
trans signalling with HDS, and Il6-/- mice receiving both bacteria and HDS displayed 
a similar phagocytic response to WT (Figure 6.5A).  
ImageStream also compared the morphology of infiltrating neutrophils from 
both genotypes and was used to quantify the number of bacteria actively engulfed 
by these cells (Figure 6.5B-D). Studies considered those neutrophils displaying a 
high phagocytic capacity. Neutrophils from Il6-/- mice displayed a reduced uptake 
of bacteria as compared to WT mice (Figure 6.5C & Figure 6.5D). Notably, this 
defect in bacterial uptake was restored by administration of HDS (Figure 6.5C & 
D). 
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Figure 6.5. In vivo neutrophil effector function. WT and Il6-/- mice were 
challenged with fluorescently-labelled S. epidermidis (8 µM) and the lavage obtained 
with 2 ml of APF (5 µM) at 6 h after infection. A. Total number of neutrophils 
positive for phagocytosis, respiratory burst or both. B. Spot count assessment of 
the infiltrating neutrophils using ImageStream IDEAS software, where R1 and R2 
refers to neutrophils with low and high bacterial uptake, respectively. C. 
Neutrophils with high bacterial uptake. D. Representative images in ImageStream.  
Statistical analysis was performed by one-way ANOVA with Bonferroni correction 
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6.3.5.  Relationships between CD62L and IL-6R shedding and neutrophil 
effector function 
The data presented in Figure 6.4 suggest that IL-6 activity regulates the 
functional characteristics or responsiveness of infiltrating neutrophils. To examine 
this in more detail studies monitored CD62L shedding as an index of neutrophil 
function following extravasation into the peritoneal cavity [20, 95, 280, 281]. 
Neutrophils were isolated at 3 and 6 h post infection of WT and Il6-/- mice (Figure 
6.6). Circulating neutrophils were used as control (Figure 6.6). Neutrophils from 
both WT and Il6-/- mice showed a similar reduction in CD62L expression following 
entry into the peritoneal cavity (Figure 6.6). Thus, the reduced anti-microbial 
neutrophil functions seen under IL-6 deficiency appear to reflect an impaired 
neutrophil response to the local inflammatory environment rather than an intrinsic 





Figure 6.6. CD62L shedding. WT and Il6-/- mice were challenge with SES. After 
3 and 6 h, infiltrating neutrophils were recovered by peritoneal lavage and the 
levels of CD62L assessed by flow cytometry. Circulating neutrophils were used as 
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6.4.  Discussion 
Studies investigated the effector characteristics of neutrophils in WT and 
Il6-/- mice during acute resolving bacterial peritonitis. Infiltrating neutrophils from 
Il6-/- mice showed a defective anti-microbial response at the site of infection, as 
illustrated by a reduction in bacterial phagocytosis and respiratory burst. 
Conversely, ex vivo stimulation of neutrophils from whole blood with S. epidermidis 
showed a similar effector activity of these cells between both genotypes. These data 
suggest that the local microenvironment contributes to the control of bacterial 
infection by neutrophils.  
Previous studies illustrate that IL-6 does not directly activate neutrophil 
effector characteristics [278, 279]. Indeed, infiltrating neutrophils rapidly shed 
IL-6R from their surface following entry into inflamed tissues [200]. This sIL-6R 
release moderates IL-6 responsiveness and promotes IL-6 trans-signalling within 
the stromal compartment. We propose that this mechanism may orchestrate the 
release of other regulatory factors that help shape neutrophil activation. In line with 
this idea, previous studies in our laboratory have shown that the induction of 
bacterial peritonitis in Il6-/- mice receiving HDS resulted in improved bacterial 
clearance and reduced dissemination to the bloodstream. In the present study, 
reconstitution of IL-6 trans-signalling in Il6-/- mice with HDS was accompanied by 
a restoration of neutrophil phagocytosis. However, HDS administration did not 
restore respiratory burst. Circulating neutrophils are typically quiescent, which 
minimizes the release of ROS and proteolytic granules that would otherwise induce 
tissue damage [174]. Neutrophils therefore require prior activation or priming to 
be fully effective at the site of infection. This is usually a multistep process that is 
initiated during their extravasation from the blood to the inflamed tissue [174]. 
Data presented herein suggest that the cytokine control of phagocytosis and 
respiratory burst may require different signals. Previous studies are in close 
agreement with these findings. For example, Dewald and co-workers have 
reported that two independent signalling pathways are necessary for neutrophil 
activation and the subsequent respiratory burst response [282]. This is akin to the 
signalling differences observed in response to neutrophil-activating chemokines. 
For example, neutrophil degranulation and chemotaxis in response to IL-8/CXCL8 
  127 
and GROa/CXCL1 are mediated by the chemokine receptors CXCR1 and 
CXCR2. In contrast, the activation of respiratory burst and associated 
phospholipase D activity is exclusive to CXCR1 [176]. Taken together, these 
studies support the idea that phagocytosis and respiratory burst responses are 
primed by two independent mechanisms. While phagocytosis is directly mediated 
by IL-6 trans-signalling, it is proposed that additional signals, (e.g., PGD2 
signalling) are needed to fully promote respiratory burst [200]. Interestingly, these 
priming mechanisms are independent to CD62L or IL-6R shedding, which is a 
hallmark of actively recruited neutrophils [20, 95, 280, 281].  
Neutrophil phagocytosis and respiratory burst were monitored by flow 
cytometry and imaging flow cytometry. Respiratory burst was examined using 
APF. While APF provides a specific measurement of the reactive oxygen species 
OH-, NO3- and ClO-, it does not account for the production of other radicals such 
as H2O2 or NO. Therefore, these limitations should be taken into consideration. In 
this regard, the use of better fluorescent dyes or novel nanoprobes could be used 
to improve specificity and sensitivity for ROS detection [283].   
The advantages of imaging flow cytometry over conventional flow 
cytometry consist in integrating two components: the spatial resolution provided 
by fluorescence microscopy with the quantitative analysis of flow cytometry [284]. 
In this case, imaging flow cytometry allowed evaluation of the co-localisation of the 
bacterial uptake and the subsequent respiratory burst within the phagosome. 
Imaging flow cytometry also allowed for the quantification of internalised particles. 
Here, the enhanced phagocytosis detected in WT neutrophils and Il6-/- neutrophils 
receiving HDS was the consequence of a substantial increase in bacterial uptake. It 
is proposed that the elevated phagocytic index facilitates bacterial clearance at the 
site of infection, preventing their dissemination to the circulation and therefore 
ensuring a successful host defence [102].  
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 Il6st gene splicing generates a soluble 
gp130 in mice 
  
  129 
7.1.  Introduction 
The signalling complex for IL-6 comprises two receptor subunits: the non-
signalling a-receptor (CD126, IL-6Ra, encoded by the Il6ra gene) and the signal 
transducing b-receptor glycoprotein 130 kDa (CD130, gp130, encoded by Il6st) 
[48]. Interleukin-6 binds both a membrane-associated and soluble form of the IL-6R 
(sIL-6R). These interactions afford IL-6 with the capacity to signal through two 
distinct mechanisms, termed classical IL-6R signalling and IL-6 trans-signalling [41, 
48]. Both mechanisms rely on the membrane bound signal-transducing gp130 to 
transmit the IL-6 signal in target cells. While gp130 is ubiquitously expressed, 
IL-6R is restricted to hepatocytes, leukocytes, megakaryocytes and some 
specialised stromal cells [41]. These cells respond directly to IL-6 through classical 
IL-6R signalling. Conversely, cells that express gp130 remain responsive to IL-6 
once IL-6 is bound to sIL-6R. Interleukin-6 trans-signalling is tightly regulated and 
is blocked by soluble forms of gp130 (sgp130) [78, 80]. Indeed, an engineered Fc-
dimerized variant of sgp130 (sgp130-Fc) provides protection in several 
inflammatory diseases and cancer [81-83]. This modality is currently in clinical 
development under the drug name olamkicept [112].   
To date, four variant forms of sgp130 with apparent molecular weights of 
50, 75, 90 and 110 kDa have been detected in humans [285-288]. Although their 
mechanism of generation is still under investigation, studies suggest they are 
derived from alternative processing of the Il6st transcript. Limited proteolysis of 
the membrane bound gp130 may also contribute to the generation of sgp130, but 
this process only accounts for a minimal proportion of sgp130 [78, 79]. While a 
murine equivalent of sgp130 has been identified [289], the mechanism of generation 
of this sgp130 has not been defined. 
The murine Il6st has 10 different annotated transcripts predicted by the 
Ensembl project [290] (Figure 7.1). Of them, only 2 transcripts (Il6st-203 and Il6st-
206) have been annotated with a Transcript Level of Support of 1 (TSL1) [225] – a 
method to assess whether a given transcript is supported by primary data (mRNA 
and Expressed Sequence Tag) from the Ensembl and UCSC projects [225]. All 
other transcripts have been annotated with a TSL of 5 (TSL5), which means that no 
single mRNA transcript has been found to support the model structure, and 
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therefore their annotation should be considered speculative [225]. Importantly, 
only the transcript Il6st-203 (derived by RefSeq) has been demonstrated to encode 
for the membrane-bound murine gp130.  
The human and murine Il6st share 86% and 77% homology at the genetic 
and protein level, respectively. Given the degree of homology between both genes, 
and the presence of several forms of sgp130 in human, it is proposed that similar 
sgp130 variants should co-exist in mice. This Chapter aims to investigate potential 
forms of sgp130 in mice using the RNA-seq data described in Chapter 3. 
Specifically, studies aim to: 
a. Identify a soluble form of gp130 in mice.  
b. Annotate a new transcript encoding for a viable form of sgp130 in mice. 
c. Purify and characterize a murine form of sgp130.  
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7.2.  Materials and methods 
7.2.1.  Differential exon usage analysis and de novo transcript assembly 
The Ion Torrent System provides an opportunity to investigate high-
throughput sequencing data from relatively long sequencing reads. This includes 
the analysis of exon boundaries and predictions of alternative mRNA splicing 
variants. The Bioconductor package DEXSeq [291] was used to generate a statistical 
evaluation of differential exon usage within the RNA-seq datasets.  
Reads mapping to the Il6st gene were used to construct de novo transcripts 
from these region using the computational software Cufflinks [292]. 
7.2.2.  Affinity purification of sgp130 
Soluble gp130 was purified from WT peritoneal lavage samples using the 
GlycoLink Micro Immobilization Kit affinity columns (Thermo Fisher Scientific) as 
described by manufacturer’s instructions. Briefly, a hydrazide-linked resin was used 
to prepare affinity columns conjugated a with polyclonal goat anti-mouse gp130 
antibody (500 µg/column; AF468; R&D Systems). Peritoneal lavage samples 
(300 µl) were loaded onto the affinity column and incubated overnight at 4oC with 
agitation. After incubation, columns were centrifuged at 10000xg for 1 min to 
collect the flow-through fraction. The loading step was repeated 2 times with fresh 
sample to a total of 3 rounds of overnight incubation. Proteins attached to the 
columns were eluted with 200 µl of eluting buffer (0.1M glycine, pH 2.5). Eluted 
samples were equilibrated with 10 µl of Tris-HCl (1M, pH 9.0) and stored at -80oC 
in the presence of protease inhibitors (Promega). 
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7.2.3.  Protein SDS-PAGE electrophoresis and detection using silver staining 
Proteins were detected by silver staining following electrophoretic 
separation by SDS-PAGE. Briefly, samples were diluted in 4x protein sample buffer 
under reducing conditions (40% w:v glycerol, 240 mM Tris-HCl pH 6.8, 8% w:v 
SDS, 0.04% v:v bromophenol blue, 5% v:v b-mercapto-ethanol) and incubated for 
5 min at 95oC to denature proteins prior to SDS-PAGE. Denatured samples were 
loaded onto a precast 12% (w:v) polyacrylamide gel (Bio-Rad). Electrophoretic 
separation was performed at 100 V in electrophoresis running buffer containing 25 
mM Tris, 192 mM Glycine, 0.1% SDS (w:v) (pH 8.3) using a Mini-PROTEAN 
Electrophoresis Cells System (Bio-Rad).  
After separation, proteins were detected by silver staining using the 
ProteoSilverTM Silver Stain Kit (Sigma) as per manufacturer’s instructions. All steps 
were conducted at room temperature on an orbital shaker with agitation of 60 rpm. 
Gels were fixed overnight in 100 ml 50% (v:v) ethanol and 10% (v:v) acetic acid 
diluted in deionised water. After fixation, gels were washed in 100 ml of 30% (v:v) 
ethanol and 200 ml of deionized water for 10 min each prior sensitization (10 min) 
with 100 ml of sensitizer solution. Sensitized gels were washed twice with 200 ml 
of deionised water (10 min each) and equilibrated with 100 ml of silver solution 
(10 min). Gels were then washed with 200 ml of deionised water for 1 min prior 
to development with 100 ml of developer solution. Due to the low yield of sgp130 
purified, gels were developed for 8-10 min. After development, 5 ml of 
ProteoSilver stop solution were added to the gels for 5 min. Gels were visualized 
using the Fluor-S Multi-imager (Bio-Rad). 
7.2.4.  Western blotting 
Proteins separated by SDS-PAGE (Section 7.2.3) were transferred onto 
polyvinylidene difluoride (PVDF) membranes (Bio-Rad) by semidry electro-
blotting (60 V for 1 h 30 min). Transfer buffer contained 25 mM Tris, 192 mM 
glycine, 10% (v:v) methanol. Membranes were blocked in a solution of Tris-
buffered saline (TBS; 10 mM Tris-HCl, pH 7.6 and 150 mM NaCl) supplemented 
with 0.1% (v:v) Tween 20 (termed TBST) and 5% (w:v) skimmed milk powder 
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for 1 h, prior to overnight incubation with polyclonal goat anti-mouse gp130 
antibody (0.2 µg/ml; AF468; R&D Systems). This was followed by a 1 h incubation 
at room temperature with horseradish peroxidase-conjugated secondary antibody 
(polyclonal rabbit anti-goat; 1:2000 dilution; DAKO) in TBST with 5% BSA. 
Proteins were detected using the chemiluminescent kit SignalFireTM ECL Reagents 
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7.3.  Results 
7.3.1.  Differential exon usage identifies alternative splicing of Il6st gene  
Experiments determined the expression of IL-6 receptor components in 
RNA-seq datasets from the peritoneal membrane of SES challenged mice. Data was 
derived from both mice treated with SES alone or in combination with adoptively 
transferred Th1 cells. Differential exon usage (DEXSeq package, Bioconductor, 
Section 7.2.1) identified a spliced variant of Il6st (encoding for gp130) in all datasets. 
Comparison of datasets from WT and Il6-/- mice showed the alternate Il6st 
transcript to be differentially expressed at 6 h post SES challenge (Figure 7.1). This 
difference was however lost following the adoptive transfer of Th1 cells. No 
differences in Il6ra (encoding the cognate IL-6Ra) were observed in any condition. 
7.3.2.  Prediction of alternative splicing of Il6st in the peritoneal membrane 
correlates with increased sgp130 in the peritoneal cavity 
To investigate whether the splicing of Il6st in the peritoneum accounted for 
the presence of sgp130 in the peritoneal cavity, WT and Il6-/- mice were challenged 
(i.p.) with either SES alone or in combination with Th1 cells (Sections 2.3.2 & 2.3.4, 
respectively). Peritoneal lavage samples were collected at 3 and 6 h post injection. 
Soluble gp130 and sIL-6R were quantified using ELISA (R&D Systems, Section 
2.5.8) (Figure 7.2). Peritoneal sgp130 was detected in both SES challenged WT 
and Il6-/- mice (Figure 7.2A). Consistent with the DEXSeq prediction shown in 
Figure 7.1, peritoneal sgp130 levels were significantly higher in WT mice at 6 h 
post SES challenge (Figure 7.2). Transfer of Th1 cells enhanced the detection of 
peritoneal sgp130 in SES challenged mice (Figure 7.2B). Interestingly, sgp130 
levels correlated with the detection of peritoneal sIL-6R lavage samples (Figure 
7.2C). Thus, this data illustrates a close association between the control of positive 
and negative regulators of IL-6 trans-signalling.   
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Figure 7.2. Detection of sgp130 in the peritoneal cavity. A & B. Levels of 
sgp30 in peritoneal lavage of mice receiving SES (A; n = 4 mice per group) or 
Th1+ SES (B; n = 3 mice per group). C. Correlation between the levels of sgp130 
and sIL-6Ra in mice receiving SES alone. Statistical analysis was performed by two-




























































































Figure 7.1. Differential exon usage analysis. Alternative splicing (DEXSeq 
package, Bioconductor, p<0.01) was assessed in RNA-seq data sets from the 
peritoneal membrane of WT and Il6-/- mice at 6 h post SES stimulation. Pink 
corresponds to predicted significant alternative exon usage. 
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7.3.3.  Identification of a novel transcript for sgp130 
Studies next explored the annotated transcripts for Il6st based on the 
Ensemble annotation database [290] (Figure 7.3). The Il6st gene has 10 transcripts 
(outlined in Figure 7.1). However, only two of these have been identified with a 
TSL1 definition [225]. Transcripts annotated with a TSL5 were considered 
speculative, and therefore discarded from further analysis.  
The transcript Il6st-203 encodes a protein of 917 amino acids that encodes 
the canonical membrane-bound gp130 (Figure 7.3). Il6st-203 remains the only 
murine gp130 transcript that has been functionally characterised in vivo [293]. The 
shorter Il6st-206 transcript encodes a protein of 164 amino acids (Figure 7.3B). 
Sequence analysis of the Il6st-206 variant suggested that the expression of this 
transcript would generate a protein lacking the type-I cytokine receptor-binding 
determinant – the WSXSW amino acid motif [294, 295]. Thus, if the Il6st-206 
variant were expressed in vivo it would generate a functionally inactive form of 
sgp130.  
To evaluate the expression of alternative transcripts for the Il6st gene, de 
novo transcript assembly was performed using Cufflinks [292]. Samples obtained 
from WT and Il6-/- mice at 6 h after SES challenge were used for this analysis. De 
novo transcript assembly identified a novel Il6st transcript that is predicted to 
contain two additional exons as compared to Il6st-206 (termed Il6st-SES; Figure 
7.3A). This new form retains the correct reading frame of the reference sequence 
and predicts a stop codon just after the end of exon 7. Sequence analysis of the new 
transcript predicted a protein of 271 amino acids (Figure 7.3B). Although longer, 
this variant would also lack the WSXSW motif.  
To establish whether other cell populations within the peritoneal cavity 
could generate sgp130, studies examined the contribution of tissue resident and 
infiltrating mononuclear cells. In collaboration with Professor Philip R. Taylor 
(Division of Infection & Immunity, The School of Medicine, Cardiff University), 
RNA-seq datasets were obtained for peritoneal resident macrophages isolated from 
zymosan treated mice (Figure 7.4). Cufflinks assembly identified a new transcript 
for the Il6st gene, which included exon 10 (Figure 7.4A). The identity of this 
transcript was also verified using the DEXSeq prediction (Figure 7.1). 




Figure 7.3. Sequence analysis of Il6st transcripts. A. Schematic 
representation of the transcripts Il6st-203 (membrane bound gp130, RefSeq), Il6st-
206, and computationally predicted novel transcript (termed Il6st-SES). B. Amino 
acid sequence for the transcripts Il6st-203, Il6st-206 and Il6st-SES.  
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Figure 7.4. De novo assembly of Il6st gene transcripts. A. RNA-seq data 
derived from resident peritoneal macrophages isolated from zymosan treated mice 
were subjected to de novo transcript assembly. B. Amino acid sequence analysis of 
the potential novel transcript when compared with the reference sequence. C. 
Quantification of IL-6 and sgp130 in the culture supernatant of SES-stimulated 
resident peritoneal monocytic cells by ELISA (n = 2 mice). nd, not detected.    
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Translation of this gene sequence predicted a protein of 424 amino acids, 
which includes the WSXSW motif (Figure 7.4B). However, analysis of conditioned 
media from ex vivo SES stimulated resident peritoneal monocytic cells (Section 
2.4.2) could not detect the secretion of this protein (Figure 7.4C). 
7.3.4.  Purification of sgp130 from peritoneal lavage 
Experiments next aimed to purify sgp130 from the peritoneal cavity by 
affinity chromatography. Peritoneal lavage samples from WT mice at 3 h after SES 
stimulation were used. The purity and identity of the putative sgp130 isolated was 
verified by silver staining of PAGE-SDS gels (Figure 7.5A). The eluted monomeric 
protein had a predicted molecular mass of approximately 97 kDa (Figure 7.5A). 
However, the identity of this protein could not be confirmed by Western blot using 
the same polyclonal anti-gp130 antibody utilised during the purification (Figure 
7.5B). Here, protein standards for sIL-6R and sgp130 were used as negative and 
positive control, (Table 2.3). It is proposed that the low yield of the purification, 
together with the low specificity of the polyclonal anti-gp130, made detection of 
sgp130 challenging.  
Figure 7.5. Purification of sgp130. A. Sgp130 was purified by column 
affinity, and eluted fractions (1, 2 and 3) loaded in an SDS-PAGE gel prior 
protein detection by silver staining. Goat anti-mouse gp130 antibody was used 
as a control. B. Western blot of sgp130 eluted fractions (lane 3: eluted fraction 
2; lane 4: eluted fraction 3) using anti-mouse gp130 (left) or anti-goat IgG (right) 
as primary probes. Recombinant sgp130 obtained from the standard of gp130 
ELISA (R&D; lane 1) and recombinant IL-6Ra obtained from the standard of 
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7.4.  Discussion 
Glycoprotein 130 is the common signal transducing receptor for all 
IL-6-related cytokines [48]. Several forms of soluble gp130 have been identified in 
humans that are generated through alternative splicing of the Il6st gene [285-288]. 
All forms retain a capacity to block IL-6 trans-signalling in vivo [78, 80]. 
Importantly, studies have shown that an engineered Fc-dimerized variant of sgp130 
(sgp130-Fc) provides protection in several experimental models of inflammation 
and cancer [81-83]. In mice, a murine equivalent of human sgp130 has been 
previously identified [289]. However, the mechanisms of generating sgp130 in 
mice remain unclear.  
De novo assembly was used to identify potential new transcripts for the Il6st 
gene in mice. This analysis relies on the combination of high quality sequencing data 
and complex computer algorithms to produce the most accurate assembly [227]. In 
the present study, de novo assembly was performed using next generation 
sequencing reads from two different platforms. RNA obtained from peritoneum 
samples after SES stimulation (Chapter 3) were sequenced using the Ion Torrent 
System (Life Technologies). This technology produces relatively long, singled-end 
(SE) reads. In contrast, data from peritoneal resident macrophages was obtained 
with the Illumina platform, which generates short paired-end sequencing reads 
(Table 7.2) [296-298]. In this regard, neither the Illumina nor the Ion Proton 
Systems provided optimal data for de novo transcript assembly. While the longer 
sequencing reads generated with the Ion Torrent System allows improved mapping 
of differential transcripts, the relative low depth of coverage and SE reads obtained 
in this experiment made the computational analysis for de novo discovery 
challenging. Conversely, data from zymosan-stimulated peritoneal resident 
macrophages, albeit produced with higher coverage and PE reads, was only 
available from a single experimental sample. Here, the putative transcript identified 
in datasets derived from peritoneal macrophages was predicted to extend through 
exon 10. Recently, Garbers et al. identified a human sg130 variant (termed sgp130-
E10) that terminates in exon 10 as a consequence of alternative polyadenylation 
[288]. However, mice lack an alternative polyadenylation site in intron 10 [288]. 
In addition, culture of peritoneal resident cells with SES did not produce a 
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detectable form of sgp130 in the culture supernatants. In conclusion, while the data 
generated is interesting and will be investigated further, based on current analyses 
only speculative conclusions can be drawn.  
 
Table 7.1. Characteristics of the sequencing platforms relative to de 
novo assembly 
 
 Ion Torrent Illumina 
End sequencing Singled-End Paired-End 
Read length 120 bp 50-75 bp 
Replicates 3 1 
 
 
Although the identification of a sgp130 variant in mice has been elusive at 
the transcript level, a putative form of sgp130 could be isolated from the peritoneal 
lavage of WT mice stimulated with SES, with or without Th1 cell co-transfer. The 
eluted putative protein had an approximate molecular mass of 97 kDa, which 
resembles to the only form of murine sgp130 previously described in the literature 
[289]. In addition, a sgp130 of similar molecular mass has been identified in human 
serum [285].  
The purification of sgp130 encountered several challenges. First, 
purification required several rounds of incubation between the sample and the 
resin-linked polyclonal anti-mouse gp130 antibody to obtain a sufficient yield that 
could be detected by silver staining. Second, the eluting conditions had to rely on 
a lower pH than that recommended in the manufacturers’ instructions (GlycoLink 
Micro Immobilization Kit affinity columns; Thermo Fisher Scientific). This led to 
partial damage of the conjugated antibody, and was identified in the sgp130 elute 
fractions (Figure 7.5A). Finally, the detection of sgp130 by silver staining relied on 
fixation in 50% ethanol and 10% acetic acid overnight in order to minimize the 
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background due to the long exposure time during detection. Unfortunately, 
western blotting was unable to detect sgp130 due to antibody affinity or cross-
reactivity with other proteins.  
In conclusion, while a soluble form of gp130 has long been identified in mice 
[289], the mechanism by which it is produced remains to be elucidated. In the 
context of peritoneal inflammation, we proposed that alternative splicing in the 
Il6st gene occurring in the peritoneal membrane might account for the sgp130 
detected in peritoneal lavage. However, further studies are needed to determine 
the precise sequence of the transcript that encodes this form of sgp130, as well as 
to determine whether other forms of sgp130 are generated in mice. 
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 General Discussion 
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8.1.  Introduction 
Research conducted in this thesis aimed to evaluate how inflammatory 
responses elicited with the peritoneal membrane contribute to the control of 
competent host-defence, and inflammation-induced tissue damage. Combining 
RNA-seq analysis and bioinformatic pathway analysis, studies explored the 
interplay between stromal tissue and infiltrating leukocytes in an acute model of 
resolving inflammation. These investigations contributed to some new and exciting 
findings relevant to the biological activity of IL-6 in infection. 
 
8.2.  Relative activities of STAT1 and STAT3 ultimately define the 
transcriptional profile of the peritoneal membrane during 
inflammation  
The transcriptome is a complex “dynamic entity” that is constantly being 
modified and adjusted to deliver specific responses that shape the outcome of 
inflammation. Understanding these dynamics requires a systematic evaluation of 
these broad changes [299, 300]. The novelty of this thesis, thus, resides in the use 
of a holistic approach to investigate the course of inflammation and the mechanisms 
that determine an effective immune response. 
Studies focused on the changes that occur in the peritoneum during acute 
resolving inflammation, and in a setting that promotes a more pro-fibrotic 
outcome. In our model of peritoneal inflammation, both situations rely on IL-6 and 
IFN-g signalling through the Jak-STAT pathway, and a selective activation of the 
latent transcription factors STAT1 and STAT3 [21, 33, 95, 243]. Increased 
evidence over the last decade has shown that the ultimate transcriptional output 
associated to these transcription factors depends on the fine balance between their 
relative activities [301, 302]. They frequently oppose each other. For example, 
STAT1 and STAT3 depict opposing roles in IL-21 signalling in CD4+ T cells [303]. 
Similarly, genetic mutations that limit the activity of one of these transcription 
factors is often associated with increased activity of the other [90, 264, 304, 305]. 
This is especially relevant in situations where cytokines that signal through STAT1 
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and STAT3 dictate opposite outcomes. For example, STAT3 and STAT1 have 
contrary roles in regulating survival, proliferation, motility and immune tolerance, 
and their cross-regulation affects tumor expansion, survival and metastasis [301, 
306]. During peritonitis, our data shows that pro-fibrotic Th1-driven STAT1 
activity in the membrane triggers a more robust and sustained response than that 
observed during acute inflammation, where STAT3 activity was predominant in 
WT mice (Figure 8.1). Current studies in our laboratory are in line with these 
findings. Here, preliminary data from chromatin immuno-precipitation and next-
generation sequencing (ChIP-seq) of peritoneal samples after inflammation show 
an increase in the number of peaks controlled by STAT1 as compared to STAT3-
associated peaks (Dr David Millrine, unpublished observations). Conversely, 
studies assessing the impact of IL-6 or IL-27 signalling in T cells have shown that 
STAT3 contributes to the overall transcription output associated with both 
cytokines, whereas STAT1 is responsible for specificity [302]. These findings 
illustrate that the activities of STAT1 and STAT3 are closely aligned, and that the 
transcriptional output delivered by IL-6 and IL-27 illustrates the context-
dependent nature of the cytokine receptor signal. 
A major challenge posed by this thesis was to investigate how temporal 
changes in the transcriptome determine competent host defence, and the potential 
transition to inflammation associated tissue damage and fibrosis. Here, statistical 
analysis of the datasets proposed that changes in the peritoneal transcriptome are 
organised in three distinct and very defined patterns of gene expression. The 
importance of such approach resides in the idea that genes that are expressed 
together share common functions [226]. Indeed, analysis of the datasets in such a 
fashion allowed the identification of common and unique biological processes in 
WT and Il6-/- mice during acute inflammation and in a situation where pro-fibrotic 
Th1 cells drive tissue remodelling. Importantly, this approach demonstrated that 
IL-6 signalling has a broad impact on the overall transcriptional output seen is 
stromal tissue during acute resolving inflammation. This observation was illustrated 
by the degree of overlap in the overall transcriptional output between WT and Il6-/- 
mice during IL-6/STAT3 acute or IFN-g/STAT1 pro-fibrotic setting (76% and 
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89%, respectively). This overlap was also striking when individual gene 
‘Behaviours’ were studied. 
 






















































Figure 8.1. Temporal mechanisms of gene expression during acute 
resolving inflammation. During acute inflammation, genes can be divided in 
two phases: (1) those genes downstream TLR2, which are independent of IL-6 
signalling, and (2) genes that are expressed as a consequence of IL-6 mediated 
STAT3 signalling in the peritoneum. B. IFN-g-mediated STAT1 signalling in the 
peritoneal membrane induced changes in gene expression that were more robust 
and sustained over time than to those observed during acute resolving inflammation 
(A).  
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8.3.  The balance between STAT1 and STAT3 activities determines host 
defence and the outcome of inflammation-induced tissue damage 
The activation of STAT3 in non-hematopoietic stromal cells during acute 
inflammation suggests a regulatory role for this latent transcription factor in anti-
microbial immunity. In this regard, IL-6/STAT3 signalling is essential for host 
defence against different pathogens [61-65, 252]. Importantly, mutations in the 
human or mouse STAT3 gene result in hyper-immunoglobulin E syndrome and 
higher susceptibility of infection [307, 308]. In addition, STAT3 activation in 
endothelial cells is protective in endotoxin models of inflammation [309]. During 
acute bacterial peritonitis, IL-6/STAT3 activation in the peritoneal membrane 
coincides with neutrophil infiltration and bacterial clearance. Here, Il6-/- mice have 
a reduced capacity to contain the infection and present increased bacterial 
dissemination into the bloodstream. Studies presented in this thesis demonstrated 
that this defect is partly due to an impairment of effector characteristics of 
infiltrating neutrophils at the site of infection. 
Importantly, IL-6 does not directly affect neutrophil activity [200, 278, 
279]. It was therefore hypothesised that the impact of IL-6 on neutrophil effector 
functions was indirect, and mediated through responses governed by IL-6/STAT3 
activity in stromal tissue cells. This hypothesis is in line with the idea that circulating 
neutrophils are “dormant” so as to prevent the release of ROS and proteolytic 
granules that could induce tissue injury [174, 310]. After infection, neutrophils 
rapidly migrate to the site of infection and become fully activated in response to 
several pro-inflammatory stimuli [174]. Thus, the nature and quality of the signals 
provided by the local inflamed microenvironment ultimately define the success of 
the inflammatory response. Here, we showed that IL-6 acting via STAT3 plays a 
major role in triggering these signals. For example, bioinformatic analysis linked 
the activation of STAT3 in the peritoneal membrane to enhanced anti-microbial 
activities in WT mice (Figure 8.2). In particular, IL-6-mediated activation of the 
peritoneal lining directs neutrophil priming and enhances phagocytosis. However, 
reconstitution of IL-6 trans-signalling in Il6-/- mice did not restore neutrophil 
respiratory burst activity, suggesting that both activities are regulated by different 
mechanism. This regulation may be akin to the control of neutrophil activities by 
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different neutrophil-activating chemokines [311]. Taken all together, we propose 
a model that outlines the interplay between stromal tissue and infiltrating 
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Figure 8.2. Novel mechanisms of IL-6 control of anti-microbial 
immunity. IL-6 signalling was associated with the upregulation of different genes 
that collectively ensure a successful host defence. These include complement 
molecules and soluble antimicrobial mediators, iron-chelating proteins, atypical 
chemokine receptors and adhesion molecules.   





















































Transfer of CD4+ Th1 cells into WT and Il6-/- mice was accompanied by an 
increase in STAT1 activity in the peritoneum [33]. Importantly, STAT1 activation 
compensated for the loss of STAT3 activity seen in Il6-/- mice during acute 
inflammation. In fact, restoration of the defects in host defence predicted in these 
mice was associated with a shift in the relative activities of STAT3 and STAT1 in 
the stromal tissue. In this regard, while the presence of Th1 cells only recovered 
40% of the genes uniquely regulated by IL-6 in WT mice, these included genes 
linked with antimicrobial defence in this inflammatory context (e.g., Selp, Lcn2, 
Saa1, Cdkn1a, Vcan, Il4ra, Hp, Fcgr1 and Ccr5) (Figure 8.4). These results support 
the idea that STAT1 and STAT3 have, to a certain extent, compensatory or 
overlapping roles [304, 305]. These observations also support a role of IFN-g in 
innate immunity and host defence [263, 264], and highlight the correspondence in 
the activities elicited by both cytokines [25].  
  
Figure 8.3. Model of competent host defence. A. TLR2 activation by 
S. epidermidis induces the expression of several neutrophil chemokines, such as 
CXCL1, and cytokines, including IL-6 and IL-1b. B. CXCL1 mediates the 
recruitment of neutrophils to the peritoneal cavity. C. Upon transmigration, 
infiltrating neutrophils quickly shed their CD62L and IL-6R. The release of sIL-6R 
allows now the peritoneal lining to be responsive to IL-6 signalling. In this way, 
IL-6 acting via STAT3 induces the expression of several genes (i.e., atypical 
chemokine receptors, adhesion molecules, complement, soluble mediators, etc.). 
These molecules collectively enhance the immune response by different 
mechanisms, including neutrophil priming, ion sequestration, and an overall 
increase in oxidative stress. As a result, the host is capable to successfully clear the 
infection. D. Finally, the switch of chemokine expression mediated by IL-6 leads 
to apoptotic clearance of the infiltrating neutrophils and the recruitment of a 
monocyte population, which eventually leads to the correct resolution of the 
inflammatory response. 





 While the adoptive transfer of CD4+ Th1 cells had a positive impact in the 
inflammatory response in the peritoneum, studies remain to understand the impact 
of these cells in the effector characteristics of infiltrating neutrophils. Studies in the 
literature have shown that, in contrast to IL-6, IFN-g directly activates neutrophil 
effector functions [312, 313]. This is particularly relevant in the management of 
chronic granulomatous disease, where IFN-g has been used as a therapy [314]. In 
the context of peritoneal infection, it would be interesting to investigate how 
IFN-g/STAT1 signalling in the peritoneal membrane may influence neutrophil 
responses to infection. From our transcriptomic and pathway analysis, we predict 
that IFN-g not only activates neutrophil function directly, but may also influence 
the stromal microenvironment to prime neutrophil responses locally.  
On the other hand, STAT1 activity in the peritoneal membrane was also 
associated with an altered expression of molecules implicated in the physiological 
maintenance of the peritoneal lining. These included matrix proteases and their 
inhibitors, structural proteins and enzymes linked with immune homeostasis and 
tissue integrity. This is particularly relevant for the development of fibrosis after 
repetitive inflammation, where IFN-g and STAT1 signalling disrupts the turnover 
of extracellular matrix by metalloproteases [33]. Importantly, fibrosis develops in 
response to recurrent episodes of inflammation through the IL-6-mediated 
















Figure 8.4. Genes unpaired in 
Il6-/- during acute resolving 
inflammation are rescued by 
the adoptive transfer of Th1 
cells. This is relevant to the impact 
of Th1 recruitment in the 
peritoneal cavity as an adaptive 
immune response to support 
successful host defence.    
  152 
expected to support antimicrobial immunity but inadvertently drives tissue 
damage. This may include the generation of SES targeted antibodies that are 
generated as a response to repeat peritoneal inflammation, and may lead to 
complement activation [33]. Consequently, peritoneal fibrosis may represent itself 
a component of anti-microbial host defence to encapsulate bacteria and prevent the 
dissemination of infection. [32]. Nevertheless, it is clear that the balance of STAT1 
versus STAT3 activity ultimately determines the inflammatory outcome associated 
with infection control (Figure 8.5). This is akin to previous observations in several 
models of experimental hepatitis, where IFN-g/STAT1 and IL-6/STAT3 signalling 
counteract each other. Here, STAT1 induces tissue injury, whereas STAT3 
protects against inflammation induced tissue damage [152, 315].  
In the present study, ex vivo expanded Th1 cells were adoptively transferred 
to WT and Il6-/- mice together with SES to mimic the pro-fibrotic setting observed 
after four rounds of acute resolving peritonitis [33]. While this approach provided 
an opportunity to assess the impact of these cells on the peritoneum to direct host 
defence, it is unclear whether this single challenge with SES and Th1 is sufficient to 
drive fibrosis. This seems unlikely for several reasons. First, although IFN-g-driven 
STAT1 activation only occurs after the fourth episode of peritonitis, it seems 
obvious that inflammatory activation of the membrane during repetitive challenge 
will alter its responsiveness to subsequent stimuli. This may include epigenetic 
modifications or changes in surface receptors (e.g., IFNGR1 and IFNGR2) that 
determine the responsiveness of the peritoneal membrane to IFN-g. Likewise, 
STAT3 associated activities observed during repetitive inflammation may become 
modified through changes in cooperative interactions with other transcription 
factors or transcriptional regulators (e.g., SP1, p300, glucocorticoid receptor) 
[316, 317]. These alterations may be particularly relevant at cis-regulatory modules 
or super-enhancer sites, where clustering of transcription factors have profound 
influences on gene expression [311]. In addition, studies in T cells have shown that 
STAT3 binding is required for the binding of STAT1 and subsequent STAT1-
derived gene transduction [302]. Akin to these studies, repetitive STAT3 activation 
in the peritoneum may be required for the specific activity of STAT1 in the 
peritoneal membrane and the development of fibrosis. Thus, multiple mechanisms 
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may contribute to the transcriptional landscape seen in stromal tissue following 
inflammatory activation. In conclusion, future studies will need to determine 
whether the onset of fibrosis uniquely requires IFN-g-driven STAT1 activation in 
the peritoneum, or whether recurrent episodes of inflammation are a prerequisite 
to prime the tissue for the development of fibrosis.  
  























































Figure 8.5. Balance between the relative activities of STAT1 and STAT3 
in determining the outcome of inflammation. A. IL-6 is essential for the 
control of infection in a murine model of S. epidermidis induced peritonitis. Here, 
Il6-/- mice are less capable to contain the infection and present higher bacterial 
dissemination to the blood stream. This outcome is associated to a strong STAT3 
activation in the peritoneal membrane. Conversely, during recurrent episodes of 
acute resolving sterile peritonitis (as produced by the repetitive (i.p.) challenge of 
S. epidermidis cell-free supernatant – SES), IL-6 promotes the proliferative 
expansion of CD4+ Th1 cells in the peritoneal cavity and the onset of fibrosis (A & 
B). This outcome is associated to a strong IFN-g-derived STAT1 activation in the 
membrane. C. Studies detailed in this thesis have explored the interplay between 
IL-6/STAT3 and IFN-g/STAT1 signalling in the peritoneal membrane during acute 
inflammation by adoptively transferring ex vivo polarised Th1 cells together with 
SES into WT and Il6-/- mice. While this approach has provided exciting findings in 
the involvement of the peritoneal membrane in determining competent host 
defence versus inflammation-induced tissue damage, future studies need to 
elucidate whether the onset of fibrosis uniquely requires IFN-g-driven STAT1 
activation in the peritoneum, or whether recurrent episodes of inflammation are a 
prerequisite to prime the tissue for the development of fibrosis. 
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8.4.  Future work 
Data presented in this thesis provides an holistic view on the transcriptome 
changes occurring in episodes of acute resolving inflammation. Specifically, studies 
have considered the role of IL-6 and IFN-g signalling and the activation of STAT1 
and STAT3 in the peritoneum. Several mechanisms were unearthed through this 
approach, highlighting the role of Jak-STAT signalling in “educating” the immune 
response against infection. Future studies are however required to further 
investigate different issues.  
× The balance in the relative activities of STAT1 and STAT3 ultimately define 
the effect of a given cytokine. Studies need to define the significance of 
STAT1-STAT3 crosstalk in the peritoneal membrane to determine the 
balance between successful host defence and inflammation-induced tissue 
injury. In this regard, our laboratory has recently conducted a ChIP-seq 
analysis of STAT1 and STAT3 activities in the inflamed peritoneum. This 
approach will provide valuable information on transcriptional crosstalk and 
potential cooperative interactions relevant to the control of gene 
expression.  
× Repetitive episodes of acute resolving peritonitis led to the proliferative 
expansion of pro-fibrotic Th1 cells in the peritoneal cavity following 
recurrent inflammatory activation. Studies need to determine whether a 
single transfer of Th1 cells is sufficient to drive fibrosis. This approach will 
allow us to consider whether potential long-term changes in epigenetic 
mechanisms are involved in these processes. 
× In line with the bullet points 1 and 2, studies will need to investigate the 
impact of epigenetic regulation in the stromal compartment as a prerequisite 
for the development of peritoneal fibrosis. These may include histone 
trimethylation and ATAC-seq (Assay for Transposase Accessible Chromatin 
with high-throughput sequencing) studies to evaluate chromatin 
accessibility to STAT1 and STAT3 during acute or repetitive inflammation. 
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In this regard, various transcription factors and co-activators are known to 
influence STAT-mediated gene transduction (e.g., p300, SP1, AP-1). Thus, 
their implication in host defence and fibrosis will need to be assessed.  
× The effector function characteristics of infiltrating neutrophils are impaired 
as a result of IL-6 deficiency. However, the precise mechanism by which 
neutrophil phagocytosis and respiratory burst are primed needs further 
investigation. In particular, studies will need to investigate how candidate 
genes identified by RNA-seq affect neutrophil function.  
× The assessment of the production of ROS depends on the quality of the 
sensors used for their detection. In this regard, APF only accounts for the 
detection of OH-, NO3- and ClO-, and does not illustrate the overall ROS 
production within the neutrophils. Thus, studies will require the use of 
alternative sensors or the combination of several techniques (e.g., APF 
staining and assessment of cytochrome B actives) to accurately reflect the 
respiratory burst status in neutrophils. The use of specific inhibitors for the 
enzymes SOD and MPO could also be used to determine the specific 
implication of NOX2 in the respiratory burst. 
× Transcriptome analysis predicted that signatures relevant to the immune 
response (i.e. activation of leukocytes) were controlled by IL-6. Th1 cell 
adoptive transfer and IFN-g signalling in the peritoneal membrane 
supplemented this level of control. Studies need to further investigate the 
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